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Abstract 
Diabetes Mellitus (diabetes) is today a worldwide problem, accounting for approximately 1.5 mil-
lion deaths worldwide in 2012. No cure is currently available in treating diabetes hence; there is a 
need for better early diagnostic biomarkers and therapeutics. One potential molecule could be micro 
ribonucleic acid (miRNA or miR). It has for example been shown that hsa-miR-29a is up-regulated 
in β-cells, when glucose levels are elevated. The muscles are the greatest consumer of glucose in 
the body, and therefore it could be of interest to investigate the expression of miR-29a in this kind 
of tissue, and furthermore miR-29a’s role in the regulation of the metabolism. One way to examine 
this is to generate a muscle cell line, which would stably overexpress the miR-29a.  
Different methods have, in this study been used in doing so. First, a cloning was executed making a 
valid control plasmid. Then a transfection, infection and selection were performed, creating the 
C2C12 cell line that should stably overexpress miR-29a. This creation was however not completely 
successful, but knowledge concerning the infection procedure has been gained. This knowledge 
could be used in future studies to investigate miR-29a’s role in muscle cells in regards to diabetes.  
Resumé 
Diabetes Mellitus (diabetes) er et verdensomspændende problem og denne sygdom var i 2012 skyld 
i 1,5 millioner dødsfald på verdensplan. Diabetes kan ikke behandles, og der er derfor et behov for 
bedre, tidlige diagnostiske biomarkører og terapeutiske midler. Et potentielt molekyle, kunne være 
mikro ribonukleinsyre (miRNA eller miR). Det har vidst sig, at hsa-miR-29a er opreguleret i β-
celler, når glucose niveauerne er forhøjet. Musklerne er den største forbruger af glucose i kroppen, 
og det kunne derfor være spændende at undersøge udtrykket af miR-29a i den slags væv, samt vide-
re at undersøge miR-29as rolle i reguleringen af metabolismen. En mulig måde at gøre dette på, er 
ved at skabe en muskelcellelinje, der stabilt overudtrykker miR-29a. En sådan model kan bruges i 
forskellige eksperimenter.  
Igennem dette studie er der blevet brugt forskellige metoder i forsøgt på at skabe en C2C12 cellelin-
je der stabilt overudtrykker miR-29a. Først udførtes en kloning for at skabe et brugbart kontrol 
plasmid, efterfulgt af transfektion, infektion, og selektion. Denne kreation var dog ikke helt vellyk-
ket, men der er opnået viden om inficeringsproceduren, hvilket kan bruges i fremtidige studier til at 
undersøge miR-29as rolle i muskelceller, i forhold til diabetes.  
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Introduction 
Diabetes Mellitus (diabetes) is a worldwide problem and about 347 million people are today diag-
nosed with this disease. In 2012 it resulted in 1.5 million deaths and is one of the leading causes of 
blindness, amputation, and kidney failure 1951. 
Diabetes is a chronic disease that manifests when insulin production in the pancreas is either insuf-
ficient or when the body cannot effectively utilize the secreted insulin. The result is an accumula-
tion of glucose in the system, also referred to as hyperglycemia2. This can over time lead to serious 
multi-organ damage, especially to the nerves and blood vessels. Currently no long-term cure is 
available in treating diabetes, and therefore an investigation of novel early biomarkers and therapeu-
tics for diabetes is needed. An example of one such biomarker is micro ribonucleic acids (miRNA 
or miR). Evidence shows that altered miRNA expressions, are linked to several diseases including 
diabetes2.  
miRNAs are small single-stranded noncoding ribonucleic acids (RNAs) of approximately 22 nucle-
otides3. They alter protein expression by targeting the 3' untranslated region (UTR) of gene tran-
scripts, thereby inducing transcriptional repression or transcript degradation4. Recent work suggests 
that miRNAs regulate multiple biological processes, including cell proliferation and differentiation5. 
A review by Lorenzen et al., (2012) found that several miRNAs, such as miR-503, -146a, -125b, -
375, -29a/b/c, have been associated with diabetes4. Furthermore, a study by Bagge et al. (2012) ob-
served increased levels of miR-29a in β-cells of the pancreas, in response to elevated blood glucose 
levels. This was moreover accompanied by mitochondrial dysfunction. 
But what about other kinds of tissues? The muscles are the greatest consumer of glucose6, and 
therefore it is of interest to investigate expression patterns of miRNAs in this kind of tissue. One 
way to examine miR-29a’s possible role in muscle metabolism is to create a cell line, which stably 
overexpresses the miR-29a. This cell line could then be used in various experiments. 
 As a result, this project aims to examine:  
How is it possible to create a C2C12 cell line stably overexpressing miR-29a, with a special focus 
on infection procedures in regards to the use of frozen or fresh viral medium?  
The problem is explored through experimental work in the laboratory. The work was divided into 
two parts. In the first part, a novel control plasmid was created. In the second part, Phoenix cells are 
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transfected with either the pMSCV PIG (Puro IRES GFP) plasmid (#21654)7, or two modified ver-
sions containing a control sequence or the mature miR-29a sequence. This transfection creates a 
rodent retrovirus, which is used to infect C2C12 cells in different ways. 
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Theory 
In order to investigate a possible role of miR-29a in muscle cells, knowledge of the metabolism and 
how it is regulated in regards to high or low levels of glucose in blood, is necessary. Furthermore, 
an overview of the general synthesis of miRNA is provided, with a particular focus on the miR-29 
family and their possible relation to the regulation of metabolism. Moreover, an insight into diabe-
tes is provided, in order to clarify miR-29a's possible roles in this disease.  
Glucose metabolism in muscles 
Metabolism is the overall network of enzyme-catalysed pathways, both catabolic and anabolic8. In 
muscle cells, it is specialized to generate adenosine triphosphate (ATP), which is the immediate 
source for contraction. ATP is generated by cellular respiration8. 
Depending on the activity intensity and duration, skeletal muscles can use different kinds of fuels. 
During high intensity activity, such as explosive weight lifting, the muscles use creatinephosphate 
to create ATP. As the activity goes on or during moderate activity, creatinephosphate resources run 
out, and the energy source switches to stored muscle glycogen and then blood glucose, see Figure 1. 
In the end or under prolonged duration of low intensity activity the blood glucose level drops and 
fatty acid will take over as fuel source9. In this project, the focus will only be the conversion and 
uptake of glycogen and blood glucose to yield ATP, since this is relevant concerning diabetes. 
 
Figure 1 shows the different changes in substrates during long periods of exercise. On the figure approximately 260 min. The exer-
cise begins at time 0. It is seen how the stored glycogen is the first substrate used and it continues so the first 30 min. of the exercise. 
Then fatty acids and blood glucose take over as the major sources of energy. Most of the glucose found in the blood at this time 
comes from the breakdown of glycogen in the liver. After approximately 60 min. of exercise, the energy metabolism will depend 
increasingly upon the fatty acids as the major source of fuel. The blood glucose level will thereafter fall to a stable level. After ap-
proximately 250 min. of exercise the individual will “hit the wall”, meaning that the glucose level will drop below the stable level, 
which will lead to dizziness, loss of vision and ultimately collapse. The fatty acids are at this time the primary source of fuel10. 
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The use of blood glucose and muscle glycogen as fuels for muscular activity is tightly regulated by 
the secretion of hormones such as the peptide hormones insulin and glucagon, both secreted by the 
pancreas8. 
Regulation of glucose levels 
In the pancreas three cell types, the α- β- and δ-cells, produce three different types of peptide hor-
mones. The α-cells produce glucagon, the β-cells produce insulin, and the δ-cells produce Somato-
statin. These three types of cells are placed in clusters, called the islet of Langerhans, in the pancre-
as8. Somatostatin is an inhibitory hormone. It inhibits the secretion of insulin and glucagon, and 
other hormones, such as gastrin. Somatostatin receptors have been identified on both β- and α-cells. 
Still the specific function of the somatostatin is unclear11. However, a study by Hauge-Evans et al., 
(2009) found that when either α- or β-cells are activated, δ-cells are simultaneously activated and 
therefore releases somatostatin11. 
The two other hormones secreted by the pancreas play a more specific role in maintaining the blood 
glucose homeostasis. Postprandial glucose will enter the bloodstream from the intestine, resulting in 
an increased blood glucose concentration. In response, the β-cells in the pancreas will release insu-
lin, which will induce the uptake of glucose by the cells. Furthermore, the secretion of glucagon by 
the α-cells will be decreased8. How the β-cells are regulated by glucose to secret insulin is shown in 
Figure 2 on the following page. 
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Figure 2 shows how glucose regulates the secretion of insulin by the pancreatic β-cells. When blood glucose levels are high, glucose 
will bind to the glucose transporter type 2 (GLUT2). When it does so, GLUT2 will transport the glucose molecules into the β-cells, 
where the glucose will immediately enter the glycolysis. This will in turn increase the glucose catabolism, and therefore a rise in the 
[ATP]. The increase in [ATP] will cause the ATP-gated K+ channels, in the plasma membrane, to close. Therefore the flux of K+ in 
to the cell is reduced, which will depolarize the membrane. This depolarisation will cause the voltage-gated Ca2+ channels to open, 
resulting in an increase in cytosolic [Ca2+]. This increase triggers the release of insulin by exocytosis8. 
Insulin is secreted into the blood and will travel to its target tissues, which include liver, adipose, 
and muscle tissue12. The cells of the target tissues will be induced by insulin, to take up glucose 
through activation of the insulin response pathway8 as seen in Figure 3.  
 
Figure 3 illustrates how glucose in response to insulin is taken up by the cell. First insulin activates the insulin receptor. This leads 
to a phosphorylation of the tyrosine of insulin receptor substrate 1 (IRS-1) and insulin receptor substrate 2 (IRS-2), which activates 
them. When activated, IRS-1 and IRS-2 can phosphorylate phosphoinositide 3 kinase (PI3K) enzymes, whose activation in turn 
stimulates the phosphorylation of the serine in protein kinase B (Akt). The activated Akt then stimulates the glucose transport in 
muscle and adipose tissue through the stimulated translocation of the glucose transporter type 4 (GLUT4) isoform13. 
   
Page 11 of 128 
 
The glucose level in the blood will now continuously drop. If glucose levels in the blood drops to a 
level around 4-5.9 mmol/L, as seen after a starvation period, glucagon will be secreted from the α-
cells. Glucagon induces liver cells to release stored glucose, thus increasing the glucose level in the 
blood8. However the mechanism regulating glucagon secretion is not completely understood14. 
Once in the blood, glucagon can regulate the target cells in severable ways, which will help increase 
the blood glucose concentration, as seen in Figure 4. 
 
Figure 4 shows the fasting state in the liver. It is seen how glucagon is secreted from the α-cells in the pancreas, which will affect the 
liver. Glucagon will stimulate the breakdown of glycogen in the liver by activating glycogen phosphorylase and inactivating the 
glycogen synthase. This will produce glucose 1-phosphate, which can be converted to glucose 6-phosphate and glucose through the 
gluconeogenesis. Furthermore, glucagon will inhibit the breakdown of glucose by inhibiting the glycolysis. The glucose will be re-
leased to the bloodstream. The figure also shows how amino acids and glycerol are used in the gluconeogenesis. The amino acids 
come from the degradation of proteins in the muscles, and glycerol comes from the breakdown of triacylglycerol (TAG) in the adi-
pose tissue. Lastly, the figure shows how the liver uses fatty acids as fuel. The excess fatty acids are converted to acetyl-Coenzyme A, 
which is further converted to ketone bodies. These can be exported to other tissues, such as the brain8.  
Another hormone, regulating the amount of glucose available for uptake is epinephrine, which 
stimulates the release of glucose from the liver and glycogen from the muscle tissue. 
Once the glucose is taken up by the cell, it is, similarly to glycogen, phosphorylated and further 
degraded by glycolysis to pyruvate. This pyruvate is converted to acetyl-Coenzyme A (acetyl-CoA) 
and oxidized via the citric acid cycle (CAC) and lastly it enters the electron transport chain in the 
mitochondria8. 
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Glycolysis 
In the glycolysis, glucose is degraded in ten step enzyme-catalysed reaction, to form two molecules 
of pyruvate. During this process, shown in Figure 5 and Figure 6, some free energy is released in 
the form of ATP and NADH. The glycolysis can be divided in to two phases; the preparatory phase, 
Figure 5, which constitutes the first five steps and cost 2 ATP, and the payoff phase, Figure 6, 
which constitutes the last five steps, which produces 4 ATP. Altogether the yield of the glycolysis is 
2 ATP8. The glycolysis is tightly regulated to ensure a constant amount of ATP in the cell. This 
regulation is done in several ways, especially in its three irreversible steps, which are step 1, 3 and 
10 on Figure 5 and Figure 6. The rate of the glycolysis is furthermore regulated by the interplay 
between ATP consumption, NADH regeneration, and by allosteric regulation of some of the en-
zymes used in the glycolysis. Lastly the glycolysis can also be regulated by different hormones8. 
 
Figure 5 shows the preparatory phase of the glycolysis. First glucose enters the glycolysis, and is phosphorylated at C-6, the hydrox-
yl group (1). The glucose 6-phosphate is then converted into fructose 6-phosphate, by the enzyme phosphohexose isomerase (2). Then 
another phosphorylation occurs on C-1 to form fructose 1,6-biphosphate (3). In both phosphorylations ATP has donated its phosphor 
group. Next fructose 1,6-biphosphate is cleaved by aldolase, creating two 3-carbon sugar phosphates called glyceraldehyde 3-
phoshate and dihydroxyacetone phosphate (4). Dihydroxyacetone phosphate is isomerized to a second glyceraldehyde 3-phoshate 
(5), which means there are two glyceraldehyde 3-phoshate in the beginning of the payoff phase8 (Modified).  
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Figure 6 shows the payoff phase of the glycolysis. First glyceraldehyde 3-phosphate is oxidized and phosphorylated to 1,3-
biphosphoglycerate by glyceraldehyde 3-phosphate dehydrogenase (6). Then it is converted into 3-phosphoglycerate by phospho-
glycerate kinase. A phosphoryl group is transferred to ADP thereby creating an ATP (7). Next phosphoglycerate mutase relocates 
the phosphoryl group of 3-phosphorglycerate creating 2-phosphoglycerate (8). Enolase then dehydrates the 2-phosphoglycerate to 
phosphoenolpyruvate (9). The pyruvate kinase facilitates the final step of the glycolysis, by transferring a phosphoryl group from 
phosphoenolpyruvate to ADP creating ATP and pyruvate (10). The yield of the payoff phase is four ATP and two py-
ruvate8(Modified).  
Glycolysis is one of the major pathways in glucose metabolism in skeletal muscles. Another im-
portant pathway is the CAC. To enter this pathway, happening in the mitochondria, pyruvate has to 
be converted to acetyl-CoA. This conversion is carried out by the enzyme pyruvate dehydrogenase8.  
Citric acid cycle 
In the CAC, seen on Figure 7 on the following page, each molecule of acetyl-CoA is converted to 
oxaloacetate under the formation of one ATP or GTP, one FADH2, and three NADH. The overall 
regulation of the CAC is done in response to the need of energy and the concentration of substrate 
and products. Meaning a high [ATP] and [NADH] are inhibitory to the cycle, while high [AMP] 
and [NAD+] are considered to be stimulatory8.  
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Figure 7 shows the citric acid cycle (CAC). In the first step, Acetyl-Coenzyme A (acetyl-CoA) donates its acetyl group to oxaloace-
tate which create citrate (1). Next citrate is dehydrated by aconitase creating cis-aconitate (2a), and then cis-aconitate is rehydrated 
by aconitase creating isocitrate (2b). Then isocitrate dehydrogenase catalyses the oxidative decarboxylation of isocitrate, forming α-
ketoglutarate (3). α-ketoglutarate is then converted to succinyl-CoA in a oxidative decarboxylation catalysed by α-ketoglutarate 
dehydrogenase complex (4). Succinyl-CoA is converted to succinate by breakage of the thioester bond creating either GTP or ATP, 
depending on the catalyst (5). Next succinate is oxidized by removing 2H+ forming fumarate and FADH2 (6). Thereafter fumarate 
undergoes hydration creating L-malate, catalysed by fumarate (7). Lastly L-malate is converted to oxaloacetate (8), using NAD+ as 
an electron acceptor8. 
NADH and FADH2 from the CAC are further oxidised in the electron transport chain, which is the 
most efficient pathway in the ATP production8.  
Oxidative phosphorylation 
Oxidative phosphorylation is the culmination of energy yielding metabolism in aerobic organisms. 
It begins with electrons in the form of NADH and FADH2 from the CAC entering the electron 
transport chain. All reactions takes place in the mitochondria. The electron transport chain consists 
of a series of sequentially acting electron carriers, which are able to accept or donate either one or 
two electrons. The three types of electron carriers are ubiquinone (Q), cytochromes, and iron-sulfur 
proteins. For each NADH molecule entering the electron transport chain 2.5 ATP molecules are 
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produced, and equivalently 1.5 ATP molecules are produced for each FADH2. Figure 8 summarizes 
the electron transport chain8. 
 
Figure 8 shows the four different complexes in the electron transport chain. Complex I consists of two overall reactions, the exergon-
ic transfer of a hydride ion from NADH to ubiquinone (Q) (1), and the endergonic transfer of four protons from the matrix to the 
intermembrane space (2). Complex II is a succinate dehydrogenase, which means that it catalyses the conversion of succinate to 
furmarate, by transferring electrons to FAD. Then the electrons from FAD move through complex II to Q. Once the hydride ions bind 
to Q it becomes qbiquinol (QH2). Complex III couples the transfer of electrons from QH2 to cytochrome c, and at the same time, four 
hydride ions are transferred from the matrix to the intermembrane space. Complex IV is the final step of the electron transport chain. 
This complex carries electrons from cytochrome c to molecular oxygen, reducing it to water. Electron flow is accompanied by proton 
transfer across the membrane, producing both a chemical and an electrical gradient. Because the inner mitochondrial membrane is 
impermeable to protons, the protons can reenter the matrix through specific proton channels (Fo). This flow provides energy for ATP 
synthesis, which is catalysed by the F1 complex associated with Fo8. 
To summarise blood glucose homeostasis is maintained by balancing the concentration of different 
hormones, including insulin, epinephrine, and glucagon. The glucose will, when taken up by the 
cell, be used to generate energy in the form of ATP. It is the homeostasis of glucose in the blood 
that will be disrupted in diabetes8. 
Diabetes 
Diabetes is a complex metabolic disorder characterised by hyperglycemia8. The level of glucose in 
the blood will normally be high postprandial. As seen in Table 1 on the following page, around two 
hours postprandial, glucose levels in the blood of non-diabetic humans will be around 7.8mmol/L. 
Preprandial the blood glucose level will normally be around 4mmol/L8. 
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Table 1 shows the glucose levels in blood  for diabetic and non-diabetic individuals preprandial and 2 hours postprandial15. 
Type Preprandial 2 hours postprandial 
Non-diabetic 4 to 5.9mmol/L Under 7.8mmol/L 
Type 2 diabetes 4 to 7mmol/L Under 8.5mmol/L 
Type 1 diabetes 4 to 7mmol/L Under 9mmol/L 
 
There are two subtypes of diabetes: Type 1 diabetes (T1D) and type 2 diabetes (T2D). T1D is re-
ferred to as insulin dependent and T2D is referred to as insulin independent. Individuals with T1D 
or T2D are all unable to take up glucose efficiently from the blood8.  
Because glucose becomes unavailable to the cell, fatty acids will be the principal fuel, which leads 
to a characteristic metabolic change. This metabolic change is an excessive and incomplete oxida-
tion of fatty acids in the liver8. 
Diabetes is a disease occurring worldwide, and several life-threatening complications are seen in-
volved with it. This is for example different metabolic risk factors such as elevated blood pressure, 
elevated levels of triglycerids in the blood, hyperglycemia and unusual levels of lipids in the form 
of cholesterol in the blood. Which can lead to heart diseases, kidney damage etc16. 
Type 1 diabetes 
T1D is an autoimmune condition8. An autoimmune disease is a result of an activation of B- and T-
cells which will act against substances and tissues normally found in the body. This can cause tissue 
damage, which in the case of T1D is the destruction of β-cells. The activation can be due to either a 
genetic or environmental trigger17. How this dysfunction appears, is still not completely clear, how-
ever the result is a build-up of glucose in the blood, and therefore individuals with T1D require a 
daily dosage of insulin2. This is the reason why this subtype of diabetes is referred to as insulin de-
pendent. 
Alternatively, to daily administration of insulin, T1D patients can be treated through procedures 
such as pancreatic or pancreatic islet-cell transplantations. However, these procedures are complex 
and can cause complications2. The complications could be bleedings and/or blood clots formation. 
Furthermore, there might be complications with the transplanted cells, meaning they would only 
work inefficiently or not at all18.   
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Type 2 diabetes 
T2D is the most common type of diabetes19. It is a complex metabolic disorder, which involves two 
kinds of defects: Insulin resistance and β-cell dysfunction20. 
The first kind of defect, the insulin resistance, arises when the sensitivity of the peripheral tissue has 
been compromised in a way that makes it incapable of responding to insulin, which will cause the 
glucose to accumulate in the blood8. The sensitivity by the peripheral tissue will over time become 
progressively reduced, and therefore the balance between insulin output and demand is disrupted2.  
The second defect related to T2D, β-cell dysfunction, is not completely understood. However, it has 
been proposed that it involves mitochondrial dysfunction and β-cell exhaustion. This exhaustion can 
be caused by continued insulin release. Furthermore, elevated glucose levels in blood plasma can 
also lead to a decrease in the insulin secretion and β-cell dysfunction20,21. 
T2D is often seen in conjunction to obesity. Patients with T2D, particularly obese or very lean indi-
viduals, are characterised by continuously elevated concentrations of free fatty acids in the plasma. 
The high concentrations will in these cases not be suppressed postprandial or in response to 
insulin22,23, and has been shown to possibly cause insulin resistance in both muscle and liver 
cells24,25. Moreover it could also impair the secretion of insulin by the β-cells26.  
A class of drugs used in treating diabetes, work by reducing these high levels of free fatty acids in 
the blood, and thereby increasing the sensitivity to insulin8. Unlike T1D the risk of developing T2D 
can be reduced significantly by practicing a healthy lifestyle2. Three factors are known to improve 
the health of people with T2D: dietary restriction, regular exercise, and drugs that increase insulin 
sensitivity and production. The reason why diet and regular exercise can be used in treating T2D, is 
that this help treat the associated elevated levels of glucose and free fatty acids, as well as blood 
pressure abnormalities27.  
However no cure is currently available in treating diabetes, hence there is a need for better early 
diagnostic biomarkers and therapeutics. One potential molecule could be miRNA. 
microRNA 
miRNA is a class of non-coding RNA molecules, which are about 22 nucleotides in length8. They 
regulate gene expression at the post-transcriptional level by targeting messenger RNA (mRNA) or 
inducing target degradation, ultimately resulting in gene silencing8. They are found in both animals 
and plants. In humans there may be as many as 1000 distinct miRNAs28,29.  
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There are two intermediates in the production of mature miRNA; primary miRNA (pri-miRNA) and 
the second is the precursor miRNA (pre-miRNA)8,30. Both are seen in Figure 9, showing the biosyn-
thesis of miRNA. 
 
Figure 9 shows the biosynthesis of microRNA (miRNA). First, in the nucleus, the primary microRNA (pri-miRNA) is made by RNA 
polymerase II or III. Then the pri-miRNA is cleaved by the microprocessor complex Drosha-DGCR8. The result is the precursor 
miRNA (pre-miRNA), which is exported from the nucleus to the cytoplasm by the Exportin-5-Ran-GTP. In the cytoplasm, the pre-
miRNA hairpin is cleaved by the RNase called Dicer, which is in a complex with the double-stranded RNA-binding protein called 
TAR RNA binding protein (TRBP). The resulting functional strand of mature miRNA is loaded together with Argonaute (Ago2) pro-
teins into a complex called RNA-induced silencing complex (RISC). Once in RISC, miRNA can participate in either translational 
repression or messenger RNA (mRNA) degradation. The strand not developed into the mature miRNA is degraded30 (Modified). 
Pri-miRNA is the product of RNA polymerase II or III30. The trademarks of polymerase II tran-
scription is polyadenylation, the addition of a poly(A) tail to a primary RNA transcript, and further 
an addition of the 5’-cap. Both of these features are seen on many pri-miRNA30, indicating RNA 
polymerase II is the primary polymerase for transcription of the miRNA genes.  
An average human pri-miRNA has a hairpin structure with a stem of 33 base pairs (bp)30. Following 
the transcription, pri-miRNA is cleaved by a microprocessor complex composed by the ribonucle-
ase (RNase) III enzyme Drosha and the DGCR8 protein. Drosha consists of two RNase domains, 
which cleave the pri-miRNA at the 5’ and 3’ arms of the hairpin31. The specific cleavage site is de-
termined by DGCR8, which functions as a molecular ruler through stable interactions with the pri-
miRNA. The specific cleavage is done 11 bp away from the junction between the single-stranded 
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RNA and the double-stranded RNA, and yields the hairpin structured pre-miRNA, as seen in Figure 
932.  
Export of pre-miRNA from the nucleus to the cytoplasm is facilitated by Exportin 5 (Exp5), see 
Figure 9. Exp5 is a Ran-GTP dependent nucleo/cytoplasmic cargo transporter33. Pre-miRNA is rec-
ognized by Exp5 independently of its sequence or the loop structure. Instead a defined length of the 
double-stranded stem and the 3’ overhangs are important for its recognition and successful binding 
by Exp534. This ensures that it is only the correctly processed pre-miRNAs, which are transported 
out to the cytoplasm. 
Once in the cytoplasm, the pre-miRNA is cleaved by Dicer together with its interactor TAR RNA 
binding protein (TRBP), as seen in Figure 9. Dicer is a RNase III enzyme, which cleaves off the 
loop of the pre-miRNA hairpin, which generates a miRNA duplex of approximately 22 nucleotides, 
with two nucleotides protruding as overhangs at each 3’ end. This cleavage is essential for miRNA 
processing, and because there is only a single copy of Dicer in the mammalian genome, it has an 
essential role in the miRNA biosynthesis30.  
Once Dicer has cleaved the pre-miRNA, it will together with TRBP dissociate from the miRNA 
duplex. The double-stranded miRNA duplex will then be separated into two strands. One becomes 
the functional guide strand, complementary to the mRNA target. The other stand, referred to as the 
passenger strand, is subsequently degraded30, as seen in Figure 9. Whether one strand becomes the 
functional or passenger strand, is determined by the thermodynamic stability of the base pairs at the 
two ends of the duplex. Meaning the miRNA strand with the less stable base pairs at its 5’ end in 
the duplex is incorporated into RNA-induced silencing complex (RISC), while the other is degrad-
ed30.  
Once in RISC, miRNA can participate in either posttranscriptional repression or degradation 
mRNA, as seen in Figure 10 on the following page. 
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Figure 10 shows how mature microRNA (miRNA) is incorporated into the protein complex called RNA-induced silencing complex 
(RISC). When the miRNA is bound to RISC, the complex is called miRISC. Bound to RISC, the mature RNA can bind to the target 
mRNA. If the miRNA is perfectly or nearly-perfect complementary to the target mRNA, the target mssengerRNA is cleaved. If this 
complementarity is only partial, the miRISC complex will only block the translation of the target mRNA 8(Modified).  
Posttranscriptional repression is the predominantly way in human miRNAs regulate their targets33. 
The degree of which is determined by the number of miRNA binding sites35. When RISC is loaded 
with miRNA it is called miRISC. It can bind to target mRNA by forming a bulge sequence in the 
middle of the target mRNA. This sequence is not suitable for mRNA cleavage, and will therefore 
inhibit the translational machinery36. This posttranscriptional repressed mRNA can either be stored 
in processing bodies (P-bodies) or enter a pathway called the mRNA-decay pathway for destruc-
tion37. P-bodies are cytoplasmic foci that contains posttranscriptional repressed mRNA-protein 
complexes38. Depending on the conditions in the cells and other stimulations, this stored mRNA can 
either re-enter the translation pathway or the mRNA-decay pathway37.  
The different types of miRNA can be either up- or down-regulated in response to various conditions 
in the organism. In the recent years it has been shown that miRNA expression are linked to different 
pathological conditions, such as cancer or diabetes2. One such example is the miR-29 family. 
miRNA-29 
miR-29a is a part of the miR-29 family. This family includes in humans: hsa-miR-29a, hsa-miR-
29b-1, hsa-miR-29b-2 and hsa-miR-29c39. Mature miR-29s share identical sequences, as seen in 
Figure 11 on the following page. 
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Figure 11 shows the identical sequence at nucleotide position 2-7 in the microRNA-29 (miR-29) family. This sequence is called the 
seed region. Mature sequences of the miR-29 family members are conserved in human (hsa-), mouse (mmu-), and rats (rno-). The 
nucleotides that differ among the three types in the family are shown in red39. 
Of significant interest are the identical sequences in position 2-7. This is called the seed region, as 
seen on Figure 11. The seed region is considered to be the most important sequence for selecting 
mRNA targets. Because each of the miR-29 family members consist of the same seed region, their 
predicted target genes generally overlap40.  
The different kinds of miR-29s have different subcellular locations. miR-29a is primarily located in 
the cytoplasm41. The gene encoding miR-29a and -29b-1 are in humans located on chromosome 
7q32.3. It has been confirmed that they are in fact transcribed together as a polycistronic primary 
transcript, which is a primary transcript encoding for more than one gene product39,42.  
The miR-29 family are transcribed by polymerase II. The regulation of which can be done in sever-
al ways. For example, some studies have identified several critical cis elements in the proximal re-
gion of miR-29 gene promoters, while others found strong myc binding in the transcription start site 
of the miR-29b-1/a and miR-29b-2/c clusters42,43. Furthermore, additional transcriptionfactor bind-
ing sites have also been found together with various transcriptional regulators39. 
The miR-29 family have been shown to target at least 16 genes that are related to the extracellular 
matrix. These 16 genes encode numerous key proteins involved in the physiological or pathological 
formation of the extracellular matrix44–46. 
In a study by Bagge et al., (2012) only miR-29a was investigated. Instead of muscle cells they chose 
to investigate the role of miR-29a in the pancreatic β-cells20. It was shown that miR-29a could be 
regulated by glucose in pancreatic β-cells and mediate glucose-induced dysfunction. This in turn 
suggested that glucose-mediated up-regulation of miR-29a in β-cells, could possibly mediate dys-
function of the β-cells. Furthermore, they also found that an increase in β-cell proliferation, while 
inhibiting miR-29a could improve the glucose stimulated insulin secretion. These findings suggest 
that there could be a link between glucose-induced proliferation and β-cell dysfunction20. 
We have in this study chosen to look closer to miR-29a’s role in muscle cells, using C2C12 cells to 
create a model. 
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Experiment 
To understand the procedures done in this study, an overview of the experiment will first be provid-
ed, followed by a description of the methods used. For more detailed descriptions concerning the 
work done in the laboratory, see the protocol in the appendix B. 
The aim of the experiment was to investigate methods to create a cell line, which would stably 
overexpress miR-29a.  
The experiment can cumulatively be divided into two parts: 
1) Creations of the control plasmid by cloning.  
2) Transfection of phoenix cells with the empty plasmid, control plasmid, and miR-29a plasmid, 
creating a rodent retrovirus, for further infection of C2C12 cells.  
A flowchart of the entire experiment performed in this study can be seen in Figure 12.  
 
Figure 12 shows a flowchart, which provides an overview of all the procedures performed in this study. 
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C2C12 
The cells used in this study as a model of muscle cells, are C2C12 cells. The C2C12 cell line is a 
mouse myoblast, originally obtained by David Yaffe and Ora Saxel from the leg muscles of an adult 
C3H mouse47.  
Research in C2C12 cells concluded that these cells can function as an appropriate model in vitro, 
for the myoblast in vivo. Manabe et al., (2012) found that the C2C12 cells could contract in re-
sponse to electrical stimulations in vitro in the same way as in exercising muscles in vivo. They 
came to that conclusion by investigating the phosphorylation of intracellular marker proteins, and 
comparing it with the phosphorylation that normally occurs of these proteins during exercise48.   
Furthermore, the C2C12 cells have been shown to be suitable for transfection of foreign DNA, be-
cause they are able to take up the DNA and express the desired genes49. It has moreover been 
demonstrated that the functionality of the cell does not change after a transfection48. 
In this study, C2C12 were transfected with versions of the pMSCV PIG plasmid, using virus har-
vested from phoenix cells.  
Phoenix cells 
Phoenix cells (HEK 293) are used in this experiment to produce a rodent retrovirus, which will be 
transfected with the pMSCV PIG plasmid or modified versions of it. Phoenix cells originate from 
Human Embryonic Kidney cells and were in 1977 the first human cell to be transformed with ade-
noviruses50. Using the Phoenix cells, it is possible to create a rodent retrovirus, which has taken up 
the plasmid. The rodent retrovirus will be secreted into the growth medium, which can be harvested. 
The advantages of using a retrovirus is that it is a single-stranded RNA-virus which use the DNA-
polymerase in the cell to convert the single-stranded RNA to double-stranded DNA by reverse tran-
scription. It could thereby be incorporated into the genome of the host, in this experiment C2C12 
cells. Furthermore, the virus produced by the Phoenix cells are a rodent virus, which is not capable 
of infecting humans, thus reducing the risk of unwanted infections of the individuals working with 
them.   
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Method 
Part 1 
In the first part of the study, the control plasmid was created. The control plasmid is made and used 
in order to compare the cells infected with the miR-29a in part 2 of this study. The plasmid contain-
ing the control sequence have thus been treated in the same way as the one containing the mature 
miR-29a sequence, and can therefore be used as a suitable control. The plasmid containing the miR-
29a sequence has previously, to this study been created under the same conditions by Ph.D. student 
Julian Geiger in the miRNA research laboratory at Roskilde University, supervised by Lector 
Louise Torp Dalgaard. 
The control plasmid was created by inserting the following non-coding sequence at base pair posi-
tion 1410 of the pMSCV PIG plasmid after certain procedures. 
Control sequence: 
GATCCCAATCATGACCCTATTGACGTTTTCAAGAGAAACGTCAATAGGGTCATGAT-
TTTTTTGG 
Control antisequence:  
AATTCCAAAAAAATCATGACCCTATTGACGTTTCTCTTGAAAACGTCATAGGGTCA-
TGATTGG 
The annealing of these two complimentary oligonucleotides sequences created two sticky ends that 
matched the insertion site, determined by the use of the two restriction enzymes EcoRI and BglII. 
In this study the pMSCV PIG plasmid was used. This plasmid contains a gene encoding ampicillin 
resistance, which can be used to differ between those bacteria, which have taken up the plasmid 
from those who have not. This is possible because only those who have taken up the plasmid are 
capable of growth on agar plates containing ampicillin. Equivalently the plasmid also contains a 
gene for puromycin resistance, which is used to distinguish between the cells that have been infect-
ed by the viral medium containing the plasmid, and those that have not. Lastly, the plasmid contains 
a gene for green fluorescence protein (GFP), which is used as an indicator of the success of the 
transfection, infection, and selection doing part 2 of this study. GFP is a protein consisting of 238 
amino acids, which will light up when exposed to light in the blue or ultraviolet spectra. Therefore 
when cells containing GFP is placed under a microscope then green light will be observed51.  
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The plasmid created in this study, is seen on Figure 13 and will be referred to as the control plas-
mid.  
 
Figure 13 shows the control plasmid created during this study. The plasmid contains genes for ampicillin and pyromycin resistance, 
seen as amp marker and puro marker in orange. The possible restriction sites are marked in blue. The inserted sequence is marked 
in pink. The plasmid also contains a gene for green fluorescence protein, EGFP reporter, marked in purple. The plasmid contains 
more sites of different kinds, but they have been neglected on this figure, because they are not of importance in this study52 (Modi-
fied).  
The other two plasmids used are the pMSCV PIG plasmid containing the mature miR-29a se-
quence, and the pMSCV PIG plasmid, which has not been modified. These plasmids are called the 
miR-29a plasmid and the empty plasmid respectively, see Figure 14 and Figure 15 on the following 
pages.  
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Figure 14 shows the empty pMSCV PIG plasmid of 7657bp. The plasmid has several restriction sites, which are marked in dark blue. 
Furthermore, it contains genes for various resistances and a gene for green fluorescence protein (EGFP). All of which are marked in 
red. All of these features will be used in this study. The plasmid contains more sites of different kinds, but they have been neglected 
on this figure, because they are not of importance in this study53.  
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Figure 15 shows the miR-29a plasmid created by Ph.D student Julian Geiger, Roskilde University. The plasmid contains genes for 
ampicillin and pyromycin resistance, seen as amp marker and puro marker in orange. The possible restriction sites are marked in 
blue. The inserted sequence is marked in black. The plasmid also contains a gene for green fluorescence protein, EGFP reporter, 
marked in purple. The plasmid contains more sites of different kinds, but they have been neglected on this figure, because they are 
not of importance in this study52. 
Annealing 
To ensure that the nucleotides of the insert had a 100% complimentary match of base pair, they 
were annealed.  
The two solutions containing either the single-stranded control sequence or control antisequence 
oligonucleotides were mixed together in a 1:1 ratio. The sample was then diluted with annealing 
buffer, consisting of 10mM Tris, 1mM EDTA, 50mM NaCl, and milli-Q water, with pH = 8.0, 
yielding a final DNA concentration of 1pmol/µL. The solution was incubated in boiling water for 5 
min. and cooled down to room temperature overnight (O.N.), before it was spun down and used for 
phosphorylation.  
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Phosphorylation 
Phosphorylation was performed to make the control sequence ready for ligation into the pMSCV 
PIG plasmid.  
2L annealed oligonucleotides were mixed with 1L T4 PNK buffer, 1L 10mM ATP, 5L milli-
Q water and 1L T4 PNK. T4 PNK is an enzyme that catalyses the transfer of Pi from ATP to 5´-
hydroxyl terminus of polynucleotides54. After mixing, it was incubated for 30 min. at 37°C, fol-
lowed by 10 min. incubation at 70°C. This raise in temperature was done to inactivate the T4 PNK 
enzyme. After the inactivation the solution was spun down and stored at -20°C. 
Restriction digestion 
The purpose of the restriction digestion was to linearize the plasmid and thereby prepare it for the 
insertion of the control sequence. Two restriction enzymes were used, BglII and EcoRI, which were 
chosen based on the pMSCV PIG plasmid, seen in Figure 14, obtained from addgene.org53.  
The restriction solution was made by mixing 1L BglII (10000U/mL), 0.5L EcoRI (20000U/mL), 
5L EcoRI buffer (10x stock), 40.5L milli-Q water, and 3g pMSCV PIG plasmid (3L). There-
after the sample was vortexed and spun down, and incubated for 60 min. at 37°C. For evaluation of 
the restriction digestion, an electrophorese was preformed, were the obtained DNA fragments were 
run on a 1% agarose gel, to separate them by size.  
Purification of DNA from gel 
The plasmid was purified from the agarose gel for further studies. This purification was performed 
using QIAquick Gel Extration kit (#28104) according to the manufacturer’s instructions. The prin-
ciple behind this kit is first to dissolve the gel pieces containing the DNA by adding solution buffer. 
Then the solution is incubated at 50C, followed by the addition of isopropanol. Isopropanol binds 
the DNA to the filter in the spin column used. When the DNA is bound, the sample is washed with 
wash buffer to remove contaminants. The DNA sample was eluted in 50µl elution buffer during the 
final step and subsequently stored at -20°C.   
Ligation 
In order to create the control plasmid the phosphorylated oligonucleotides are ligated with the line-
arized plasmid. 
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The ligation was performed using the Rapid DNA Ligation kit from Roche. 2L of phosphorylated 
oligonucleotides, 60ng linearized plasmid, and 2L DNA dilution buffer (5x) were mixed, followed 
by the addition of 10L ligase buffer and 1L ligase (5U/L). The sample was incubated for 5 min. 
at room temperature and subsequently stored at –20C. 
Transformation 
To amplify the amount of the circular control plasmid, it was transferred into competent Escherchia 
coli (E. coli) MT102 bacteria.  
In this procedure 5µl of the following plasmid solutions were added to three tubes containing 50µl 
thawed competent E. coli cells as shown: 
 Linearized plasmid, negative control (pMSCV PIG cut with BglII and EcoRI) 
 Circular plasmid, positive control (pMSCV PIG)  
 Control plasmid (pMSCV PIG with the control sequence inserted)  
The circular plasmid is the empty plasmid, which has not endured anything, whereas the linearized 
plasmid has been cut with BglII and EcoRI in a double digestion followed by purification.  
The samples were incubated for 30 min. on ice, followed by 45sec. in 42C and then returned to the 
ice for 2 min. After the heat shock, 900µL LB medium with 100µg/mL ampicillin were added, and 
the solutions were incubated for 60 min. at 37C. Following the incubation, 20µL of each sample 
were added to separate agar plates containing ampicillin (100mg/mL) and incubated O.N. at 37C. 
Two additional plates were prepared containing either 200µL of the control plasmid or 20µL of the 
competent cells. The five types of plates are shown in Figure 16. 
 
Figure 16 shows the different samples made during the transformation. The plate called 200µL control plasmid and the plate 20µL 
called control plasmid contained respectively 200µL and 20µL of the transformation sample with the control plasmid. The plate 
called Negative control was added linearized pMSCV PIG plasmid, which had been cut with the two restriction enzymes BglII and 
EcoRI in a double digestion followed by purification. The plate called positive control, contained circular pMSCV PIG plasmid that 
had not endured anything. Lastly, the plate called 20µL competent cells contained the competent Escherchia coli cells that had not 
been transfected. 
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Due to an unknown concentration of the control plasmid, the transformation sample was plated out 
twice, 200µL or 20µL. This was done to ensure there would be a plate, which would be countable 
with single colonies 
Pick colonies for overnight culture 
Following the 24 hours of incubation, single bacterial colonies were picked from the agar plates for 
further experiments. Ten separate colonies were transferred with pipette tips to ten different tubes 
containing 5mL LB medium and 100µg/mL ampicillin. The samples were incubated at 37C O.N.  
Glycerol stock 
Glycerol stocks were made because it is the best way to conserve bacteria for a longer period. The 
glycerol protects the cells from bursting under very low temperatures55. The stocks were made by 
mixing 500µL 50% glycerol with 500µL medium from the O.N. culture, and then stored at -80°C. 
When the glycerol samples were used, a restrike was performed followed by purification of the 
plasmids.   
Plasmid preparation from bacteria  
During this study both a mini- and maxi-preparation (prep) were performed according to the manu-
factured guidelines using kits from Invitrogen and NucleoBond (Ref: K210011, REF: 740414.50). 
The general principle in these preparations is to first separate the bacteria from the medium, through 
centrifugation. The bacteria will thereafter be resuspended in a resuspension buffer followed by the 
addition of lysate buffer and neutralization buffer. This will ensure the bacteria are lysated and the 
DNA will be bound to the filter column, once the samples run through. While the DNA is bound to 
the filter, the sample is washed with wash buffer to elute contaminants. Finally, the filter column is 
moved to a new collecting tube before elution buffer is added to elute and collect the DNA.  
Afterwards NanoDrop Spectrophotometer ND-1000 can be used to measure concentration and puri-
ty of the sample. NanoDrop is a spectrophotometric analysis, which in the case of RNA or DNA 
relies on nucleic acids absorbing ultraviolet light at a wavelength of 260nm. The purity is deter-
mined by a ratio between the absorbance at 260nm and 280nm. At 260nm nucleic acids, or more 
precisely ribose, absorb the light. At 280nm amino acids absorb the light. The amino acids absorb-
ing are phenylalanine, tyrosine, and tryptophan, thus those with an aromatic ring. A ratio of ~1.8 is 
generally accepted as “pure” when looking at a DNA sample56. For RNA a ratio of ~2.0 is consid-
ered pure. A ratio lower than 1.8, in the case of measuring purity in DNA samples, may indicate the 
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presence of contaminants, such as protein, phenol or other contaminants that absorb strongly at or 
close to 280nm56.  
Restriction analysis  
Restriction analysis was done to ensure the plasmid had taken up the gen of interest, and further-
more that the plasmid obtained doing the purification was in fact the control plasmid. 
In this study, varies restriction analyses were performed, changing the enzymes, incubation time, 
and/or buffer. The various digestion analyses can be seen in Table 2. For the complete procedure of 
each analysis, see appendix B.    
Table 2 shows the various restriction analyses performed. A total number of six restriction digestions were done, using different 
restriction enzymes, incubation time, and/or buffer. In restriction number 1, both of the enzymes were added at the same time. In 
restriction number 3, RNAse free water was used instead of the previously used milli-Q water. In restriction number 4, new plasmid 
samples were used. These plasmid samples were obtained after a restrike of the original glycerol stocks. In restriction number 6 a 
purification was preformed between the two digestions. 
RESTRICTION 
NUMBER 
ENZYME 1 
(20000U/ML) 
INCUBATION ENZYME 2 
(10000U/ML) 
INCUBATION BUFFER 
(10X CONCEN-
TRATE) 
1 1µLAgeI   0.5µL Bg1II  1 hour 37C EcoRI 
2 1µL NdeI  1 hour 37°C 1µL BsaBI  1 hour 60C CutSmart  
3 1µL NdeI  1 hour 37C 1µL BsaBI  1 hour 60C CutSmart  
4 1µL NdeI 1 hour 37 C 1µL BsaBI  1 hour 60C CutSmart  
5 1µL NdeI 10 min. 37 C 1µL BsaBI  1 hour 60C CutSmart  
6 1µL NdeI  12 min. 37 C 1µL BsaBI  1 hour 60C NEBuffer 2  
 
Restriction analysis number 6 showed promising results, and was therefore, together with the results 
obtained from NanoDrop, examined to select which plasmid samples should be sent for sequencing. 
Sequencing  
Beckmann Coulter Genomics performed the sequencing of the control plasmids using a method 
called Chain Terminator Sequencing, also referred to as Sanger sequencing. The Sanger sequencing 
method is performed by first denaturing the double-stranded DNA of interest to single-stranded 
DNA by heat. The single-stranded DNA is then referred to as the template DNA. Then this DNA 
sample containing the DNA template is divided into four tubes, as seen in Figure 17 on the follow-
ing page, which each are containing one of the four fluorescent dideoxynucleotidetriphosphates 
(ddNTPs: dideoxyadenosine, -cytosine, -guanosine and –thymidine) together with all the four types 
of the normal deoxynucleotidetriphosphates (dNTPs), a primer, and a DNA polymerase, more pre-
cisely a Taq polymerase. 
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The primer will anneal to this single-stranded DNA template and be extended by the use of the Taq 
polymerase, until one of the four ddNTP is added. Since these lack the hydroxyl group at the 3´end 
it is not possible to extend any further. This results in various lengths of DNA stands, which can be 
separated according to size on a gel. The DNA sequence can thereafter be determined57.     
 
Figure 17 shows the principle behind Chain Terminator sequencing also referred to as Sanger sequencing. First, the double-
stranded DNA sample is denatured to a single-stranded template strand (A). Then a primer, complementary to the 3’end of the DNA 
template, is annealed (B). Next, four solutions are made, containing the template DNA annealed with the primer, a DNA polymerase 
and all the four types of free deoxynucletides (dATP, dTTP, dCTP and dGTP). One of the four types of the dideoxynucletides (ddTTP, 
ddCTP, ddATP or ddGTP) is added to one of the four solutions respectively. In these solutions the DNA sample is transcribed by the 
use of a DNA polymerase. The sample will be extended until one of the four dideoxynucleotide is added (C). The result is samples at 
various lengths, which will be separated on a gel, according to size (D)58(Modified). 
After receiving the sequence from Beckmann Coulter Genomics the sequence of the plasmid was 
compared to the control sequence through the use of Multi Sequence Alignment at ClustalW259.  
Plate out  
After having established which bacteria samples that contained the control plasmid, a restrike of 
one of successfully cloned the glycerol samples was performed on agar plates containing 100µg/mL 
ampicillin. The plates were incubated O.N. at 37C. Following incubation, 5mL of the O.N. culture 
were mixed in a tube containing LB medium and ampicillin with a final concentration of 
100µg/mL. This solution was also incubated O.N. at 37°C. Thereafter, this O.N. culture was trans-
ferred to a flask containing 250mL 100µg/mL ampicillin LB medium, which was incubated O.N. at 
37C. Then the plasmid could be purified from the culture, by the principles mentioned in the kit, 
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NucleoBond Xtra Maxi (REF: 740414.50). The purified control plasmid could then be transfected 
into the Phoenix cells (HEK293). 
Part 2 
When the control plasmid was successfully created, the creation of a cell line stably overexpressing 
miR-29a could be performed. This was done in two different sets of experiments, I and II. The 
overall principles are the same, but they have variations in order to compare them. These will be 
presented and discussed later. The two experiments were never mixed, so transfection I is used in 
infection I, which is for selection I. The same goes for experiment II. In experiment I the empty 
plasmid and the miR-29a plasmid are used, whereas in experiment II the same two, and the control 
plasmid are used.  
First, the different plasmids were transfected into different dishes containing Phoenix cells, which 
secreted a rodent retrovirus in to the medium they were kept in. This medium, containing the virus, 
could then be added to confluent C2C12 cells to infect them with one of the plasmids.  
During part 2 of the experiment, the cells were monitored using a Leica DM IRB microscope, 
which is an inverted microscope. This means that the light source together with a condenser is 
placed on the top, and thus the object is lighted from above. The Leica DM IRB microscope used in 
this study is distinctively designed to use to cell culture experiments60. 
Because the pMSCV PIG plasmid contains the GFP, the fluorescence of the cells is used as an indi-
cation of how successful the transfection, infection, and selection were.  
Transfection 
To produce retroviral particles for ectopic expression, Phoenix cells were transfected with either the 
control plasmid, the empty plasmid, or the miR-29a plasmid, following incubation with PEI-25. The 
cells were cultured in Dulbecco`s Modified Eagle Medium (DMEM) containing 1mM pyruvate, 
4.5g/mL glucose, 10% fetal calf serum (FCS), and 5mL Penicillin/Streptomycin, and kept at 37C, 
5% CO2. The medium was changed after 24 and 48 hours. The supernatant (the medium), contain-
ing viral particles, was harvested after 48, 72 and 144 hours. 
The medium could then be used directly for infection of the C2C12 cells or stored. If chosen to be 
stored the medium had to be centrifuged in order to remove the precipitation. The viral medium was 
then stored at -80°C for later use.  
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The difference between transfection I and transfection II was the harvest of the viral medium. In 
transfection I the medium was harvested twice and frozen, and only used fresh in the infection pro-
cedure once. The medium harvested from transfection II was used fresh and directly in the infection 
procedure both times.  
Infection of C2C12 cells 
Before infection, the C2C12 cells, ~10000 cells per dish, was cultured in DMEM containing 10% 
FCS and 5mL Penicillin/Streptomycin, and kept in 37°C, 5% CO2. 24 hours after the first infection, 
the medium was replaced with a 1:1 ratio of serum-free medium and fresh viral medium mixed with 
polybrene. The fresh medium containing the virus was made by first filtering the medium to remove 
potential dead cells, and then mixing with polybrene (5mg/mL), before adding it to the C2C12 cells.  
In infection I, eight dishes of 10cm containing C2C12 cells, were infected as seen in Figure 18. 
 
Figure 18 shows the eight 10cm dishes containing ~10000 C2C12 cells per dish used in infection I. Dish A and B are selection dish-
es, containing only the C2C12 cells. Dish C and D contains C2C12 cells, which have been infected two times with the rodent retrovi-
rus containing the miR-29a plasmid. Dish E contains C2C12 cells, which have been infected only once with the rodent retrovirus 
containing the miR-29a plasmid. Dish F and G contains C2C12 cells, which have been infected 2 times with the rodent retrovirus 
containing the empty plasmid with no insert. Finally, dish H contains C2C12 cells, which have been infected only once with the 
rodent retrovirus containing the empty plasmid with no insert. The C2C12 cells which have been infected twice, were infected first 
with fresh viral medium and secondly with thawed viral medium. The infections were performed with a 24 hours intermediate. 
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In infection II, four dishes of 10cm, containing C2C12 cells, were infected, as seen in Figure 19. 
 
Figure 19 shows the four 10cm dishes containing ~10000 C2C12 cells per dish used in infection II. Dish A is a selection dish, con-
taining only the C2C12 cells. Dish B contains C2C12 cells, which have been infected two times with the rodent retrovirus containing 
the miR-29a plasmid. Dish C contains C2C12 cells, which have been infected two times with the rodent retrovirus containing the 
control plasmid. Finally dish D contains C2C12 cells, which have been infected two times with the rodent retrovirus containing the 
empty plasmid. The infections were performed with a 24 hours intermediate. 
For infection I only four of the eight 10cm dishes were re-infected. The four dishes were randomly 
chosen for a second infection. Once again, the addition of medium was done in a 1:1 ration between 
new medium and viral medium mixed with polybrene (5mg/mL) however, this time the viral medi-
um was not fresh, but instead thawed. The medium had been harvested 48 hours after the first trans-
fection. 
For both infection procedure I and II, the infections were performed with a 24 hours intermediate. 
For infection II, all three dishes already infected, were infected again with fresh viral medium in a 
1:1 ratio between viral medium and polybrene and new medium.  
For both infection procedure I and II, the infections were performed with a 24 hours intermediate. 
Selection 
120 hours after the first infection, selection of the C2C12 cells were executed to kill the cells, which 
had not obtained a form of the pMSCV PIG plasmid in both experiments I and II. 
B 
miR-29a 
infectedx2 
	
D 
Empty 
plasmid 
infectedx2 
	
C 
Control 
infectedx2 
	
A 
Selection 
	
   
Page 36 of 128 
 
The selection of C2C12 cells were done by changing the medium to DMEM containing 2µg/mL 
puromycin. The cells were kept in this medium at 37C, 5% CO2 until all cells in the selection dish, 
containing non-infected C2C12 cells, were dead.  
Results 
During this experiment, various results were obtained. Some are presented here, and the rest can 
be seen in the appendix A. This section will only present the results, for a discussion of them, see 
the discussion.  
Creation of control plasmid 
Figure 20 shows the successful cutting of the pMSCV PIG plasmid with the restriction enzymes 
BglII and EcoRI. The plasmid is 7657bp, and cutting with the two restriction enzymes results in a 
linearized plasmid of 7639bp seeing as the enzymes cut at 1410bp and 1428bp respectively. By 
using two restriction enzymes, it is ensured that the plasmid cannot realign on its own. Figure 20 
shows the result of a gel electrophoresis of the cut plasmid. Bands are seen with a size of ~7600bp, 
as indicated by the use of Gene Ruler 1kb plus ladder (#SM1333), see appendix C for ladder. This 
is as expected, indicating the plasmid has been cut as wanted. Due to the volume of the restriction 
digestion sample, it was divided into eight wells.  
 
Figure 20 shows the pMSCV PIG plasmid cut with the restriction enzymes BglII and EcoRI. The sample has been run on a 1% aga-
rose gel for 140 min at 50V and 15 min at 100V. The ladder used is Gene Ruler 1kb plus ladder (#SM1333). 
The linearized plasmid was then purified from the gel, yielding a concentration of 9.85ng/μL 
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Transformation 
The success of a transformation is indicated by the growth of bacteria colonies on the selected agar 
plates. Because the plasmid used, contains a gene encoding ampicillin resistance, only the bacteria 
that had taken up the plasmid, are capable of growing on the agar plates containing ampicillin. The 
amount of colonies on the plates is thus an indication of the success of the transformation. The suc-
cess of the transformation between E. coli and various versions of the pMSCV PIG plasmid can be 
seen on Figure 21, for bigger pictures see appendix A. The number of colonies on each plate are 
listed in Table 3. 
Table 3 lists the results of the different transformation samples, which were plated out on agar plates containing ampicillin 
(100µg/mL). Five different plates were made, with four different solutions.  
PLATE TRANSFORMATION SAMPLE VOLUME NUMBER OF COLONIES 
A Control plasmid 200μL ~95 
B Control plasmid 20μL 7 
C Negative control, linearized plasmid 20μL 20 
D Positive control, circular plasmid 20μL ~600 
E Only competent cells 20μL No colonies 
 
 
Figure 21 shows the agar plates with the different transformation samples. Plate A has been added 200μL of the control plasmid 
transformation sample. ~95 bacteria colonies were found on this plate. Plate B has been added 20μL of the control plasmid. On this 
plate 7 colonies are observed. Plate C is the linearized plasmid without insert, also referred to as the negative control. Plate D is the 
positive control, which is the circular empty plasmid. On plate C 20 colonies are observed and on plate D ~600 colonies are ob-
served. Plate E is the plate containing the competent Escherichia coli cells without any plasmid. No colonies are observed on this 
plate. Plate C, D, and E are each added 20μL (Modified). 
Plate A as seen on Figure 21 has been added 200μL of the ligated plasmid transformation sample. 
~95 colonies were observed on this plate. Plate B contains the same transformation sample, but the 
plate was only added 20μL. Therefore, as expected, this plate contains approximately a tenth of the 
colonies observed on plate A. More precisely, the plate showed seven colonies. Plate C is the nega-
tive control. On this plate linearized plasmids have been used in the transformation, 20 colonies 
were observed. Plate D is the positive control with the circular plasmid. On this plate ~600 colonies 
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were observed. Lastly, plate E is a plating of the competent E. coli cells. On this plate no growth 
was expected, because the cells are not capable of growing on the ampicillin infused plates, if they 
had not taken up the plasmid with the ampicillin resistance. 
Mini preparation 
In order to use the plasmids, following the transformation, they need to be extracted from the bacte-
ria. This is done through a mini prep as explained in the method section. The result from the first 
round of mini prep can be found in the appendix A. Due to ambiguous results from the following 
restriction analysis the mini prep was repeated, which yielded plasmid concentrations, as listed in 
Table 4. These are the samples used throughout the project.  
Table 4 shows the result of the mini preparation volume II. The table lists the concentration in ng/μL and the 260/280 ratio of the ten 
samples. The values were obtained using NanoDrop spectrophotometer ND-1000.  
PLASMID 
SAMPLE 
CONCENTRATION 
[NG/µL] 
260/280 
RATIO 
1 141.7 2.22 
2 51.4 1.99 
3 111.6 1.96 
4 65.4 1.98 
5 83.3 1.95 
6 59.3 2.04 
7 62.1 1.93 
8 138.0 1.96 
9 72.9 1.97 
10 201.2 2.01 
 
The 260/280 ratio is desired to be between 1.8 and 2.0. This is the case for seven of the ten samples. 
The concentration varies from 51.4ng/μL to 201.2ng/μL, as seen in Table 4.  
Restriction analysis 
The restriction analysis was done multiple times with various types of digestions, using different 
enzymes and buffers, and a new mini prep following a restrike of the glycerol stocks, because of 
ambiguous results. For the results and the procedures, see appendix A and B. The results of the 
sixth and final digestion can be seen in Figure 22 and Figure 23. This result was reasoned satisfacto-
ry. A successful cutting with the two restriction enzymes, BsaBI and NdeI would have resulted in 
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fragments with a size of 5738bp and 1965bp, which are easily distinguishable. However, the result 
was not as excepted as seen in Figure 22 and Figure 23 on the following page.  
 
Figure 22 shows the result of the restriction analysis #6 preformed on the nine plasmid samples. The restriction enzymes used in the 
analysis were NdeI and BsaBI. The gel shows two out of the four different analysis samples. Well A1 is added the 1 kb plus DNA 
ladder (#SM1333).Well A2-A10 contains the control plasmids, which have been through a double digestion with both NdeI and 
BsaBI with a purification step in between. Well A12-A20 are added the samples, which have been through a digestion with only 
BsaBI. Each sample was added loading dye and the gel was run 60 min. at 120V (Modified). 
 
Figure 23 shows the result of the restriction analysis #6 preformed on the nine plasmid samples. The restriction enzymes used in the 
analysis were NdeI and BsaBI. The gel show two out of the four different analysis samples. Well B1 is added the 1 kb plus DNA 
ladder (#SM1333). Well B2-B10 are added the samples, which have been cut with only NdeI followed by purification. In the last set 
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of wells, B12-B20, the control plasmids were added. Each sample was added loading dye and the gel was run on a 1% agarose gel 
for 60 min. at 120V (Modified). 
Sequencing 
The only way to make entirely sure the plasmid and the control sequence have been ligated properly 
together is to sequence the samples. The five samples showing promising results on the gel, well 
A5, A6, A7, A8, and A9 in Figure 22, were sent to Beckmann Coulter Genomics in England and 
sequenced using Sanger Sequencing. The result of this sequencing was three complete matches in 
both directions and two that did not show complete matches. The sequencing result for sample 5 in 
the forward direction can be seen in Figure 24. Figure 25 shows the result of the sequencing in the 
reverse direction. Both show a complete match to the inserted sequence, indicated by the aster-
isk dots, meaning that the cloning was successful and the ligated plasmid had been created as de-
sired.  
The analysis of the sequencing is done using the Multi Sequence Alignment at ClustalW259. See 
appendix A for the remaining four sequencing results.  
 
Figure 24 shows the sequencing result of sample 5 in the forward direction. A match is indicated by an asterisk dot, meaning that this 
cloning was successful and the control plasmid has been created as desired.  
 
Figure 25 shows the result of the sequencing of sample 5 in the reverse direction. A match is indicated by an asterisk dot, meaning 
that this cloning was successful and the control plasmid has been created as desired. 
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Transfection  
By transfecting the Phoenix cells it was possible to create a rodent retrovirus containing one of the 
desired plasmids.  
Transfection I 
In this transfection, the Phoenix cells were either transfected with the miR-29a plasmid, the empty 
plasmid, or nothing.  
The result of the transfection of the Phoenix cells with the miR-29a plasmid can be seen in Figure 
26, while Figure 27 on the following page, shows the result of the transfection with the empty 
plasmid. Figure 28 on the following page, is the selection dish, which had not been transfected and 
is used prove that the cells did not fluoresce on their own. All pictures are taken 24 hours after the 
transfection.  
Each of the three figures shows two images of the same location of the dish. The left is a phase con-
trast image, while the right image is showing the fluorescing cells when exposed to ultraviolet (UV) 
light. The phase contrast image shows how many cells are in that area of the dish, while the fluores-
cence is an indication of how many of the cells have successfully been transfected, because only 
those will fluoresce.  
 
Figure 26 shows the result of the transfection I of Phoenix cells with the microRNA-29a (miR-29a) plasmid after 24 hours. Image A 
is a phase contrast, showing all the cells in that area of the dish, while image B shows the cells which fluoresce when exposed to 
ultraviolet light. The cells observed to fluoresce with a green light, are the cells which has successfully been transfected. 
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Figure 27 shows the result of the transfection I of Phoenix cells with the empty plasmid after 24 hours. Image A is a phase contrast, 
showing all the cells in that area of the dish, while image B shows the cells which fluoresce when exposed to ultraviolet light. The 
cells observed to fluoresce with a green light, are the cells which has successfully been transfected. 
 
Figure 28 shows the selection dish, from transfection I, which was not transfected. Image A is a phase contrast, showing all the cells 
in that area of the dish, while image B shows the cells when exposed to ultraviolet light. No fluorescence is observed. The pictures 
are taken 24 hours after the other dishes were transfected.  
On Figure 26 and Figure 27 an equal amount of fluorescing cells are seen, because they have both 
been exposed to a version of the pMSCV PIG plasmid. The cells seen on Figure 28 do not fluoresce 
because these cells have not been transfected. All three dishes show the same amount of cells.  
Transfection II 
During transfection II, an additional plasmid, the control plasmid, was used to transfect the Phoenix 
cells. The result of the various transfections can be seen in the following figures. Figure 29 shows 
the selection dish, which was not transfected. Figure 30 is the transfection with the empty plasmid, 
while Figure 31 shows the images from the transfection using the control plasmid. Figure 32 shows 
the result from the transfection using the miR-29a plasmid.  
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Figure 29 shows the selection dish, from transfection II, which was not transfected. Image A is a phase contrast, showing all the cells 
in that area of the dish, while image B shows the cells when exposed to ultraviolet light. No fluorescence is observed. The images are 
obtained 24 hours after the other dishes were transfected. 
 
 
Figure 30 shows the result of the transfection II of Phoenix cells with the empty plasmid after 24 hours. Image A is a phase contrast, 
showing all the cells in that area of the dish, while image B shows the cells which fluoresce when exposed to ultraviolet light. The 
cells observed to fluoresce with a green light, are the cells which has successfully been transfected. 
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Figure 31 shows the result of the transfection II of Phoenix cells with the control plasmid after 24 hours. Image A is a phase con-
trast, showing all the cells in that area of the dish, while image B shows the cells which fluoresce when exposed to ultraviolet light. 
The cells observed to fluoresce with a green light, are the cells which has successfully been transfected. 
 
 
Figure 32 shows the result of the transfection II of Phoenix cells with the microRNA-29a (miR-29a) plasmid after 24 hours. Image A 
is a phase contrast, showing all the cells in that area of the dish, while image B shows the cells which fluoresce when exposed to 
ultraviolet light. The cells observed to fluoresce with a green light, are the cells which has successfully been transfected. 
All four dishes are expected to show approximately the same amount of cells, whereas only the 
dishes from Figure 30, Figure 31, and Figure 32 are expected to show fluorescence, and in equal 
amounts. The first one was not transfected, and thus do not have the capacity to fluoresce. However, 
this is not observed. In the transfection of the Phoenix cells with the empty plasmid and the control 
plasmid more cells were observed than the transfection with the miR-29a plasmid. Therefore, an 
equal amount of fluorescence is not seen in the three different transfections, as seen in Figure 
30,Figure 31, and Figure 32. 
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Infection of C2C12 cells 
Following the creation of the rodent retrovirus with the plasmids, the C2C12 cells were infected 
with the virus as described in the method section.  
The result of infection II can be seen in the following figures. Infection I showed similar results, but 
those pictures were unfortunately not archived. Figure 33 shows the selection dish. The dish infect-
ed with the empty plasmid is seen in Figure 34. On Figure 35 the dish infected with the control 
plasmid is seen, and Figure 36 shows the dish infected with the miR-29a plasmid. Each dish is pho-
tographed 48 hours post infection.  
Like in the images obtained in the transfection procedures each figure consists of two images. The 
left is a phase contrast image, while the right image is showing the fluorescing cells when exposed 
to UV light.  
 
Figure 33 shows the selection dish, from infection II, containing the C2C12 cells, which have not been infected. Image A is a phase 
contrast, showing all the cells in that area of the dish, while image B shows the cells when exposed to ultraviolet light. No fluores-
cence is observed. The images are obtained 48 hours after the infection of the other dishes.  
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Figure 34 shows the infection II of C2C12 cells with the empty plasmid 48 hours after the first infection. Image A is a phase contrast, 
showing all the cells in that area of the dish, while image B shows the cells which fluoresce when exposed to ultraviolet light. No 
fluorescence is observed.  
 
 
Figure 35 shows the infection II of C2C12 cells with the control plasmid 48 hours after the first infection. Image A is a phase con-
trast, showing all the cells in that area of the dish, while image B shows the cells which fluoresce when exposed to ultraviolet light. 
No fluorescence is observed. 
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Figure 36 shows the infection II of C2C12 cells with the microRNA-29a plasmid 48 hours after the first infection. Image A is a phase 
contrast, showing all the cells in that area of the dish, while image B shows the cells which fluoresce when exposed to ultraviolet 
light. No fluorescence is observed. 
Each of the four figures are expected to show approximately the same amount of cells in image A, 
but only Figure 34, Figure 35, and Figure 36 are expected to show fluoresce in image B. However, 
this is not the case, no fluorescence is seen and furthermore fewer cells are observed on the selec-
tion dish, seen in Figure 33, compared to the other three dishes. 
Selection 
The selection of the C2C12 cells was done using puromycin. Because the pMSCV PIG plasmid 
encodes a puromycin resistance gene, adding puromycin will result in the death of those cells, 
which had not been infected with the rodent retrovirus containing a version of the plasmid.  
Selection I of C2C12 cells 
The results of selection I can be seen in the figures below. Figure 37 shows the result of the selec-
tion in the selection dish. Figure 38 shows the result of the selection of the C2C12 cells, which had 
been infected twice with the rodent retrovirus containing the miR-29a plasmid. Figure 39 shows the 
result of the selection, of the dish containing C2C12 cells, which had only been infected once with 
the miR-29a plasmid. Figure 40 shows the result of the selection of the dish infected with the empty 
plasmid twice, while Figure 41 shows the result of the selection of the C2C12 cells only infected 
with the empty plasmid once. Like the images obtained previously in this study each of the five 
figures consists of two images. The left is a phase contrast image, while the right image is showing 
the fluorescing cells when exposed to UV light.  
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Figure 37 shows the selection dish, from selection I, with C2C12 cells 96 hours after the first selection. Image A is a phase contrast, 
showing all the cells in that area of the dish, while image B shows the cells when exposed to ultraviolet light. No fluorescence is 
observed. The images are obtained 48 hours after the infection of the other dishes. 
 
Figure 38 shows C2C12 cells, after selection I, 96 hours after the first selection. The C2C12 cells on the image have been infected 
twice, with fresh and frozen medium containing miR-29a virus, with a 24 hours intermediate. Image A is a phase contrast, showing 
all the cells in that area of the dish, while image B shows the cells which fluoresce when exposed to ultraviolet light. 
 
Figure 39 shows C2C12 cells, after selection I, 96 hours after the first selection. The C2C12 cells on the image have been infected 
once, with fresh medium containing miR-29a virus, with a 24 hours intermediate. Image A is a phase contrast, showing all the cells 
in that area of the dish, while image B shows the cells which fluoresce when exposed to ultraviolet light. 
   
Page 49 of 128 
 
 
Figure 40 shows C2C12 cells, after selection I, 96 hours after the first selection. The C2C12 cells on the image have been infected 
twice, with fresh and frozen medium containing the empty plasmid, with a 24 hours intermediate. Image A is a phase contrast, show-
ing all the cells in that area of the dish, while image B shows the cells which fluoresce when exposed to ultraviolet light. 
 
 
Figure 41 shows C2C12 cells, after selection I, 96 hours after the first selection. The C2C12 cells on the image have been infected 
once, with fresh medium containing the empty plasmid, with a 24 hours intermediate. Image A is a phase contrast, showing all the 
cells in that area of the dish, while image B shows the cells which fluoresce when exposed to ultraviolet light. 
Only Figure 38, Figure 39, Figure 40, and Figure 41 are expected to show cells, and potentially flu-
oresce if the infection was successful. Figure 37 was not infected, and functions as a control dish to 
compare the selection process.  
Because all the cells on the selection dish were not dead yet, the selection process was continued. 
After an additional 48 hours all the cells on the selection dish were dead, indicating the selection 
had finished. However, the same were observed on the other dishes which had been infected, indi-
cating that the infection was not successful, see appendix A.  
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C2C12 selection II 
The results of selection II can be seen in the following figures. Figure 42 shows C2C12 cells in the 
selection dish, which was not expected to survive the selection, because they had not been infected. 
Figure 43 shows the result of the selection of the C2C12 cells infected with the rodent retrovirus 
containing the empty plasmid, while Figure 44 on the following page, shows the result of the selec-
tion of the C2C12 cells infected with the control plasmid. Lastly, Figure 45 on the following page, 
shows the selection of the C2C12 cells infected with the miR-29a plasmid. All pictures are obtained 
60 hours after the selection process was begun.  
 
Figure 42 shows the selection dish, from selection II, with C2C12 cells 60 hours after the first selection. Image A is a phase contrast, 
showing all the cells in that area of the dish, while image B shows the cells when exposed to ultraviolet light. No fluorescence is 
observed. 
 
Figure 43 shows C2C12 cells, after selection II, 60 hours after the first selection. The C2C12 cells on the image have been infected 
twice with fresh medium containing the empty plasmid, with a 24 hours intermediate. Image A is a phase contrast, showing all the 
cells in that area of the dish, while image B shows the cells which fluoresce when exposed to ultraviolet light. 
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Figure 44 shows C2C12 cells, after selection II, 60 hours after the first selection. The C2C12 cells on the image have been infected 
twice with fresh medium containing the control plasmid, with a 24 hours intermediate. Image A is a phase contrast, showing all the 
cells in that area of the dish, while image B shows the cells which fluoresce when exposed to ultraviolet light. 
 
 
Figure 45 shows C2C12 cells, after selection II, 60 hours after the first selection. The C2C12 cells on the image have been infected 
twice with fresh medium containing the microRNA-29a plasmid, with a 24 hours intermediate. Image A is a phase contrast, showing 
all the cells in that area of the dish, while image B shows the cells which fluoresce when exposed to ultraviolet light. 
None of the dishes showed fluorescence, and the amount of living cells varies on each dish. Be-
cause there are seen viable cells on the selection dish, in Figure 42, the selection is at this time not 
complete.  
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Discussion  
The results found, and moreover the methods used, through the experiment done in this study, will 
now be discussed. Furthermore, a short discussion of the possible role of miR-29a in diabetes is 
provided. 
In part 1 of the experiment a transformation was performed. On the resulting agar plates different 
amount of bacteria colonies were seen. This has to do with the concentration and the structure of the 
different plasmids. Linearized plasmids have a lower transformation efficiency than circular plas-
mid, and therefore the linearized sample, also referred to as the negative control, see plate C on Fig-
ure 21, page 37, does not show as many colonies as observed on the agar plate containing a circular 
empty plasmid, also referred to as the positive control, see plate D Figure 21. This result was as 
excepted. The reason why linearized plasmid can be used as a negative control is that it will poten-
tially be degraded by intracellular nucleases. Circular plasmids on the other hand, will remain in a 
steady state, and could so forth quickly begin replication after entering the cell61. 
However, 20 colonies were observed on the negative control plate. This could be due to an unsuc-
cessful restriction digestion of the plasmid. The plasmid is cut with the two restriction enzymes 
BglII and EcoRI. It is not of interest to cut with only one restriction enzyme, because it creates 
complementary ends and the plasmid would therefore reform on its own. If this digestion was un-
successful, it is plausible that the plasmid would reform and become circular. It would therefore be 
better suited to be taken up by E. coli, thus making the bacteria ampicillin resistant. Hence the 20 
colonies on the plate, is probably a mix of realigned plasmids and linearized plasmids, which have 
not been degraded by intracellular nucleases as expected. The concentration of the linearized plas-
mid is 56.8ng/μL. The 260/280 ratio is 1.59 which is not very good, indicating that the sample is not 
entirely pure. This could further influence the transformation. 
More colonies are observed on the positive control, than on the plates added either 20μL or 200μL 
of the control plasmid, see plate A and B on Figure 21. The reason explaining this could be that the 
concentration of the circular empty plasmid in the positive control is much greater than the concen-
tration of the control plasmid. The empty plasmid has a concentration of 957.9ng/μL, and a 260/280 
ratio of 1.9, whereas concentration of the control plasmid is expected to be very low. The exact 
concentration of the control plasmid before the transformation is not known, however before the 
ligation procedure the concentration of the linearized control plasmid was 9.85ng/μL.  
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Following the transformation and purification, restriction analysis was performed to control whether 
the purified plasmid had taken up the desired sequence or not. 
Due to unexpected and indefinite results, the restriction analysis was performed several times with 
modified approaches; see Table 2, page 31, for the various digestions, or appendix B for the entire 
protocol. The enzymes used in the first restriction analysis, AgeI and BglII, had been stored in the 
freezer for an uncertain amount of time, and the unexplainable result, as seen in the appendix A, 
was for that reason thought to be because of their questionable function. Therefore, other enzymes 
were used in the second restriction analysis. These were NdeI and BsaBI.  These two restriction 
enzymes were chosen because of their predicted restriction sites. BsaBI has a restriction site inside 
the inserted control sequence, and NdeI has a site an appropriate distance away. Meaning that cut-
ting with those two restriction enzymes would make two clearly visible bands on the agarose gel. 
This is favourable because the control sequence is very small, and the difference between the plas-
mid with and without the control sequence is only 64bp. This is not separable on the gel. Using 
these two enzymes, we would instead expect the resulting gel electrophorese to show two clear 
bands, which would indicate that the ligation was successful. The double digest would only be suc-
cessful if the inserted sequence was in the plasmid. If the gel on the other hand only showed one 
band, it would indicate that the plasmid had not been cut. The one band seen on the gel would thus 
be uncut plasmids, which had not taken up the control sequence.  
However, the result of the second restriction analysis was not as expected. After doing the digestion 
with the new enzymes, and running the sample on a gel electrophoresis, smears were observed, see 
Figure 46 on the following page. 
The results of the second restriction analysis was thus the same as the first restriction analysis, both 
showing a gel with an unclear smear and no clearly visible bands.  
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Figure 46 shows the result of the second digestion analysis, using the two restriction enzymes NdeI and BsaBI. Ten samples were run 
on a 1% agarose gel. Well A1 is added the 1 kb plus DNA ladder (#SM1333).Well A2-A12 contains the control plasmids, which have 
been through a double digestion with both NdeI and BsaBI. Sample 2 is added to both A3 and A4. Each sample was added loading 
dye and the gel was run 60 min. at 120V (Modified). 
Following these two failed restriction analyses a possible contamination was hypothesised as being 
the reason for the unexpected results. Therefore the previously used milli-Q water was replaced 
with new RNase free water in the following third restriction analysis, as seen in Table 2. Possible 
RNase in the previously used milli-Q water would cut the plasmid without specificity, and thus cre-
ate samples which had been cut into tiny pieces. However, the results from this third restriction 
analysis gave rise to results similar to the previous two, where the smears were still present. See 
appendix A for the picture. Therefore a contamination of the milli-Q water was excluded. Addition-
al restriction analyses were done, with a repetition of the mini-prep and changed incubation time, 
but it all resulted in smears on the gel similar to Figure 46. 
The CutSmart buffer was replaced with a NEBuffer 2, in which both NdeI and BsaBI had 100% 
efficiency as well. In order to find the origin of the smear, four different restriction analyses were 
performed with the NEBuffer 2. One was performed individually for each of the two enzymes, 
while also doing a double digestion with an additional purification in-between. Furthermore, the 
undigested ligated plasmid was run on the gel. The result of this digestion, as seen in Figure 
22Figure 23, page 39, was still not as expected, the gel showed more than the two expected bands. 
However, this restriction analysis was still concluded successful because no or very little smear was 
observed. The undigested control plasmid showed no smear, and neither did the result of the NdeI 
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digestion, but both the double digestion and the BsaBI digestion did. Thus, we could conclude that 
BsaBI might be the restriction enzyme that caused the smear. Such a smear could be due to BsaBI 
having lost its specificity for unknown reasons and cut the plasmid randomly, also known as star 
activity.  
Star activity is a condition where restriction enzymes loose or alter their specificity. This occurs 
when the enzyme is present in a solution that differs significantly from what the enzymes optimally 
prefers62. Normally star activity happens if one or more of the following situations occurs: the ionic 
strength is low, pH is high, if the glycerol concentrations is high (>5%), if the reaction time is pro-
longed, the enzyme to DNA ratio is too high resulting in over digestion or if the buffer used does 
not suit the enzymes62.  In this study the combination between the CutSmart buffer and BsaBI could 
be the reason for the smear because of possible star activity. Both enzymes and buffers used in all 
but the first restriction digest are bought from New England Biolabs Inc. The firm warns that BsaBI 
may result in star activity, if the digestion is extended further than the recommended 60 min. at 
60C63. There is no reason to believe that any of the other listed circumstances occurred during the 
restriction analyses.  
However, the desired two bands do not show in the sixth restriction analysis. This could be because 
the plasmids have supercoiled and thus are incapable of being cut. The bands look similar on Figure 
22 and Figure 23, page 39, no matter what restriction enzymes were used, indicating the control 
plasmid cannot be cut. In other cases this could have been avoided by adding more of the restriction 
enzymes or running the digestion longer, so that the enzymes had more time to uncoil the plasmid 
and cut it.  
In part 2 of the experiment infections were performed. In infection I some cells were infected once, 
and others twice. The cells infected once, were only infected with fresh viral medium, whereas 
those infected twice were infected with both fresh and then frozen viral medium. This was done in 
order to investigate whether it would be possible to infect the cells efficiently only once. It is of 
interest to see if the cells can be successfully infected, only doing it once, because each time the 
infection procedure is performed the cells will be brought from the 37°C, 5% CO2 incubator, to the 
laminar flow cabinet (LAF) bench, and therefore be exposed to the environment, and risk contami-
nations. 
As mentioned in the result section, none of the cells showed fluorescence 24 or 48 hours after infec-
tion, but in selection I it was seen that the cells fluoresced once the selection was begun. Looking at 
   
Page 56 of 128 
 
the various dishes infected with the miR-29a plasmid, see Figure 38 and Figure 39, page 48, it is 
clear that we see a difference in the fluorescence of the cells infected once compared to those in-
fected twice. The same was observed for the dishes infected with the empty plasmid. No fluores-
cence was seen in the selection dish, which is as expected, because it was not infected, however 
there are still viable cells 96 hours after the selection was begun, see Figure 37, page 48 and for-
ward, thus the selection was continued. On both dishes infected twice, Figure 38 and Figure 40, 
there is seen a clear increase in the amount of cells compared to the dishes only infected once, see 
Figure 39 and Figure 41. While the cells in selection I does not look completely healthy, they do 
fluoresce, indicating that the infection was successful. Comparing the dishes infected once with 
those infected twice, there is evidence, in the form of fluorescence, suggesting that two infections 
are preferred to one.  
Through this study, it was furthermore investigated whether it would be of interest to use either 
fresh or frozen medium containing the rodent retrovirus, when infecting the C2C12 cell line. The 
idea was to compare infection I and II, but because the cells from infection II did not fluoresce, we 
will base our discussion on the results of infection I, with the proviso that the difference could have 
as much to do with the difference in times infected. 
When studying the different protocols for transfection using phoenix cells and further infection, it is 
recommended that one uses fresh medium. When the medium containing the virus of interest is fro-
zen its titer will drop by one-half each time it is frozen and thawed64,65. 
An advantage in using frozen medium is that it can be stored for later use. The first time the infec-
tion was performed, infection I, the C2C12 cells were first infected with fresh medium directly used 
from the phoenix cells. The condition of this medium was however questionable, because the medi-
um on the phoenix cells had not been changed for 96 hours, and thus contained a lot of dead cells. 
These same cells were infected a second time, 24 hours after the first infection, with medium which 
had been stored at -80°C. This medium had originally been obtained 48 hours after the transfection 
of the phoenix cells. Looking at the results of infection I, as seen on Figure 37-Figure 41, page 48 
and forward, and the previous part of this discussion, a clear difference was seen in the dishes in-
fected once compared to those infected twice. This indicates the use of frozen medium was not en-
tirely useless.  
While the frozen medium was useful in the infection, we can see by comparing experiment I and II 
that the cells in experiment II, looked much healthier. This is potentially due to the fact that they 
   
Page 57 of 128 
 
had been infected twice with fresh medium. Though this factor can also be attributed to the fact that 
the viral medium used in infection I had not been changed for 96 hours previous to the infection. 
The colour of the medium had changed to yellow, indicating the Phoenix cells were dead. While the 
medium was filtrated before it was used for infection, it cannot be excluded that some undesired 
substances was included in the infection procedure and have affected the health of the C2C12 cells. 
Furthermore, this raises the question as to why experiment II did not succeed in the infection, be-
cause the cells looked much healthier and they were more numerous.  
A possible answer to this might be because the C2C12 cells had not yet managed to express the 
GFP. Furthermore, as seen on the selection II dishes, as seen in the Figure 42 Figure 45, all the 
dishes infected with a plasmid, shows more cells in the phase contrast image than the selection dish 
did. This can be interpreted as the cells not yet having expressed the GFP, but having incorporated 
it, seeing as they are alive and the cells of the selection dish dies.  
Due to unfortunate circumstances, there cannot through this study be concluded on the use of frozen 
versus fresh medium and it furthermore cannot be definitively stated whether it is possibly to effi-
ciently infect the cells once. 
During this experiment, many methods have been used. One of which is transfection done to Phoe-
nix cells. There are in general two types of transfection methods; Transient and stable 
transfection66,67. In transient transfections, nucleic acids are introduced to the cells, which they will 
take up, however the nucleic acids will only exists in the cells for a limited period, because they are 
not integrated into the genome66. The other type is the stable transfection, where the material is in-
corporated into the genome. The cells will thus be capable of passing the foreign DNA on to their 
progeny67. In this study a stable transfection method was used. 
There are several subtypes to transient and stable transfection. The subtype of the stable transfection 
used in this study is called viral transfection. The advantage with viral transfection is its high gene 
delivery efficiency of 95-100%, and furthermore that it is a fairly simple method to perform. The 
disadvantage of viral transfection is that it is a labour intensive, and the best results are obtained, if 
only a single gene that is desired to be transfected. 
Another subtype of the stable transfection method is to transfect cells using a chemical-based trans-
fection, for example lipid-mediated transfection. This form of transfection makes the cell absorb 
genetic material via liposomes, which can merge with the cell membrane68. The advantage of using 
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lipid-mediated transfection are similar to those concerning viral transfection, but the disadvantages 
differs68. For example the disadvantage of lipid-mediated transfection is that not all cell types are 
able to be transfected using this method68. 
After transfection, the C2C12 cells were infected with the viral media obtained from the Phoenix 
cells to create a cell line stably overexpressing the desired gene. Another possible way to overex-
press a specific gene in a cell line is using the method called Nucleofector. The method is also 
called electroporation, and is a procedure where an electrical field is applied to cells in order to in-
crease the permeability of the cell membrane69,70. The permeability created makes the cells able to 
take up the sequence of interest. A study by Bagge et al., (2012) chose to nucleofect oligonucleo-
tides of miR-29a into β-cells. These olionucleotides were then taken up by the cell, and incorpo-
rated into the RISC complex, and was thus shortly overexpressed by the β-cells. 
One disadvantage of doing a nucleofection is the high amount of cell deaths caused by high voltage. 
Therefore, there is a need for a higher amount of cells than under a viral transfection. A second dis-
advantage is a partially successful membrane repair by the cell, post the transfection71. 
However, in regards to the method used in this study, the greatest disadvantage in using the Nu-
cleofector method is that it creates a cell line, which would only overexpress the miR-29a for a 
short period. This is due to the fact that the oligonucleotides are not incorporated into the genome of 
the cells. It could be of interest to overexpress a certain gene at a specific time in the cell cycle, 
however the aim of this study, was to create a cell line, which would stably overexpress miR-29a, 
and this is not possible if using the Nucleofector method. 
The reason why it is of interest to create one such cell line is that it could be used as a model in in-
vestigating the possible role of miR-29a in metabolism of muscle cells in regards to the develop-
ment of diabetes. 
It has been shown that some miRNAs are linked to insulin production and secretion20. Furthermore, 
some miRNAs have also been shown to be involved in controlling insulin signalling in target tis-
sues of insulin33,72. Together with these, and other studies showing miRNAs role in the regulation of 
insulin, a huge number of miRNAs related to glucose metabolism has been identified both in vivo 
and in vitro2,73. For example, in a study by Herrera et al., (2010), it was found that the expression 
patterns of different miRNAs were significantly altered in response to hyperglycemia. This study 
observed analogous patterns for three other miRNAs, in response to amplified glucose levels in 
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adipocytes. Together these findings suggest that the miRNAs could possible play a role in the de-
velopment of diabetes. One of the miRNAs examined by Herrera et al., (2010) was miR-29a73. 
A study by He et al., (2007) showed that the miR-29 family was up-regulated, when cells were ex-
posed to high levels of glucose and insulin. When the expression of the three types of miR-29 were 
up-regulated, the glucose uptake was decreased, compared to cells not up-regulating the miR-29 
expression. This led to a conclusion that miR-29 might target members of the insulin mediated up-
take of glucose40. 
Furthermore, it was found that the phosphorylation of protein kinase B (Akt), which is involved in 
the insulin mediated uptake of glucose, was significantly decreased when the miR-29 family was 
up-regulated compared to control cells. This led to a decrease in the intake of glucose to the cells. 
However, they found that Akt is not a direct target for the miR-29 family, and therefore it is an indi-
rect regulator of the phosphorylation of Akt40.  
Previous studies have investigated the specific roll of miR-29a20,39,40. But as seen the action of miR-
29a it is not completely clear and further research have to be done. The unclear action could be due 
to the possibility that there are many factors involved besides miR-29a and the fact that miR-29a 
only has an indirect effect on the metabolism as it is incident with the activity of Akt. It is therefore 
necessary to investigate which others factors could play a role and how they do so.           
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Conclusion 
Through this project the possibility of creating a C2C12 cell line which stably overexpresses miR-
29a has been investigated. In doing so, a control plasmid was first created. In the process of creating 
this control plasmid difficulties were found, perhaps pertaining to the use of the restriction enzyme 
BsaBI and the CutSmart buffer. It was found that it could cause star activity. 
Following the construction of the control plasmid, it was used together with the miR-29a plasmid 
and the empty plasmid in a transfection, infection, and selection procedures with C2C12 cells. 
Knowledge concerning the infection procedures was gained. It was found more efficient to infect 
the cells two times compared to one, based on the fluorescence observed by microscopy after the 
selection procedure. Furthermore, it was found that there are no significant difference in using fresh 
or frozen medium for infection of the cells. However, healthier cells were observed when infecting 
the C2C12 cells using fresh medium. Due to time limitations, it was not possible to fully investigate 
the efficiency of the infection, in experiment II, and thus whether the C2C12 cell line was capable 
of stably overexpressing miR-29a. 
Based on other studies there is a connection between miR-29a and diabetes. Therefore, had the 
C2C12 cell line been successfully created it could possibly be used in investigating miR-29a’s role 
in muscle cells, however more extensive studies are needed. 
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Future perspective  
This study aimed to find a possible way to establish a C2C12 cell line, which would stably overex-
press miR-29a. This cell line could then be used to examine miR-29a’s possible role in muscle me-
tabolism, and its possible role as a therapeutic biomarker in treating diabetes. 
Therefore, through further experiments we would have performed a real-time polymerase chain 
reaction (qPCR) on our cell line. A qPCR could be used to compare the expression of miR-29a with 
housekeeping genes. From these results, we would be able to determine the degree of which miR-
29a is overexpressed and find possible targets of miR-29a.  
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Abbreviation list  
Acetyl-Coenzyme A Acetyl-CoA 
Adenosine Diphosphate ADP 
Adenosine Triphosphate ATP 
Base pair bp 
Citric Acid Cycle CAC 
Deoxyribonucleic Acid DNA 
Dulbecco`s Modified Eagle Medium  DMEM 
Escherchia coli E. coli 
Ethylenediaminetetraacetic EDTA 
Exportin 5  Exp5 
Fetal Calf Serum FCS 
Flavin Adenine Dinucleotide FAD 
Glucose Transporter Type 2 GLUT2 
Glucose Transporter Type 4 GLUT4 
Green Fluorescence Protein  GFP 
Guanosine Triphosphate GTP 
Insulin Receptor Substrate 1 IRS-1 
Insulin Receptor Substrate 2 IRS-2 
Laminar flow cabinet LAF 
Maxi Preparation Maxi prep 
Messenger RNA mRNA 
Micro Ribonucleic Acid miRNA or miR 
Mini Preparation Mini prep 
Mitogen-activated Protein Kinase MAPK 
Nicotinamide adenine dinucleotide NAD+ 
Over night O.N. 
PhosphoInositide 3 Kinase PI3K 
Precursor microRNA Pre-miRNA 
Primary microRNA Pri-miRNA 
Processing Bodies P bodies 
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Protein Kinase B Akt 
Ribonuclease III enzyme  RNase III 
Ribonucleic Acid RNA 
RNA-induced silencing complex RISC 
Small interfering RNA siRNA 
TAR RNA binding protein TRBP 
Triacylglycerol TAG 
Type 1 Diabetes T1D 
Type 2 Diabetes T2D 
Ubiquione Q 
Ubiquinol QH2 
Untranslated Region UTR 
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Appendix A 
Results from restriction analyses 
 
Figure 47 shows the gel, which has been cut, in order to obtain the linearized plasmid after the restriction digestion with EcoRI and 
BglII to linearize the plasmid. 
 
 
Figure 48 shows the result of the gel electrophoresis after restriction analysis volume I. The digestion is performed using the re-
striction enzymes AgeI and BglII. 
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Figure 49 shows the result of the gel electrophoresis after restriction analysis volume II. The digestion is performed using the re-
striction enzymes NdeI and BsaBI. 
 
 
Figure 50 shows the result of the gel electrophoresis after restriction analysis volume III. The digestion is performed using the re-
striction enzymes NdeI and BsaBI. 
 
Figure 51 shows the result of the gel electrophoresis after restriction analysis volume IV. The digestion is performed using the re-
striction enzymes NdeI and BsaBI. 
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Figure 52 shows the result of the gel electrophoresis after restriction analysis volume V. The digestion is performed using the re-
striction enzymes NdeI and BsaBI. 
Results from the transformations 
 
Figure 53 shows the agar plate containing ampicillin with 200 μL of the ligated plasmid transformation sample. The plate showed 
~95 colonies after 24 hours incubation at 37°C. 
 
 
Figure 54 shows the agar plate containing ampicillin with 20 μL of the ligated plasmid transformation sample. The plate showed 7 
colonies after 24 hours incubation at 37°C. 
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Figure 55 shows the agar plate containing ampicillin with 20 μL of the linearized plasmid transformation sample, functioning as the 
negative control. The plate showed 20 colonies after 24 hours incubation at 37°C. 
 
 
Figure 56 shows the agar plate containing ampicillin with 20 μL of the circular plasmid transformation sample, functioning as the 
positive control. The plate showed ~600 colonies after 24 hours incubation at 37°C. 
 
 
Figure 57 shows the agar plate with 20 μL of the competent cells. The plate showed ~600 colonies after 24 hours incubation at 37°C. 
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Results from sequencing 
 
Figure 58 shows the sequencing result of sample 6 in the forward direction. A match is indicated by an asterisk dot. 
 
Figure 59 shows the result of the sequencing of sample 6 in the reverse direction. A match is indicated by an asterisk dot. 
 
Figure 60 shows the sequencing result of sample 7 in the forward direction. A match is indicated by an asterisk dot. 
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Figure 61 shows the result of the sequencing of sample 7 in the reverse direction. A match is indicated by an asterisk dot. 
 
Figure 62 shows the sequencing result of sample 8 in the forward direction. A match is indicated by an asterisk dot. 
 
Figure 63 shows the result of the sequencing of sample 8 in the reverse direction. A match is indicated by an asterisk dot. 
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Figure 64 shows the sequencing result of sample 9 in the forward direction. A match is indicated by an asterisk dot. 
 
Figure 65 shows the result of the sequencing of sample 9 in the reverse direction. A match is indicated by an asterisk dot. 
Results from transfections 
 
Figure 66 shows the result of the transfection of Phoenix cells with the empty plasmid in transfection I. The left image is a phase 
contrast, showing all the cells in that area of the dish, while the right image shows the cells which fluoresce when exposed to ultravi-
olet light. The images are obtained 48 hours after the first transfection. 
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Figure 67 shows the result of the transfection with the miR-29a plasmid in transfection I. The left image is a phase contrast, showing 
all the cells in that area of the dish, while the right image shows the cells which fluoresce when exposed to ultraviolet light. The 
images are obtained 48 hours after the first transfection. 
 
 
Figure 68 shows the fluorescence when exposed to ultraviolet light of the Phoenix cells of the selection dish, which was not trans-
fected. The image is taken in transfection I, 48 hours after the other dishes were transfected. 
 
 
Figure 69 shows the result of the transfection with the selection dish in transfection II. The left image is a phase contrast, showing all 
the cells in that area of the dish, while the right image shows the cells which fluoresce when exposed to ultraviolet light. No fluores-
cence is seen because the dish was not transfected. The images are obtained 48 hours after the first transfection. 
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Figure 70 shows the result of the transfection with the empty plasmid in transfection II. The left image is a phase contrast, showing 
all the cells in that area of the dish, while the right image shows the cells which fluoresce when exposed to ultraviolet light. The 
images are obtained 48 hours after the first transfection. 
 
 
Figure 71 shows the result of the transfection with the control plasmid in transfection II. The left image is a phase contrast, showing 
all the cells in that area of the dish, while the right image shows the cells which fluoresce when exposed to ultraviolet light. The 
images are obtained 48 hours after the first transfection. 
 
 
Figure 72 shows the result of the transfection with the miR-29a plasmid in transfection II. The left image is a phase contrast, show-
ing all the cells in that area of the dish, while the right image shows the cells which fluoresce when exposed to ultraviolet light. The 
images are obtained 48 hours after the first transfection. 
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Results from the infection 
 
Figure 73 shows the C2C12 selection dish in infection II. The left image is a phase contrast, showing all the cells in that area of the 
dish, while the right image shows the cells which fluoresce when exposed to ultraviolet light. No fluoresce is seen because the dish 
was not infected. The images are obtained 24 hours after the first infection. 
 
 
Figure 74 shows the C2C12 cells infected twice with the empty plasmid in infection II. The left image is a phase contrast, showing all 
the cells in that area of the dish, while the right image shows the cells which fluoresce when exposed to ultraviolet light. The images 
are obtained 24 hours after the first infection. 
 
 
Figure 75 shows the C2C12 cells infected twice with the control plasmid in infection II. The left image is a phase contrast, showing 
all the cells in that area of the dish, while the right image shows the cells which fluoresce when exposed to ultraviolet light. The 
images are obtained 24 hours after the first infection. 
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Figure 76 shows the C2C12 cells infected twice with the miR-29a plasmid in infection II. The left image is a phase contrast, showing 
all the cells in that area of the dish, while the right image shows the cells which fluoresce when exposed to ultraviolet light. The 
images are obtained 24 hours after the first infection.  
Results from selection 
 
Figure 77 shows the selection dish in selection I. The left image is a phase contrast, showing all the cells in that area of the dish, 
while the right image shows the cells which fluoresce when exposed to ultraviolet light. No fluoresce is seen because the dish was not 
infected. The images are obtained 120 hours after selection was begun. 
 
 
Figure 78 shows the selection dish in selection I. The left image is a phase contrast, showing all the cells in that area of the dish, 
while the right image shows the cells which fluoresce when exposed to ultraviolet light. No selection is observed, because the dish 
was not infected. The images are obtained 120 hours after selection was begun. 
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Figure 79 shows the C2C12 cells infected twice with the empty plasmid in selection I. The left image is a phase contrast, showing all 
the cells in that area of the dish, while the right image shows the cells which fluoresce when exposed to ultraviolet light. The images 
are obtained 120 hours after selection was begun. 
 
 
Figure 80 shows the C2C12 cells infected twice with the miR-29a plasmid in selection I. The left image is a phase contrast, showing 
all the cells in that area of the dish, while the right image shows the cells which fluoresce when exposed to ultraviolet light. The 
images are obtained 120 hours after selection was begun. 
 
 
Figure 81 shows the C2C12 cells infected twice with miR-29a in infection I. The left image is a phase contrast, showing all the cells 
in that area of the dish, while the right image shows the cells which fluoresce when exposed to ultraviolet light. The images are 
obtained 120 hours after selection was begun. 
   
Page 81 of 128 
 
 
Figure 82 shows the C2C12 cells infected twice with the miR-29a plasmid in selection I. The left image is a phase contrast, showing 
all the cells in that area of the dish, while the right image shows the cells which fluoresce when exposed to ultraviolet light. The 
images are obtained 120 hours after selection was begun. 
 
Figure 83 shows the C2C12 cells infected twice with miR-29a plasmid in selection I. The left image is a phase contrast, showing all 
the cells in that area of the dish, while the right image shows the cells which fluoresce when exposed to ultraviolet light. The images 
are obtained 168 hours after selection was begun. 
 
Figure 84 shows the C2C12 cells infected twice with miR-29a plasmid in selection I. The left image is a phase contrast, showing all 
the cells in that area of the dish, while the right image shows the cells which fluoresce when exposed to ultraviolet light. The images 
are obtained 168 hours after selection was begun. 
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Figure 85 shows the C2C12 cells infected once with the empty plasmid in selection I. The left image is a phase contrast, showing all 
the cells in that area of the dish, while the right image shows the cells which fluoresce when exposed to ultraviolet light. The images 
are obtained 168 hours after selection was begun. 
 
 
Figure 86 shows the C2C12 cells infected twice with the empty plasmid in selection I. The left image is a phase contrast, showing all 
the cells in that area of the dish, while the right image shows the cells which fluoresce when exposed to ultraviolet light. The images 
are obtained 168 hours after selection was begun. 
 
Figure 87 shows the C2C12 cells infected twice with the empty plasmid in selection I. The left image is a phase contrast, showing all 
the cells in that area of the dish, while the right image shows the cells which fluoresce when exposed to ultraviolet light. The images 
are obtained 168 hours after selection was begun. 
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Appendix B 
Protocol 
Annealing (1/10 – 2014)  
 First we placed 400mL water in a becher on heating plate and turned the heat on 
 Then we found the all the stuff needed including annealing buffer consistent of:  
o 10mM Tris  (1mL 1M Tris  per  100mL) 
o 1mM EDTA (1mL 0.1mM EDTA per 100mL) 
o 50mM NaCl  (1mL 5M NaCl per 100mL) 
o Add milli-Q water and adjust pH=8.0 
 Then we mixed the oligonucleotides consisting of the control sequence with equal amounts 
of the antisequence in an 0.5mL Eppendorf tube with safelock marked A for Annealed oli-
gonecleotides  
 The oligonucleotides was then diluted with annealing buffer to final concentration of 
1pmol/µL  
 Then the Eppendorf tube was placed in a foamholder to make it float and put in the boiling 
water for 5 min. 
  After 5 min. the heating plate was turn of, and the Eppendorf tube was left in the water until 
next day.  
 Next day the tube was spun down 
 
Phosphorylation (2/10 – 2014) 
 First we found the kit from the box in the LTD -20C freezer 
 Then mixed the flowing in 1.5mL Eppendorf tube, marked “P oligos” 
o 2 µL annealed oligonucleotides  
o 1 µL T4 PNK Buffer (forward) 
o 1 µL 10mM ATP  
o 5 µL H2O 
o 1 µL T4 PNK 
 The samples are vortexed and spun down 
 Then they were incubated 30 min at 37°C in waterbath 
 Lastly to inactivate them they were incubated 10 min at 70°C in heat block 
 Then they were spun down and put in our box in the -20°C freezer 
 
Restriction Digest (2/10 - 2014) 
 First we made the proper calculations to ensure how many μL plasmid were needed: 
 
m = 3μg 
c = 957.9ng/μL 
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𝑐 =
𝑚
𝑉
 ↔ 𝑉 =
𝑚
𝑐
 
𝑉 = (
3 ∙ 10−6𝑔
957.9 ∙ 10−9𝑔
) ∙ 10−6𝐿 = 3 ∙ 10−6𝐿 = 3𝜇𝐿 
 All materials from the freezer was retrieved 
 The following materials were mixed: 
o 40.5μL milli-Q 
o 3μL pMSCV PIG plasmid 
o 5μL EcoRI buffer 
o 0.5μL EcoRI 
o 1μL BglII 
 The total volume was 50 μL 
 The mixture was then incubated for 60 min. in a 37°C heating block 
 
Gel electrophoresis (2/10 - 2014) 
 In the meantime the 1% agarose gel was prepared  
 First 1g agarose (Multipurpose, JT-lab) is dissolved in 100 mL TAE-buffer by heating in a 
microwave oven 
 While it cooles down, the chamber was prepared 
 Then 3μL ethidium bromide (EtBr) was mixed with the dissolved agarose – NB: EtBr is 
highly intoxicating 
 The gel was poured in the chambers to be solidified 
 The now solidified gel was placed in the running chamber – The chamber was filled with 
TAE 1X until the wells were completely covered 
 The first well was loaded with 4μL ladder (Generuler 1kb) 
 The complete content of the of the mixture was added to the gel 
 The gel ran for 1 hour and 20 min. by 50V, and thereafter for 15 min. by 100V 
 
Gel extraction (2/10-2014) 
 The kit used in the procedure is Gel Extration kit QIAGEN 28704 
 First the four 1.5mL Eppendorf tubes were weighed (wearing gloves)  
 Then the other materials were collected 
 The gel was photographed  
 The gel was brought to the dark chamber, and the plasmid bonds were cut using a small 
scalpel 
 A new picture was taken  
 Then the four 1.5mL Eppendorf tubes were weighed again. The results are shown in the ta-
ble below 
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 Weight (mg) 
Eppendorf tube Tube ÷ gel Tube + gel Gel 
1 991.3 1152.5 161.2 
2 987.1 1104.6 117.5 
3 990.3 1207.9 217.6 
4 981.7 1122.2 140.5 
 
 Then solution buffer was added to each of the four Eppendorf tubes: 
o Tube 1 was added 484μL solution buffer 
o Tube 2 was added 353μL solution buffer 
o Tube 3 was added 653μL solution buffer 
o Tube 4 was added 422μL solution buffer 
 Then all four Eppendorf tubes were incubated in 49.7oC for 10 min. The tubes were mixed 
gently after 3 min. and then again after 8 min. 
 After the incubation the gel was completely dissolved and the mixture had a yellow colour 
 Isopropanol was then added to the four Eppendorf tubes: 
o Tube 1 was added 161μL isopropanol 
o Tube 2 was added 118μL isopropanol 
o Tube 3 was added 218μL isopropanol 
o Tube 4 was added 141μL isopropanol 
 Thereafter the four tubes was gently whirl mixed 
 The total volume was: 
o Tube 1 = 806μL  
o Tube 2 = 589μL  
o Tube 3 = 1089μL  
o Tube 4 = 704μL 
 The total volume of tube 1 plus 850μL from tube 3 was added together in to the filter of tube 
a 
 Filter tube a was then centrifuged for 1 min. at 17.9 G (=13000rpm) 
 The supernatant was discarded from filter tube a 
 The total volume of tube 2 plus the rest of the volume of tube 3 was added to filter tube b 
 The total volume of tube 4 was added to filter tube a 
 Then filter tube a and b was centrifuge for 1 min. at 17.9xG (=13000rpm) 
 The supernatant from both filter tubes was discarded 
 Filter tube a and b were both added 750μL wash buffer  
 Both filter tubes were centrifuged for 1 min. at 17.9xG (=13000rpm) 
 The supernatant from both filter tubes was discarded 
 Both filter tubes were centrifuged again for 1 min. at 17.9 G (=13000rpm) 
 The filter from both filter tube a and b were placed in two new Eppendorf tubes marked a’ 
and b’ 
 50μL Elution Buffer was added to both tube a’ and b’ 
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 Tube a’ and b’ were centrifuged together for 1 min. at 17.9xG (=13000rpm) 
 The filter from both tubes were discarded  
 The concentration of DNA in both tubes was measured using NanoDrop Spectrophotometer 
ND-1000 to make sure the plasmid was in fact in the samples.  
 Tube a’ and b’ were placed in the freezer at -20oC 
 
Ligation (3/10 - 2014) 
 The kit used is called Ligation kit Rosche diagnostic 11635 379001 
 The total volume of tube a’ was added to tube b’ 
 The concentration of the sample was measured using NanoDrop Spectrophotometer ND-
1000 
o The Elution buffer  
o Doing a double determination the concentration was measured to 10.0ng/mL and 
9.7ng/mL  
 The ligation kit was localized, as well as the tube marked “oligo p” (From freezer) 
 A new Eppendorf tube was marked “plasmid Julian” 
 Then 2μL of the mixture in the tube called “oligo p” was added to the tube called “plasmid 
Julian” 
 6μL from tube b’ was added to the tube called “plasmid Julian” 
 Then 2μL DNA dilution buffer was added to the mixture in “plasmid Julian” 
 The tube “plasmid Julian” was gently whirl mixed to make sure that the whole sample was 
in the bottom of the tube 
 10μL ligase buffer was added to the tube called “plasmid Julian” 
 1μL ligase was then added to the tube called “plasmid Julian” 
 The tube “plasmid Julian” was again gently whirl mixed to make sure that the whole sample 
was in the bottom of the tube – At the same time the clock was set 
 The mixture was incubated for 5 min by room temperature 
 The samples was then placed in the freezer at -20oC 
 
Transformation (7/10 - 2014) 
 All materials are found 
 Our own ligated plasmid (In the tube called “plasmid Julian”), competent E. coli cells, cut 
plasmid (pMSCV PIG cut with BglII and EcoRI) and the original empty plasmid (pMSCV 
PIG) was found in the freezer -20oC 
 2 new Eppendorf tube are marked with + and ÷ respectively 
 The competent cells are thawed 
 5μL uncut plasmid are added to tube +. This is our positive control 
 5μL cut plasmid are added to tube ÷. This is our negative control 
 The sample containing our ligated plasmid are marked with a “O” 
 The competent cells are now thawed 
 50μL of the competent E.coli cells are added to both tube +, ÷ and O.  
 All three mixtures was resuspended 
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 The three tube +, ÷ and O are placed on ice for 30 min. 
 In the meantime the LB medium are prepared 
 LB broth, a 1000 mL bottle and a measuring tube are found 
 10.11g LB Broth are added to the 1000mL bottle 
 Then 500mL distilled water are added to the 1000mL bottle  
 Then bottle is gently shaken 
 Autoclave tape are put on the top of the 1000mL bottle  
 On the 1000mL bottle is written “Julian LB med” 
 The bottle was placed besides the autoclave (It was running), and was autoclaved later that 
same day 
 The heating block was set at 42oC. 
 The three tubes was then done incubating 
 All three tubes was heat choked for 45 sec. in the 42oC warm heating block 
 The three tubes +, ÷ and O are then placed on ice for 2 min. 
 After 900μL LB medium are added to both tube +, ÷ and O 
 All three tubes are incubated for 60 min. at 37oC 
o A fourth tube was at the same time incubated. The tube contained competent E. coli 
– The tube is marked (*) 
 The work is now preformed sterile. Everything is cleaned with 70% ethanol before use. 
 Afterwards 5 agar plates containing ampicillin (100µg/mL) are found and marked: 
o Plate 1 is called “Kompetente celler (*)” 
o Plate 2 is called “Ligated prøve, 200μL” 
o Plate 3 is called “Ligated prøve 20μL” 
o Plate 4 is called “Minus control (÷)” 
o Plate 5 is called “Plus control (+)” 
 20μL of the tube called “+” is added to the plate called “Plus control (+)” 
 20μL of the tube called “÷” is added to the plate called “Minus control (÷)” 
 20μL of the tube called “*” is added to the plate called “Kompentente celler (*)” 
 20μL of the tube called “O” is added to the plate called “Ligated prøve 20μl” 
 200μL of the tube called “O” is added to the plate called “Ligated prøve 200μl” 
 The 5 agar plates are placed in the incubator O.N. at 37oC. 
 
Pick Colonies (8/10 - 2014) 
 All materials are found and brought to the immune laboratory 
 The 5 agar plates called “Kompetente celler (*)”, “Ligated prøve, 200μL”, “Ligated prøve 
20μL”, “Minus control (÷)” and “Plus control (+)”, are taken out of the 37oC incubator and 
examined and the colonies are counted 
o The plate called “Kompentente celler (*)” shows no colonies 
o The plate called “Minus control (÷)” shows 20 colonies 
o The plate called “Plus control (+)” shows around 600 colonies 
o The plate called “Ligated prøve 20μl” shows 7 colonies 
o The plate called “Ligated prøve 200μl” shows 95 colonies 
 Ten colonies are chosen from the two plates containing ligated samples. Five from the plate 
called “Ligated prøve 20μL” and five from “Ligated prøve 200μL” 
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 The work is then done sterile. Everything is cleaned with 70% ethanol before use 
 Calculations are done before the work is continued: 
o The concentration of the ampicillin is from stock 100mg/mL. We want the final con-
centration to be 100μg/mL 
 
C1 * V1 = C2 * V2  𝑉1 =
𝐶2∙𝑉2
𝐶1
 
𝑉1 =
50𝑚𝑙 ∙ 100𝜇𝐿/𝑚𝐿
100000𝜇𝑔/𝑚𝐿
= 0,05𝑚𝐿 = 50𝜇𝐿 
 50μL ampicillin are added to a 50mL measure tube 
 The tube is then filled with the LB media, (The one we made the day before) from the bottle 
called “Julian LB med”, to the 50mL mark 
 Ten 50mL tubes are marked 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10 respectively 
 Each of the ten tubes are added 5mL of the LB media containing ampicillin 
 Colonies from the plate called “Ligated prøve 20μL” are added to tube 1, 2, 3, 4 and 5 (One 
colony in each tube), using a pipettip 
 Colonies from the plate called “Ligated prøve 200μL” are added to tube 6, 7, 8, 9 and 10 
(One colony in each tube), using a pipettip 
 The ten tubes are incubated at 37oC O.N. gently shaken. 
 
Glycerol Stock (9/10 - 2014) 
 The procedure is done wearing gloves 
 The cryo tubes (Fabricant?) are marked with “konc.1”, “konc.2”, “konc.3”, “konc.4”, 
“konc.5”, “konc.6”, “konc.7”, “konc.8”, “konc.9” and “konc.10” respectively 
 All materials are brought to the immune laboratory 
 The ten tubes are taken out of the incubator at 37oC 
 The pipettips are removed from each of the ten 50mL tubes (The tubes called “1”, “2”, ”3”, 
“4”, “5”, “6”, “7”, “8”, “9” and “10” using a  
 500μL Glycerol (50%) (Fabricant?) is added to each of the ten cryo tubes 
 Then 500μlLof the mixture from the ten incubated tubes are added to each of the ten cryo 
tubes: 
o 500μL from tube 1 is added to the cryo tube called “konc.1” 
o 500μL from tube 2 is added to the cryo tube called “konc.2” 
o 500μL from tube 3 is added to the cryo tube called “konc.3” 
o 500μL from tube 4 is added to the cryo tube called “konc.4” 
o 500μL from tube 5 is added to the cryo tube called “konc.5” 
o 500μL from tube 6 is added to the cryo tube called “konc.6” 
o 500μL from tube 7 is added to the cryo tube called “konc.7” 
o 500μL from tube 8 is added to the cryo tube called “konc.8” 
o 500μL from tube 9 is added to the cryo tube called “konc.9” 
o 500μL from tube 10 is added to the cryo tube called “konc.10” 
 Each of the ten cryo tubes is gently mixed 10 times 
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 The ten cryo tubes are then placed in the -80oC freezer (Left lower corner, in a orange box 
called “SAMMN Julian miRNA”) 
 
Mini preparation (9/10 - 2014) 
 The kit used in this procedure is Invitrogen PureLink Quick Plasmid Mini Prep Kit Ref: 
210011 
 The whole procedure is done wearing gloves 
 Ten Eppendorf tubes are marked 1-10 
 Then 2mL of the mixture from the ten incubated tubes are added to each of the ten Eppen-
dorf tubes: 
o 2mL from tube 1 is added to Eppendorf tube 1 
o 2mL from tube 2 is added to Eppendorf tube 2 
o 2mL from tube 3 is added to Eppendorf tube 3 
o 2mL from tube 4 is added to Eppendorf tube 4 
o 2mL from tube 5 is added to Eppendorf tube 5 
o 2mL from tube 6 is added to Eppendorf tube 6 
o 2mL from tube 7 is added to Eppendorf tube 7 
o 2mL from tube 8 is added to Eppendorf tube 8 
o 2mL from tube 9 is added to Eppendorf tube 9 
o 2mL from tube 10 is added to Eppendorf tube 10 
 All ten Eppendorf tubes are centrifuge for 5 min. at 7500 rpm 
 The supernatant from all ten Eppendorf tubes are discarded 
 Again 2mL of the mixture from the ten incubated tubes are added to each of the tem Eppen-
dorf tubes: 
o 2mL from tube 1 is added to Eppendorf tube 1 
o 2mL from tube 2 is added to Eppendorf tube 2 
o 2mL from tube 3 is added to Eppendorf tube 3 
o 2mL from tube 4 is added to Eppendorf tube 4 
o 2mL from tube 5 is added to Eppendorf tube 5 
o 2mL from tube 6 is added to Eppendorf tube 6 
o 2mL from tube 7 is added to Eppendorf tube 7 
o 2mL from tube 8 is added to Eppendorf tube 8 
o 2mL from tube 9 is added to Eppendorf tube 9 
o 2mL from tube 10 is added to Eppendorf tube 10 
 All ten Eppendorf tubes are centrifuge for 5 min. at 7500 rpm 
 The supernatant from all ten Eppendorf tubes are removed by pipetting 
 The remaining content in the ten O.N. incubated tubes are discarded 
 250μL Resuspension Buffer (RB) is added to each of the ten Eppendorf tubes. The samples 
are homogenised 
 250μL lysis buffer (L7) is added to each of the ten Eppendorf tubes 
 The tem samples are gently inverted 5 times 
 The ten samples are incubated at room temperature for 5 min. at room temperature 
 350μL plecipation buffer (N4) are added to each of the ten Eppendorf tubes, and the Eppen-
dorf tubes are immediately inverted until the samples were homogenised 
 All ten Eppendorf tubes are centrifuge together for 10 min. by 12000xG 
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o In the mean time ten spin columns are marked 1-10 
 The supernatant (Approximately 850μL) are added to the ten spin columns 
o The total volume of Eppendorf tube 1 is added to spin column 1 
o The total volume of Eppendorf tube 2 is added to spin column 2 
o The total volume of Eppendorf tube 3 is added to spin column 3 
o The total volume of Eppendorf tube 4 is added to spin column 4 
o The total volume of Eppendorf tube 5 is added to spin column 5 
o The total volume of Eppendorf tube 6 is added to spin column 6 
o The total volume of Eppendorf tube 7 is added to spin column 7 
o The total volume of Eppendorf tube 8 is added to spin column 8 
o The total volume of Eppendorf tube 9 is added to spin column 9 
o The total volume of Eppendorf tube 10 is added to spin column 10 
 The ten spin columns are all centrifuged at the same time for 1 min. by 12000xG 
 The flow-through from each of the ten samples are discarded 
 Each of the ten spin columns are added 700μL wash buffer (W9) 
 The tem spin columns are all centrifuged at the same time for 1 min. by 12000xG 
 The flow-through from each of the ten samples are discarded 
 The tem spin columns are all again centrifuged at the same time for 1 min. by 12000xG 
 The flow-through from each of the ten samples are discarded 
 Ten new 1.5mL Eppendorf tubes are marked 1 plas, 2 plas, 3 plas, 4 plas, 5 plas, 6 plas, 7 
plas, 8 plas, 9 plas and 10 plas 
 Each of the 10 spin columns are placed in each of the ten new Eppendorf tubes 
o Spin column 1 is placed in Eppendorf tube “1 plas” 
o Spin column 2 is placed in Eppendorf tube “2 plas” 
o Spin column 3 is placed in Eppendorf tube “3 plas” 
o Spin column 4 is placed in Eppendorf tube “4 plas” 
o Spin column 5 is placed in Eppendorf tube “5 plas” 
o Spin column 6 is placed in Eppendorf tube “6 plas” 
o Spin column 7 is placed in Eppendorf tube “7 plas” 
o Spin column 8 is placed in Eppendorf tube “8 plas” 
o Spin column 9 is placed in Eppendorf tube “9 plas” 
o Spin column 10 is placed in Eppendorf tube “10 plas” 
 75μL TE buffer is added to each of the ten 1.5mL Eppendorf tubes 
 The ten Eppendorf tubes are incubated for 1 min. at room temperature 
 All ten samples are centrifuge for 2 min. at 12000xG 
 The columns from each of the ten samples are discarded.  
 The remaining samples should contain the plasmid 
 The ten samples are put in the freezer at -20oC 
 
Enzyme Digestion Vol I (21/10 - 2014) 
 The concentration of five of the ten plasmid samples are measured using NanoDrop Spec-
trophotometer ND-1000 
o Elution buffer is used as a blank 
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Plasmid sample Concentration (ng/μL) 
1 424.9 
2 433.6 
3 488.5 
4 364.5 
5 441.2 
 
 All materials are found – Restriction enzymes (AgeI (R35525) and BglII (R0144S)) are 
placed on ice 
 The procedure is done wearing gloves 
 Ten new 1.5mL Eppendorf tubes are marked 1-10 
 A master mix is made containing 
o 143μL milli-Q water 
o 32.5μL 10x EcoRI buffer (B0101S) 
o 13μL AgeI 
o 6.5μL BglII 
 The master mix is whirl mixed 
 Each of the ten Eppendorf tubes are added 15μL of the master mix 
 10μL of each plasmid sample are added to each of the ten Eppendorf tubes containing mas-
ter mix 
o 10μL of plasmid sample 1 is added to Eppendorf tube 1 
o 10μL of plasmid sample 2 is added to Eppendorf tube 2 
o 10μL of plasmid sample 3 is added to Eppendorf tube 3 
o 10μL of plasmid sample 4 is added to Eppendorf tube 4 
o 10μL of plasmid sample 5 is added to Eppendorf tube 5 
o 10μL of plasmid sample 6 is added to Eppendorf tube 6 
o 10μL of plasmid sample 7 is added to Eppendorf tube 7 
o 10μL of plasmid sample 8 is added to Eppendorf tube 8 
o 10μL of plasmid sample 9 is added to Eppendorf tube 9 
o 10μL of plasmid sample 10 is added to Eppendorf tube 10 
 The ten samples containing master mix + plasmid samples are incubated at 37oC for 1 hour 
 Here we realise that we have added EcoRI restriction enzyme and not the buffer – There-
fore, the procedure is repeated  
 The master mix is made again containing 
o 1μL milli-Q water 
o 2.5μL 10x EcoRI buffer 
o 1μL AgeI 
o 0.5μL BglII 
 The master mix is whirl mixed 
 Each of ten new 1.5mL Eppendorf tubes are added 15μL of the master mix 
 10μL of each plasmid sample are added to each of the ten Eppendorf tubes containing mas-
ter mix 
o 10μL of plasmid sample 1 is added to Eppendorf tube 1 
o 10μL of plasmid sample 2 is added to Eppendorf tube 2 
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o 10μL of plasmid sample 3 is added to Eppendorf tube 3 
o 10μL of plasmid sample 4 is added to Eppendorf tube 4 
o 10μL of plasmid sample 5 is added to Eppendorf tube 5 
o 10μL of plasmid sample 6 is added to Eppendorf tube 6 
o 10μL of plasmid sample 7 is added to Eppendorf tube 7 
o 10μL of plasmid sample 8 is added to Eppendorf tube 8 
o 10μL of plasmid sample 9 is added to Eppendorf tube 9 
o 10μL of plasmid sample 10 is added to Eppendorf tube 10 
 The total volume of each sample is then 25μL  
 All ten samples are incubated for 1 hour at 37oC 
 In the meantime a 2% agarose gel is prepared 
 First 2g agarose (Multipurpose, JT-lab) is dissolved in 100mL TAE-buffer by heating in a 
microwave 
 While it cools down, the chambers are prepared 
 3μL EtBr is mixed with the dissolved agarose – NB EtBr is highly intoxicating 
 The gel is poured in the chamber (C. Hitchens) – We are then letting it solidify 
 The samples were now done incubating 
 The now solidified gel is placed in the running chamber (Carl Sagan running chamber) – 
The chamber is filled with TAE 1X until the wells are completely covered 
 5μL 6x loading dye is added to each of the ten samples 
o The total volume of each sample is therefore 30μL 
 The first well is loaded with 4μL ladder (50bp ladder #SM0373) 
 The total volume of each of the ten samples are added to the wells 
o Sample 1 in well 2 
o Sample 2 in well 3 
o Sample 3 in well 4 
o Sample 4 in well 5 
o Sample 5 in well 6 
o Sample 6 in well 7 
o Sample 7 in well 8 
o Sample 8 in well 9 
o Sample 9 in well 10 
o Sample 10 in well 11 
 The gel runs for 1 hour at 120 V 
 Thereafter the gel is examined and pictures are taken and saved on the computer 
 
Digestion Analysis Vol II (29/19 - 2014) 
 Because of the bad results from the first digestion analysis, a second was preformed 
 All materials are found – Restriction enzymes (NdeI (R0111L) and BsaBI (B7204S)) are 
placed on ice 
 The procedure is done wearing gloves 
 Ten new 1.5mL Eppendorf tubes are marked 1-10 
 A master mix is made containing 
o 115.5μL milli-Q water 
o 27.5μL 10x Cutsmart buffer (B7002S) 
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o 11μL NdeI 
 The master mix is whirl mixed 
 Each of the ten Eppendorf tubes are added 14μL of the master mix 
 10μL of each plasmid sample are added to each of the ten Eppendorf tubes containing mas-
ter mix 
o 10μL of plasmid sample 1 is added to Eppendorf tube 1 
o 10μL of plasmid sample 2 is added to Eppendorf tube 2 
o 10μL of plasmid sample 3 is added to Eppendorf tube 3 
o 10μL of plasmid sample 4 is added to Eppendorf tube 4 
o 10μL of plasmid sample 5 is added to Eppendorf tube 5 
o 10μL of plasmid sample 6 is added to Eppendorf tube 6 
o 10μL of plasmid sample 7 is added to Eppendorf tube 7 
o 10μL of plasmid sample 8 is added to Eppendorf tube 8 
o 10μL of plasmid sample 9 is added to Eppendorf tube 9 
o 10μL of plasmid sample 10 is added to Eppendorf tube 10 
 The ten samples containing master mix + plasmid samples are incubated at 37oC incubator 
for 1 hour 
 In the meantime a 1% agarose gel is prepared 
 First 1g agarose (Multipurpose, JT-lab) is dissolved in 100mL TAE-buffer by heating in a 
microwave 
 While it cools down, the chambers are prepared 
 Then 3μL EtBr is mixed with the dissolved agarose – NB EtBr is highly intoxicating 
 The gel is poured in the chamber (Gandalf) – We are then letting it solidify 
 The samples were now done incubating 
 Each of the ten samples are added 1μL BsaBI 
 The ten samples are incubating at 60oC for another 60 min. 
 The now solidified gel is placed in the running chamber (Carl Sagan running chamber) – 
The chamber is filled with TAE 1X until the wells are completely covered 
 5μL 6x loading dye (Termo Scientific R0611) is added to each of the ten samples 
o The total volume of each sample is therefore 25μL 
 The first well is loaded with 4μL ladder (1 Kb plus marker #SM1333) 
 The total volume of each of the ten samples are added to the wells 
o Sample 1 in well 2+3 (A bit of the sample diffused to well 3) 
o Sample 2 in well 4 
o Sample 3 in well 5 
o Sample 4 in well 6 
o Sample 5 in well 7 
o Sample 6 in well 8 
o Sample 7 in well 9 
o Sample 8 in well 10 
o Sample 9 in well 11 
o Sample 10 in well 12 
 The gel runs for 45 min. at 120 V 
 Thereafter the gel is examined and pictures are taken and saved on the computer used 
 The gel showed bad results again – Therefor a restrike of the samples containing the control 
plasmids are preformed  
o The procedure is done sterile and wearing glows 
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o 5 plates is marked and divided into two – The plates are marked “1+2”, “3+4”, 
“5+6”, “7+8” and “9+10” 
o A small amount of each of the samples is placed on one plate – And the restrike is 
performed 
 The plates are placed in a 37oC incubator O.N. 
 
Restrike Vol II (30/10 - 2014) 
 The O.N. incubated plates are examined in the immune laboratory 
 The results are bad 
 Therefor new restrikes are made 
 The procedure is done wearing gloves 
 For these new restrikes our glycerol stocks are used 
 The glycerol stocks are picked from the -80oC freezer (Left lower corner, in a orange box 
called “SAMMN Julian miRNA”) 
 The samples of glycerol stock is picked and placed on a agar plate (100μg/mL) and are im-
mediately melting 
 Each of the ten glycerol stocks are placed on a agar plate separately 
o Glycerol sample 1 is placed on agar plate 1 “Glycerol ren” 
o Glycerol sample 2 is placed on agar plate 2 “Glycerol ren” 
o Glycerol sample 3 is placed on agar plate 3 “Glycerol ren” 
o Glycerol sample 4 is placed on agar plate 4 “Glycerol ren” 
o Glycerol sample 5 is placed on agar plate 5 “Glycerol ren” 
o Glycerol sample 6 is placed on agar plate 6 “Glycerol ren” 
o Glycerol sample 7 is placed on agar plate 7 “Glycerol ren” 
o Glycerol sample 8 is placed on agar plate 8 “Glycerol ren” 
o Glycerol sample 9 is placed on agar plate 9 “Glycerol ren” 
o Glycerol sample 10 is placed on agar plate 10 “Glycerol ren” 
 Furthermore three colonies from the plates with restrike from 29/10-2014 are picked and re-
striked on three new agar plates – These three new plates are called “Re-restrygning Julian 
miRNA 1”, “Re-restrygning Julian miRNA 2” and “Re-restrygning Julian miRNA 3” 
 
Digestion Analysis Vol III (31/10 - 2014) 
 First the O.N. plates were examined. They looked okay and were placed in the refrigerator 
in building 15.0 
 Now the third digestion analysis was begun. The procedure was done wearing gloves 
o For this digestion analysis we tried using another plasmid (pUC19) for sample 1 and 
2, and furthermore we tried to use some other water (RNAse free water) to avoid a 
possible contamination from the 2 previous digestion analysis 
 First a master mix was prepared – An 1.5mL Eppendorf tube was used: 
o 6.5μL NdeI (R0111L) 
o 17.5μL CutSmart Buffer (B7204S) 
 Then twelve 1.5mL Eppendorf tubes were marked 1-12 
 All twelve Eppendorf tubes were added 1.75μL of the master mix 
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 Now we made a scheme that illustrated what solution that should be put in which tubes: 
 
 Master mix (6.5μL 
NdeI + 17.5μL 
CutSmart buffer) (μL) 
RNAse free 
water (μL) 
milli-Q water 
from previ-
ouse diges-
tion (μL) 
pUC19 
plasmid (μL) 
The plasmid 
samples con-
taining the 
miR-29a 
(μL)  
1 1.75 8.76  1.0  
2 1.75  8.76 1.0  
3 1.75 5.26   5.0 
4 1.75 5.26   5.0 
5 1.75 5.26   5.0 
6 1.75 5.26   5.0 
7 1.75 5.26   5.0 
8 1.75 5.26   5.0 
9 1.75 5.26   5.0 
10 1.75 5.26   5.0 
11 1.75 5.26   5.0 
12 1.75 5.26   5.0 
 
 Then 5.26μL RNAse free water was added to sample 3-12 
 8.76μL RNAse free water was added to sample 1 
 8.76μL of the milli-Q water used in the previous two digestion analysis was added to sample 
2 
 Then 1μL of the plasmid called pUC19 was added to sample 1 and 2 
 5μL of our own plasmid sample was added to sample 3-12 
 10μL of each plasmid sample are added to each of the ten 1.5mL Eppendorf tubes contain-
ing master mix 
o 5μL of plasmid sample 1 is added to Eppendorf tube 3 
o 5μL of plasmid sample 2 is added to Eppendorf tube 4 
o 5μL of plasmid sample 3 is added to Eppendorf tube 5 
o 5μL of plasmid sample 4 is added to Eppendorf tube 6 
o 5μL of plasmid sample 5 is added to Eppendorf tube 7 
o 5μL of plasmid sample 6 is added to Eppendorf tube 8 
o 5μL of plasmid sample 7 is added to Eppendorf tube 9 
o 5μL of plasmid sample 8 is added to Eppendorf tube 10 
o 5μL of plasmid sample 9 is added to Eppendorf tube 11 
o 5μL of plasmid sample 10 is added to Eppendorf tube 12 
 All twelve samples are incubated for 60 min at 37oC in a incubator 
   
Page 96 of 128 
 
 In the meantime a 1% agarose gel is prepared 
 First 1g agarose (Multipurpose, JT-lab) is dissolved in 100mL TAE-buffer by heating in a 
microwave 
 While it cools down, the chambers are prepared 
 Then 3μL EtBr is mixed with the dissolved agarose – NB EtBr is highly intoxicating 
 The gel is poured in the chamber (Gandalf) – We are then letting it solidify 
 The samples were now done incubating 
 Each of the ten samples are added 0.5μL BsaBI (R0537L) 
 All samples were incubated for 60 min. in a 60oC warm heating block 
 The now solidified gel is placed in the running chamber (Carl Sagan running chamber) – 
The chamber is filled with TAE 1X until the wells are completely covered 
 2μL 6x loading dye (Termo scientific R0611) is added to sample 1 and 2 
o The total volume of sample 1 and 2 are 14μL 
 2.1μL 6x loading dye (Termo scientific R0611) is added to sample 3-12 
o The total volume in each of sample 3-12 are 14.6μL 
 The first well is loaded with 4μL ladder (1 Kb plus marker #SM1333) 
 The total volume of each of the ten samples are added to the wells 
o Sample 1 in well 2 
o Sample 2 in well 3 
o Sample 3 in well 4 
o Sample 4 in well 5 
o Sample 5 in well 6 
o Sample 6 in well 7 
o Sample 7 in well 8 
o Sample 8 in well 9 
o Sample 9 in well 10 
o Sample 10 in well 11 
o Sample 11 in well 12 
o Sample 12 in well 13 
 The gel runs for 60 min. at 120 V 
 Thereafter the gel is examined and pictures are taken saved on the computer used 
 
Pick Colonies (3/11 - 2014) 
 All materials are found and brought to the immune laboratory – The plates are found in the 
refrigerator and our LB medium (Named: “Julian LB med”) is found in the big refrigerator  
 The procedure is done wearing gloves 
 Ten colonies from the plates containing restrikes of the glycerol stocks are chosen 
 The work is now preformed sterile. Everything is cleaned with 70% ethanol before use, and 
a bunsen burner are on 
 Ten 5mL tubes are marked 1-10  
 50μL ampicillin are added to a new 50mL tube 
 Thereafter the tube are filled with our LB medium (Named: “Julian LB med”) to the 50mL 
mark 
 Each of the ten tubes are added 5mL of the ampicillin/LB medium solution from the 50mL 
tube 
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 The chosen colonies are picked using a pipettip and added to the 10 tubes. On colony in 
each tube 
 The ten tubes are then placed in an incubator at 37oC O.N. gently shaking 
 
Mini preparation. Vol II (4/11 - 2014) 
 The kit used in this procedure is Invitrogen PureLink Quick Plasmid Mini Prep Kit Ref: 
210011 
 The whole procedure is done wearing gloves 
 Ten 1.5mL Eppendorf tubes are marked 1-10 
 Then 2mL of the mixture from the ten O.N. incubated tubes are added to each of the ten Ep-
pendorf tubes: 
o 2mL from tube 1 is added to Eppendorf tube 1 
o 2mL from tube 2 is added to Eppendorf tube 2 
o 2mL from tube 3 is added to Eppendorf tube 3 
o 2mL from tube 4 is added to Eppendorf tube 4 
o 2mL from tube 5 is added to Eppendorf tube 5 
o 2mL from tube 6 is added to Eppendorf tube 6 
o 2mL from tube 7 is added to Eppendorf tube 7 
o 2mL from tube 8 is added to Eppendorf tube 8 
o 2mL from tube 9 is added to Eppendorf tube 9 
o 2mL from tube 10 is added to Eppendorf tube 10 
 All ten Eppendorf tubes are centrifuge for 5 min. at 7500 rpm 
 The supernatant from all ten Eppendorf tubes are discarded 
 Again 2mL of the mixture from the ten incubated tubes are added to each of the ten Eppen-
dorf tubes: 
o 2mL from tube 1 is added to Eppendorf tube 1 
o 2mL from tube 2 is added to Eppendorf tube 2 
o 2mL from tube 3 is added to Eppendorf tube 3 
o 2mL from tube 4 is added to Eppendorf tube 4 
o 2mL from tube 5 is added to Eppendorf tube 5 
o 2mL from tube 6 is added to Eppendorf tube 6 
o 2mL from tube 7 is added to Eppendorf tube 7 
o 2mL from tube 8 is added to Eppendorf tube 8 
o 2mL from tube 9 is added to Eppendorf tube 9 
o 2mL from tube 10 is added to Eppendorf tube 10 
 All ten Eppendorf tubes are centrifuge for 5 min. at 7500 rpm 
 The supernatant from all ten Eppendorf tubes are removed by pipetting 
 The remaining content in the ten O.N. incubated tubes are discarded 
 250μL Resuspension Buffer (R3) is added to each of the ten Eppendorf tubes. The samples 
are homogenised 
 250μL lysis buffer (L7) is added to each of the ten Eppendorf tubes 
 The ten samples are gently inverted five times 
 The ten samples are incubated at room temperature for 5 min.  
 350μL plecipation buffer (N4) are added to each of the ten Eppendorf tubes, and the Eppen-
dorf tubes are immediately inverted until the samples were homogenised 
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 All ten Eppendorf tubes are centrifuge together for 10 min. by 12000xG 
o In the mean time ten spin columns are marked 1-10 
 The supernatant (Approximately 850μL) are added to each of the ten spin columns 
o The total volume of Eppendorf tube 1 is added to spin column 1 
o The total volume of Eppendorf tube 2 is added to spin column 2 
o The total volume of Eppendorf tube 3 is added to spin column 3 
o The total volume of Eppendorf tube 4 is added to spin column 4 
o The total volume of Eppendorf tube 5 is added to spin column 5 
o The total volume of Eppendorf tube 6 is added to spin column 6 
o The total volume of Eppendorf tube 7 is added to spin column 7 
o The total volume of Eppendorf tube 8 is added to spin column 8 
o The total volume of Eppendorf tube 9 is added to spin column 9 
o The total volume of Eppendorf tube 10 is added to spin column 10 
 The ten spin columns are all centrifuged at the same time for 1 min. by 12000xG 
 The flow-through from each of the ten samples are discarded 
 Each of the tem spin columns are added 700μL wash buffer (W9) 
 The ten spin columns are all centrifuged at the same time for 1 min. by 12000xG 
 The flow-through from each of the ten samples are discarded 
 The ten spin columns are all again centrifuged at the same time for 1 min. by 12000xG 
 The flow-through from each of the ten samples are discarded 
 Ten new 1.5mL Eppendorf tubes are marked “1 minip 4/11”, “2 minip 4/11”, “3 minip 
4/11”, “4 minip 4/11”, “5 minip 4/11”, “6 minip 4/11”, “7 minip 4/11”, “8 minip 4/11”, “9 
minip 4/11” and “10 minip 4/11” 
 Each of the ten spin columns are placed in each of the ten new 1.5mL Eppendorf tubes 
o Spin column 1 is placed in Eppendorf tube “1 minip 4/11” 
o Spin column 2 is placed in Eppendorf tube “2 minip 4/11” 
o Spin column 3 is placed in Eppendorf tube “3 minip 4/11” 
o Spin column 4 is placed in Eppendorf tube “4 minip 4/11” 
o Spin column 5 is placed in Eppendorf tube “5 minip 4/11” 
o Spin column 6 is placed in Eppendorf tube “6 minip 4/11” 
o Spin column 7 is placed in Eppendorf tube “7 minip 4/11” 
o Spin column 8 is placed in Eppendorf tube “8 minip 4/11” 
o Spin column 9 is placed in Eppendorf tube “9 minip 4/11” 
o Spin column 10 is placed in Eppendorf tube “10 minip 4/11” 
 75μL TE buffer is added to each of the ten 1.5mL Eppendorf tubes 
 The ten Eppendorf tubes are incubated for 1 min. at room temperature 
 All ten samples are centrifuge for 2 min. at 12000xG 
 The columns from each of the ten samples are discarded.  
 The remaining samples should contain the plasmid 
 The ten samples are put in the freezer at -20oC  
 
Glycerol Stock Vol II (4/11 - 2014) 
 The procedure is done wearing gloves 
 The cryo tubes are marked with “konc.1”, “konc.2”, “konc.3”, “konc.4”, “konc.5”, 
“konc.6”, “konc.7”, “konc.8”, “konc.9” and “konc.10” respectively 
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 All materials are brought to the immune laboratory 
 The ten tubes are taken out of the incubator at 37oC 
 The pipettips are removed from each of the ten 50mL tubes using a tweezer 
 500μL Glycerol (50%) is added to each of the ten cryo tubes 
 Then 500μL of the mixture from the ten incubated tubes are added to each of the ten cryo 
tubes: 
o 500μL from tube 1 is added to the cryo tube called “konc.1” 
o 500μL from tube 2 is added to the cryo tube called “konc.2” 
o 500μL from tube 3 is added to the cryo tube called “konc.3” 
o 500μL from tube 4 is added to the cryo tube called “konc.4” 
o 500μL from tube 5 is added to the cryo tube called “konc.5” 
o 500μL from tube 6 is added to the cryo tube called “konc.6” 
o 500μL from tube 7 is added to the cryo tube called “konc.7” 
o 500μL from tube 8 is added to the cryo tube called “konc.8” 
o 500μL from tube 9 is added to the cryo tube called “konc.9” 
o 500μL from tube 10 is added to the cryo tube called “konc.10” 
 Each of the ten cryo tubes is gently mixed ten times 
 The ten cryo tubes are then placed in the -80oC freezer in the same box as the other glycerol 
stocks were placed in. (Left lower corner, in a orange box called “SAMMN Julian miRNA”) 
 
Digestion Analysis Vol. VI (5/11 - 2014) 
 The concentration of the ten plasmid samples are measured using NanoDrop Spectropho-
tometer ND-1000 
o TE buffer is used as blank 
 
Plasmid 
sample 
Concentration (ng/μL) 260/280 
ration 
1 141.7 2.22 
2 51.4 1.99 
3 111.6 1.96 
4 65.4 1.98 
5 83.3 1.95 
6 59.3 2.04 
7 62.1 1.93 
8 138.0 1.96 
9 79.2 1.97 
10 201.2 2.01 
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 All materials are found – Restriction enzymes are placed on ice 
 The procedure is done wearing gloves 
 We are using the two restriction enzymes NdeI (NEB R0111L) and BsaBI (R0537L) 
 Ten new 1.5mL Eppendorf tubes are marked 1-10 
 A master mix is made containing 
o 115.5μL RNAse free water 
o 27.5μL 10x CutSmart buffer (B7204S) 
o 11μL NdeI 
 The master mix is whirl mixed 
 Each of the ten Eppendorf tubes are added 14μL of the master mix 
 10μL of each plasmid sample (From mini prep Vol. II) are added to each of the ten Eppen-
dorf tubes containing master mix 
o 10μL of plasmid sample “1 minip 4/11” is added to Eppendorf tube 1 
o 10μL of plasmid sample “2 minip 4/11” is added to Eppendorf tube 2 
o 10μL of plasmid sample “3 minip 4/11” is added to Eppendorf tube 3 
o 10μL of plasmid sample “4 minip 4/11” is added to Eppendorf tube 4 
o 10μL of plasmid sample “5 minip 4/11” is added to Eppendorf tube 5 
o 10μL of plasmid sample “6 minip 4/11” is added to Eppendorf tube 6 
o 10μL of plasmid sample “7 minip 4/11” is added to Eppendorf tube 7 
o 10μL of plasmid sample “8 minip 4/11” is added to Eppendorf tube 8 
o 10μL of plasmid sample “9 minip 4/11” is added to Eppendorf tube 9 
o 10μL of plasmid sample “10 minip 4/11” is added to Eppendorf tube 10 
 The ten samples containing master mix+plasmid samples are incubated at 37oC incubator 
for 60 min. 
 In the meantime a 1% agarose gel is prepared 
 First 1g agarose (Multipurpose, JT-lab) is dissolved in 100mL TAE-buffer by heating in a 
microwave 
 While it cools down, the chambers are prepared 
 Then 3μL EtBr is mixed with the dissolved agarose – NB. EtBr is highly intoxicating 
 The gel is poured in the chamber (Gandalf) – We are then letting it solidify 
 The samples were now done incubating 
 Each of the ten samples are added 1μL BsaBI 
 The ten samples are incubating at 60oC in a heating block for another 60 min. 
 The now solidified gel is placed in the running chamber (Carl Sagan running chamber) – 
The chamber is filled with TAE 1X until the wells are completely covered 
 5μL 6x loading dye (Termo Scientific R0611) is added to each of the ten samples 
o The total volume of each sample is now 25μL 
 The first well is loaded with 4μL ladder (1 kb plus marker #SM1333)  
 The total volume of each of the ten samples are added to the wells: 
o Sample 1 in well 2 
o Sample 2 in well 3 
o Sample 3 in well 4 
o Sample 4 in well 5 
o Sample 5 in well 6 
o Sample 6 in well 7 
o Sample 7 in well 8 
o Sample 8 in well 9 
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o Sample 9 in well 10 
o Sample 10 in well 11 
 The gel runs for 45 min. at 120 V 
 Thereafter the gel is examined and pictures are taken and saved on the computer used 
 The gel showed bad results again  
 
Digestion Analysis Vol. V (6/11 - 2014) 
 For reasons which are not completely clear plasmid sample “4 minip 4/11” was missing, and 
is therefore, not used in this procedure 
 All materials are found – Restriction enzymes are placed on ice (NdeI (R0111L) and BsaBI 
(R0537L)) 
 The procedure is done wearing gloves 
 13 new 1.5mL Eppendorf tubes are marked (1, 2, 3, 4, 5, 6, 7, 8, 9, 10N, 11N, 12B and 13B) 
 A master mix for sample 1-9 are made containing 
o 110μL RNAse free water 
o 25μL 10x CutSmart buffer 
o 5μL NdeI 
 The master mix is whirl mixed 
 Now we made a scheme that illustrated what solution that should be put in which tubes: 
 Mastermix (5μL NdeI 
+ 25μL CutSmart 
buffer + 110μL 
RNAse free water) 
(μL) 
RNAse free 
water (μL) 
Cutsmart 
Buffer (μL) 
NdeI (μL) BsaBI 
(μL) 
The plasmid sam-
ples containing the 
miR-29a (μL)  
 
1 14    1 10 
2 14    1 10 
3 14    1 10 
4 14    1 10 
5 14    1 10 
6 14    1 10 
7 14    1 10 
8 14    1 10 
9 14    1 10 
10N  12 2.5 0.5  10 
11N  12 2.5 0.5  10 
12B  11.5 2.5  1 10 
13B  11.5 2.5  1 10 
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 12μL RNAse free water is added to sample 10N and 11N 
 11.5μL RNAse free water is added to sample 12B and 13B 
 Then 2.5μL CutSmart buffer are added to sample 10N, 11N, 12B and 13B 
 0.5μL NdeI is added to sample 10N and 11N 
 Sample 1-9 are added 14μL of the master mix 
 10μL of each plasmid sample (From mini prep Vol. II) are added to each of the ten Eppen-
dorf tubes containing master mix 
o 10μL of plasmid sample “1 minip 4/11” is added to Eppendorf tube 1, 10N and 12B 
o 10μL of plasmid sample “2 minip 4/11” is added to Eppendorf tube 2, 11N and 13B 
o 10μL of plasmid sample “3 minip 4/11” is added to Eppendorf tube 3 
o 10μL of plasmid sample “5 minip 4/11” is added to Eppendorf tube 4 
o 10μL of plasmid sample “6 minip 4/11” is added to Eppendorf tube 5 
o 10μL of plasmid sample “7 minip 4/11” is added to Eppendorf tube 6 
o 10μL of plasmid sample “8 minip 4/11” is added to Eppendorf tube 7 
o 10μL of plasmid sample “9 minip 4/11” is added to Eppendorf tube 8 
o 10μL of plasmid sample “10 minip 4/11” is added to Eppendorf tube 9 
 The thirteen samples are incubated at 37oC for 10 min. 
 1μL BsaBI are added to sample 1-9 and 12B and 13B 
 All thirteen samples are incubated for 60 min. in a 60oC heating block 
 In the meantime a 1% agarose gel is prepared 
 First 1g agarose (Multipurpose, JT-lab) is dissolved in 100mL TAE-buffer by heating in a 
microwave 
 While it cools down, the chambers are prepared 
 Then 3μL EtBr is mixed with the dissolved agarose – NB. EtBr is highly intoxicating 
 The gel is poured in the chamber (Gandalf) – We are then letting it solidify 
 After the incubation the temperature was raised to 76oC in the heating block – The samples 
were incubated for further 20 min. 
 Then all thirteen samples were centrifuged briefly to collect the evaporated droplets at the 
bottom of the tubes 
 The now solidified gel is placed in the running chamber (Carl Sagan running chamber) – 
The chamber is filled with TAE 1X until the wells are completely covered 
 4μL 6x loading dye (Termo Scientific R0611) is added to each of the thirteen samples 
 The first well is loaded with 3μL ladder (1 kb plus marker #SM1333) 
 The total volume of each of the thirteen samples are added to the wells: 
o Sample 1 in well 2 
o Sample 2 in well 3 
o Sample 3 in well 4 
o Sample 4 in well 5 
o Sample 5 in well 6 
o Sample 6 in well 8 
o Sample 7 in well 9 
o Sample 8 in well 10 
o Sample 9 in well 11 
o Sample 10N in well 12 
o Sample 11N in well 13 
o Sample 12B in well 14 
o Sample 13B in well 15 
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 The gel runs for 60 min. at 120 V 
 Thereafter the gel is examined and pictures are taken and saved on the computer used 
 The gel showed bad results again 
 
Digestion Analysis Vol. VI (12/11 - 2014) 
 All materials are found – Restriction enzymes (NdeI (R0111L) BsaBI (R0537L)) are placed 
on ice 
 The procedure is done wearing gloves 
 Nine new 1.5mL Eppendorf tubes are marked (1, 2, 3, 5, 6, 7, 8, 9 and 10) 
 A master mix is made containing 
o 115.5μL RNAse free water 
o 28μL NEBuffer 
o 11μL NdeI 
 The master mix is whirl mixed 
 Each of the nine new 1.5mL Eppendorf tubes are added 15μL of the master mix 
 10μL of each plasmid sample (From mini prep Vol. II) are added to each of the nine Eppen-
dorf tubes containing master mix 
o 10μL of plasmid sample “1 minip 4/11” is added to Eppendorf tube 1 
o 10μL of plasmid sample “2 minip 4/11” is added to Eppendorf tube 2 
o 10μL of plasmid sample “3 minip 4/11” is added to Eppendorf tube 3 
o 10μL of plasmid sample “5 minip 4/11” is added to Eppendorf tube 4 
o 10μL of plasmid sample “6 minip 4/11” is added to Eppendorf tube 5 
o 10μL of plasmid sample “7 minip 4/11” is added to Eppendorf tube 6 
o 10μL of plasmid sample “8 minip 4/11” is added to Eppendorf tube 7 
o 10μL of plasmid sample “9 minip 4/11” is added to Eppendorf tube 8 
o 10μL of plasmid sample “10 minip 4/11” is added to Eppendorf tube 9 
 All nine samples are centrifuged briefly 
 The nine samples containing master mix + plasmid samples are incubated at 37oC in a incu-
bator for 12 min. 
 Now the digested plasmid is extracted using a kit called NucleoSpin® Extract II (REF 
740658.24) 
 First 50μL NT binding buffer is added to all nine samples 
 Nine spin columns are marked 1-9 
 The total volume of the nine Eppendorf tubes are put in nine new spin columns 
o The total volume of Eppendorf tube 1 is added to spin column 1 
o The total volume of Eppendorf tube 2 is added to spin column 2 
o The total volume of Eppendorf tube 3 is added to spin column 3 
o The total volume of Eppendorf tube 4 is added to spin column 4 
o The total volume of Eppendorf tube 5 is added to spin column 5 
o The total volume of Eppendorf tube 6 is added to spin column 6 
o The total volume of Eppendorf tube 7 is added to spin column 7 
o The total volume of Eppendorf tube 8 is added to spin column 8 
o The total volume of Eppendorf tube 9 is added to spin column 9 
 The nine columns are centrifuged for 1 min. at 11000xG 
 The flow through from all nine spin columns are discarded 
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 Then 700μL NT3 wash buffer is added to all nine spin columns 
 The nine columns are centrifuged for 1 min. at 11000xG 
 The flow through from all nine spin columns are again discarded 
 The nine columns are now centrifuged for 2 min. at 11000xG 
 The columns are placed in new nine new 1.5mL Eppendorf tubes – These new Eppendorf 
tubes was marked A1-A9 
o Column 1 was placed in Eppendorf tube A1 
o Column 2 was placed in Eppendorf tube A2 
o Column 3 was placed in Eppendorf tube A3 
o Column 4 was placed in Eppendorf tube A5 
o Column 5 was placed in Eppendorf tube A6 
o Column 6 was placed in Eppendorf tube A7 
o Column 7 was placed in Eppendorf tube A8 
o Column 8 was placed in Eppendorf tube A9 
o Column 9 was placed in Eppendorf tube A10 
 30μL Buffer NE (Elution Buffer) was added to each of the nine samples 
 All nine samples are incubated for 1 min. at room temperature 
 Then the nine samples are centrifuged for 1 min. at 11000xG 
 The column are removed from all nine Eppendorf tubes  These nine Eppendorf tubes (A1-
A9) are now containing the purified plasmid 
 Now a mastermix containing BsaBI is prepared: 
o 11.5μL RNAse free water 
o 2.5μL NEBuffer (NEB B7002S) 
o 1μL BsaBI 
 Nine new 1.5mL Eppendorf tubes are marked (B1, B2, B3, B5, B6, B7, B8, B9, B10) 
 Then 15μL of this BsaBI mastermix is added to each of these nine new Eppendorf tubes B1-
B10 
 Nine new 1.5mL Eppendorf tubes are marked (N1, N2, N3, N5, N6, N7, N8, N9, N10) 
 8.5μL of the purified plasmid are added to each of these new 1.5mL Eppendorf tubes N1-
N10 
o Thereafter N1-N10 are placed on ice 
 2.5μL NEBuffer are added to each of the nine Eppendorf tubes (A1-A10) containing the last 
of the purified plasmid 
 1μL BsaBI are added to each of the each of the nine Eppendorf tubes A1-A10 
o Thereafter the samples are centrifuged briefly 
 10μL of the plasmid samples from the mini preparation is added to the Eppendorf tubes B1-
B10 
o 10μL of plasmid sample “1 minip 4/11” is added to B1 
o 10μL of plasmid sample “2 minip 4/11” is added to B2 
o 10μL of plasmid sample “3 minip 4/11” is added to B3 
o 10μL of plasmid sample “5 minip 4/11” is added to B5 
o 10μL of plasmid sample “6 minip 4/11” is added to B6 
o 10μL of plasmid sample “7 minip 4/11” is added to B7 
o 10μL of plasmid sample “8 minip 4/11” is added to B8 
o 10μL of plasmid sample “9 minip 4/11” is added to B9 
o 10μL of plasmid sample “10 minip 4/11” is added to B10 
 All eighteen samples (A1-A10 + B1-B10) are incubated for 60 min. in a 60oC heating block 
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 In the meantime a 1% agarose gel is prepared 
 First 1g agarose (Multipurpose, JT-lab) is dissolved in 100mL TAE-buffer by heating in a 
microwave 
 While it cools down, the chambers are prepared 
 Then 3μL EtBr is mixed with the dissolved agarose – NB. EtBr is highly intoxicating 
 The gel is poured in the chamber (Gandalf) which contains to chamber markers – One at the 
top of the gel and one in the middle – We are then letting it solidify 
 The samples were now done incubating 
 The now solidified gel is placed in the running chamber (Carl Sagan running chamber) – 
The chamber is filled with TAE 1X until the wells are completely covered 
 5μL 6x loading dye (Termo Scientific R0611) is added to each of the samples B1-B10 and 
A1-A10 
 2μL 6x loading dye (Termo Scientific R0611) is added to each of the samples N1-N10 
 Nine new 1.5mL Eppendorf tubes are marked (P1, P2, P3, P5, P6, P7, P8, P9 and P10) 
 These nine new were added 5μL undigested plasmid 
o 5μL of plasmid sample “1 minip 4/11” is added to P1 
o 5μL of plasmid sample “2 minip 4/11” is added to P2 
o 5μL of plasmid sample “3 minip 4/11” is added to P3 
o 5μL of plasmid sample “5 minip 4/11” is added to P5 
o 5μL of plasmid sample “6 minip 4/11” is added to P6 
o 5μL of plasmid sample “7 minip 4/11” is added to P7 
o 5μL of plasmid sample “8 minip 4/11” is added to P8 
o 5μL of plasmid sample “9 minip 4/11” is added to P9 
o 5μL of plasmid sample “10 minip 4/11” is added to P10 
 1μL 6x loading dye (Termo Scientific R0611) is added to each of the samples P1-P10 
 The first well, in both row 1 and 2 is loaded with 4μL ladder (1 kb plus marker #SM1333) 
 We want to load the gel with the nine A-samples (That have been digested with both NdeI 
and BsaBI), the nine B-samples (That have been digested with only BsaBI), the nine N-
samples (That have been digested with only NdeI) and nine samples containing undigested 
samples of the plasmid from the mini prep. 
 5μL of each of the thirty-six samples are added to the wells (The wells were very small – 
We had used a wrong comb) 
o Sample A1 in well 2, row 1 
o Sample A2 in well 3, row 1 
o Sample A3 in well 4, row 1 
o Sample A5 in well 5, row 1 
o Sample A6 in well 6, row 1 
o Sample A7 in well 7, row 1 
o Sample A8 in well 8, row 1 
o Sample A9 in well 9, row 1 
o Sample A10 in well 10, row 1 
o Sample B1 in well 12, row 1 
o Sample B2 in well 13, row 1 
o Sample B3 in well 14, row 1 
o Sample B5 in well 15, row 1 
o Sample B6 in well 16, row 1 
o Sample B7 in well 17, row 1 
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o Sample B8 in well 18, row 1 
o Sample B9 in well 19, row 1 
o Sample B10 in well 20, row 1 
o Sample N1 in well 2, row 2 
o Sample N2 in well 3, row 2 
o Sample N3 in well 4, row 2 
o Sample N5 in well 5, row 2 
o Sample N6 in well 6, row 2 
o Sample N7 in well 7, row 2 
o Sample N8 in well 8, row 2 
o Sample N9 in well 9, row 2 
o Sample N10 in well 10, row 2 
o Sample P1 in well 12, row 2 
o Sample P2 in well 13, row 2 
o Sample P3 in well 14, row 2 
o Sample P5 in well 15, row 2 
o Sample P6 in well 16, row 2 
o Sample P7 in well 17, row 2 
o Sample P8 in well 18, row 2 
o Sample P9 in well 19, row 2 
o Sample P10 in well 20, row 2 
 The gel runs for 60 min. at 120 V 
 Thereafter the gel is examined and pictures are taken and saved on the computer used 
 The gel showed promising results 
 
Sequencing (14/11 - 2014) 
 Based on the results from restriction analysis sample 5, 6, 7, 8, and 9 from the mini prepara-
tion are chosen for sequencing 
 The concentrations of the five samples are measured using NanoDrop Spectrophotometer 
ND-1000 
o First the NanoDrop is cleaned using a small piece of paper 
o The NanoDrop is blanked using elution TE buffer (From the mini preparation kit 
(Invitrogen PureLink Quick Plasmid Mini Prep Kit Ref: 210011)) 
o The concentration of sample 5,6,7,8 and 9 are measured 
 The results are shown in the table below: 
 
Sample nr. Concentration (ng/μL) 260/280 
5 77.9 1.86 
6 49.9 1.87 
7 50.9 1.95 
8 148.1 1.53 
9 82.4 1.45 
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 The procedure is done wearing gloves 
 The samples that are going to be sent for sequencing should have a concentration of 
100ng/μL. Therefor sample eight has to be diluted: 
 
C1 * V1 = C2 * V1 
148.1ng/μL * V1 = 100ng/μL * 15μL 
𝑉1 =
100𝑛𝑔/𝜇𝐿 ∙ 15𝜇𝐿
148.1𝑛𝑔/𝜇𝐿
= 10.13𝜇𝐿 
 The primers for the sequencing are found. The stock concentrations of these primers are 
100μM. For the sequencing the concentration of the primers should be 5μM: 
 
100μM * V1 = 5μM * 20μL 
𝑉1 =
5𝜇𝑀 ∙ 20𝜇𝐿
100𝜇𝑀
= 1𝜇𝐿 
 The RNAse free water is thawed 
 Seven new 1.5mL Eppendorf tubes are marked 
o Eppendorf tube 1 is marked “primer fw” 
o Eppendorf tube 2 is marked “primer rev” 
o Eppendorf tube 3 is marked “plasmid 5” 
o Eppendorf tube 4 is marked “plasmid 6” 
o Eppendorf tube 5 is marked “plasmid 7” 
o Eppendorf tube 6 is marked “plasmid 8” 
o Eppendorf tube 7 is marked “plasmid 9” 
 19μL RNAse free water is added to each of the Eppendorf tubes called “primer fw” and 
“primer rev” 
 Then 1μL primer is added to each of the Eppendorf tubes called “primer fw” and “primer 
rev” 
 15μL of the plasmid samples are added to the four next Eppendorf tubes: 
o 15μL of plasmid sample “5 minip 4/11” is added to “plasmid 5” 
o 15μL of plasmid sample “6 minip 4/11” is added to “plasmid 6” 
o 15μL of plasmid sample “7 minip 4/11” is added to “plasmid 7” 
o 15μL of plasmid sample “9 minip 4/11” is added to “plasmid 9” 
 10μL of plasmid sample “8 minip 4/11” is added to “plasmid 8” 
 5μL RNAse free water is added to “plasmid 8” 
 The tubes are then labelled and sent of for sequencing 
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Restrike of glycerol stocks (15/11 - 2014) 
 The procedure is done wearing gloves 
 Two new ampicillin plates are found in the cold storage  
 All other materials are found 
 Plates and materials are brought to the -80oC freezer (Left lower corner, in a orange box 
called “SAMMN Julian miRNA”) 
 Glycerol sample containing the miR-29a plasmid are found in the -80oC freezer (Left lower 
corner, in a orange box called “SAMMN Julian miRNA”) 
 The plates are marked and divided in two divisions 
o The first plate is marked “miR-29a plasmid renstrygning glyc. 16/12-2014 Julian I” 
o The second plate is marked “miR-29a plasmid renstrygning glyc. 16/12-2014 Julian 
II” 
 A sample of the glycerol stock containing the miR-29a plasmid are taken by a small pipettip, 
and put on the agar plates 
 The restrike is done with a small plastic needle 
 The glycerol stock containing the miR-29a plasmid is put back in to the -80oC freezer (Left 
lower corner, in a orange box called “SAMMN Julian miRNA”) 
 The plates are put in an incubator at 37oC O.N. 
 
O.N Culture – Preparation for maxi preparation (17/11 - 2014) 
 All materials are found and brought to the immune laboratory 
o The O.N. plates are picked from the 37oC incubator and examined. It shows colonies 
o The LB medium called “Julian LB med” are found in the cold storage in 15.0 
 The work is now preformed sterile. Everything is cleaned with 70% ethanol before use, and 
done wearing glows 
 300mL of the LB medium called “Julian LB med” is added to volumetric flask 1  
 150mL of the LB medium in volumetric flask 1 is added to a second volumetric flask 
 Two colonies from the O.N. plate is chosen 
 The colonies are picked using a pipettip 
o Colony 1 is added to volumetric flask 1 
o Colony 2 is added to volumetric flask 2 
 The two volumetric flasks are placed in the incubator (Gently shaken at 37oC) O.N. 
 
Maxi preparation (18/11 - 2014) 
 The maxi preparation is done using the kit (NucleoBond Xtra Maxi Colum REF 740414.50 
 The two volumetric flasks (Volumetric flask 1 and 2) are found in the 37oC incubator 
 The flasks are examined and the pipet tips removed and thrown away 
 The procedure is done wearing gloves 
 The two volumetric flask are weighted separately 
o Volumetric flask 2 weights a bit more, so some of the content from volumetric flask 
2 is added to volumetric flask 1, so they have the exact same weight 
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 The two flasks are centrifuged together for 10 min., at 5000xG and at 4oC 
 The supernatant from both flasks are discarded 
 6mL resuspension buffer is added to each of the two flasks  Both solutions are firmly re-
suspended using a pipet 
 The complete content of the volumetric flask 1 added to the volumetric flask 2 
 Then 12mL lysis buffer is added to flask 2 
o The flask is turned/mixed five times 
 The solution is then incubates for 8 min. at room temperature 
 In the meantime the next step is prepared  
o Here the filter of a NucleoBond Xtra column is moistened with 25mL equilibrium 
buffer 
 The flask was now done incubating 
 12mL neutralization buffer is added to the solution in flask 2 
o The solution changes colour to first white, and thereafter yellow as we turn/mix the 
solution 10 times 
 The content of flask 2 is added to the NucleoBond Xtra column 
o We expect the DNA to be bound in the lower filter 
 We are letting the column drip 
 When the column doesn’t drip anymore the upper filter is removed 
 25mL wash buffer is added to the column 
 Again we are letting the column drip 
 In the meantime a new collection tube is found and marked “plasmid rør” 
 When the NucleoBond Xtra column doesn’t drip anymore the collection tube under it is 
change, so the new (“plasmid rør”) is placed under it 
 15mL elution buffer is added to the NucleoBond Xtra column 
 We are letting it run through the column until it doesn’t drip anymore 
o The plasmid should now be in the collection tube called “plasmid rør” 
 10mL isopropanol is added to the collection tube called “plasmid rør” 
 The solution is mixed firmly 
 The collection tube containing the plasmid sample is weighted 
 Another collection tube is found. This one is called “counterweight”, and is filled with wa-
ter, so it weights the exact same thing as the collection tube containing the sample 
 The two collection tubes (“plasmid rør” and “counterweight”) are centrifuged together for 
15 min., at 5000xG and around 18oC  
 The supernatant from “plasmid rør” is carefully poured in another tube which is discarded 
removed  
 5mL 70% ethanol is added to “plasmid rør” 
 Water is filled in the collection tube “counterweight”, so it weights exactly the same as the 
collection tube called “plasmid rør” 
 The two collection tubes (“plasmid rør” and “counterweight”) are again centrifuged together 
for 5 min., at 15000xG and at room temperature 
 The supernatant from “plasmid rør” is carefully removed by pipetting 
 The rest of the content of the collection tube called “plasmid rør” are we letting dry com-
pletely 
 When the content is dry, 300μL milli-Q is added to the collection tube and resuspended 
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 The complete content is then added to a new 1.5mL Eppendorf tube called “plasmid 
miR29a, 18/11 
 The concentration of this plasmid sample is measured using NanoDrop Spectrophotometer 
ND-1000 
o Milli-Q water is used as a blank 
o The concentrations of the plasmid sample was 1442.6ng/mL and the 260/280 ratio 
was 1.92 
 The sample are put in the freezer (-20oC) 
 
Polylysin Coating (24/11 - 2014) 
 The procedure is done sterile in the cell laboratory  
 All materials are found and brought to the LAF bench 
o Before it is put in the bench it is proper serialized using 70% ethanol 
 We wanted to make five 6cm dishes with each containing 3.3mL working solution 
o Therefore the total volume is 16.5mL. Here we rounded it up to 20mL 
o The finish volume should be a 20x solution 
 This solution is made containing: 
o 1mL milli-Q water 
o 0.1mg Poly-D-lysine 
o 19mL sterile PBS 
 19mL PBS is then added to a 50mL tube 
 1mL of the Poly-D-lysine solution is added to this same 50mL tube 
 Then 3.3mL of the solution in the 50mL tube is added to each of the five 6cm dishes 
 The growth medium on the five 6cm dishes is removed 
 1mL 1xPBS is added to each of the five 6cm dishes 
 1mL trypsin is added to each of the five 6cm dishes 
 The trypsin is distributes 
 Then the five 6cm dishes is incubating for 5 min. in a 37oC incubator  
 Then 2mL growth medium is added is added to each of the five 6cm dishes 
 The complete content of each of the five 6cm dishes is added to one new 15mL tube 
 Then the 15mL tube is centrifuged for 5 min. at 5000rpm 
 The medium is then removed from the 15mL tube  
 The remaining cells in the bottom of the 15mL tube are diluted in 1mL growth medium 
 Then 9mL growth medium are added  
 Then it is inverted 
 The cells are now counted 
 A small piece of glass called Turk” is used 
 A sample of the cells in the 15mL tube is added to a turk glass 
 It is placed under the microscope 
 The cells a counted 3 places on the turk and a mean is found – The mean was 118.6 cells 
 This mean is multipelt with a “kammerfactor” and the volume 
 
118.6 cell * 10
4 * 10mL = 1.19*10
7 cells/10mL = 1.19*10
6cells/mL 
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 We want 2*106 cells per dish 
 Therefore 1.6mL of the cellsolution in the 15mL tube is added to each of the five 6cm dishes 
together with 2mL growthmedium 
 The five 6cm dishes are all marked “Ø mix” and placed in the 37oC, 5%CO2 incubator O.N. 
 
Transfection with polyethylene imine (PEI-25) (25/11 - 2014) 
 First the calculations are made: 
o The concentration of the control (plasmid without insert) is 958ng/μL 
o The concentration of the miR-29a plasmid is 1443ng/μL 
o The final concentration of both the control and the miR-29a sample should be 3μL 
and the final volume should be 250μL 
 Therefor we need: 
𝑉 =
𝑚
𝑐
=
6
1.443μg/μL
= 4.2μL of the plasmid containing miR-29a 
 Of the control plasmid we need: 
𝑉 =
𝑚
𝑐
=
6
0.958μg/μL
= 6.2μL 
 The procedure is done sterile in the LAF bench wearing gloves 
o All materials are sterilized before being put in the LAF bench 
 The cells which have been incubating O.N. are brought to the LAF bench 
 First the medium is removed from each of the five 6cm dishes containing the cells 
 Then 4mL new medium is added to each of the five 6cm dishes containing phoenix cells 
 The five dishes are then put back into the 37oC, 5% CO2 incubator 
 Now we will use the calculations we made at the beginning of procedure, to dilute the plas-
mid samples 
 The plasmids are diluted in saline 
o First two E-tubes are marked (The first is called “Tube 1 - control” and the second is 
called “Tube 2 - miR-29a”) 
o 4.2μL of the miR-29a plasmid from the maxiprep is added to tube 2 
o 6.2μL of the control plasmid is added to tube 1 
o 250μL saline is added to both tube 1 and tube 2 
 500μL polyehylene imine (PEI-25) is added to each of the two tubes 
 The transfection was done by Julian 2.5 hours later that same day 
 
Monitor Cells (24 hours after transfection) (26/11 - 2014) 
 Approximately 24 hours after transfection we monitored the cells to see if the cells were 
fluorescence 
 The four transfected 6cm dishes (The five dishes called “Ø cells”) are brought to the mi-
croscopy room from the 37oC, 5% CO2 incubator 
 The microscope used is called Leica DM IRB 
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 The microscope had to be set before using it – The four dishes were put back in the 37oC, 
5% CO2 incubator in the meantime 
 When the microscope were set the four 6cm dishes were brought back to the microscopy 
room 
 The four 6cm dishes were monitored in the microscope 
o The cells were fluorescence in both the control- and miR-29a cells 
o Furthermore we observed that the phoenix cells which had not been infected, did not 
fluoresce 
o Pictures of the four 6cm dishes were taken and saved 
 The cells were put back in to the incubator at 37oC 
 
Viral Harvest I (27/11 - 2014) 
 The four 6cm dishes containing phoenix cells are picked from the 37oC, 5% CO2 incubator 
and monitored in the microscope (Leica DM IRB) 
o The cells were fluorescence in both the control- and miR-29a cells 
o Furthermore we observed that the phoenix cells which had not been infected, didn’t 
fluorescence 
o Pictures of the dishes were taken and saved 
 The procedure is now done sterile in the cell lab  
o All materials are sterilized before being put in the LAF bench 
 Eight 15mL tubes are marked (Four of the tubes are used for centrifugation, and the four 
others are used for storage in the -80oC freezer): 
o Tube 1 is marked “Frost miR-29a 1 27/11, dag 2” 
o Tube 2 is marked “Frost miR-29a 2 27/11, dag 2” 
o Tube 3 is marked “Frost control 1 27/11, dag 2” 
o Tube 4 is marked “Frost control 2 27/11, dag 2” 
o Tube 5 is marked “Centrifugation miR-29a 1” 
o Tube 6 is marked “Centrifugation miR-29a 2” 
o Tube 7 is marked “Centrifugation control 1” 
o Tube 8 is marked “Centrifugation control 2” 
 All of the growth medium is removed from the four 6cm dishes and put in the respectively 
15mL tubes 
o 4mL from dish 1 containing miR-29a is added to “Centrifugation miR-29a 1 27/11, 
dag 2” 
o 4mL from dish 2 containing miR-29a is added to “Centrifugation miR-29a 2 27/11, 
dag 2” 
o 4mL from dish 3 containing the control is added to “Centrifugation control 1 27/11, 
dag 2” 
o 4mL from dish 4 containing the control is added to “Centrifugation control 2 27/11, 
dag 2” 
 Each of these four 6cm dishes are then added 5mL new growth medium 
 The four tubes called “Centrifugation miR-29a 1”, “Centrifugation miR-29a 2”, “Centrifu-
gation control 1” and “Centrifugation control 2” are centrifuged for 5 min. at 1200rpm 
 The supernatant from the four tubes is then removed and added to the four remaining 15mL 
tubes: 
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o The supernatant from the tube called “Centrifugation miR-29a 1 27/11, dag 2” is 
added to the “Frost miR-29a 1 27/11, dag 2” 
o The supernatant from the tube called “Centrifugation miR-29a 2 27/11, dag 2” is 
added to the “Frost miR-29a 2 27/11, dag 2” 
o The supernatant from the tube called “Centrifugation control 1 27/11, dag 2” is add-
ed to the “Frost control 1 27/11, dag 2” 
o The supernatant from the tube called “Centrifugation control 2 27/11, dag 2” is add-
ed to the “Frost control 2 27/11, dag 2” 
 The four 15mL tubes containing the samples is put in a white box, and placed in the -80oC 
freezer (Freezer number 7, the third lid from the left) 
 
Viral harvest II (28/11 - 2014) 
 The four dishes containing phoenix cells are picked from the 37oC, 5% CO2 incubator and 
monitored in the microscope 
o The cells were fluorescence in both the control- and miR-29a cells 
o Furthermore we observed that the phoenix cells which had not been infected, didn’t 
fluorescence 
o Pictures of the dishes were taken and saved 
 The procedure is now done sterile in the cell laboratory 
o All materials are sterilized before being put in the LAF bench 
 Eight 15mL tubes are marked (four of the tubes are used for centrifugation, and the four 
others are used for storage in the -80oC freezer): 
o Tube 1 is marked “Frost miR-29a 1 27/11, dag 3” 
o Tube 2 is marked “Frost miR-29a 2 27/11, dag 3” 
o Tube 3 is marked “Frost control 1 27/11, dag 3” 
o Tube 4 is marked “Frost control 2 27/11, dag 3” 
o Tube 5 is marked “Centrifugation miR-29a 1” 
o Tube 6 is marked “Centrifugation miR-29a 2” 
o Tube 7 is marked “Centrifugation control 1” 
o Tube 8 is marked “Centrifugation control 2” 
 All of the growth medium is removed from the four 6cm dishes and put in the respectively 
15mL tubes 
o 4mL from dish 1 containing miR-29a is added to “Centrifugation miR-29a 1 27/11, 
dag 3” 
o 4mL from dish 2 containing miR-29a is added to “Centrifugation miR-29a 2 27/11, 
dag 3” 
o 4mL from dish 3 containing the control is added to “Centrifugation control 1 27/11, 
dag 3” 
o 4mL from dish 4 containing the control is added to “Centrifugation control 2 27/11, 
dag 3” 
 Each of these four 6cm dishes are then added 5mL new growth medium 
 The four tubes called “Centrifugation miR-29a 1”, “Centrifugation miR-29a 2”, “Centrifu-
gation control 1” and “Centrifugation control 2” are centrifuged for 5 min. at 1200rpm 
 The supernatant from the four tubes is then removed and added to the four remaining 15mL 
tubes: 
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o The supernatant from the tube called “Centrifugation miR-29a 1 27/11, dag 2” is 
added to the “Frost miR-29a 1 27/11, dag 3” 
o The supernatant from the tube called “Centrifugation miR-29a 2 27/11, dag 2” is 
added to the “Frost miR-29a 2 27/11, dag 3” 
o The supernatant from the tube called “Centrifugation control 1 27/11, dag 2” is add-
ed to the “Frost control 1 27/11, dag 3” 
o The supernatant from the tube called “Centrifugation control 2 27/11, dag 2” is add-
ed to the “Frost control 2 27/11, dag 3” 
 The four 15mL tubes containing the samples is put in the same white box as the day before, 
and placed in the -80oC freezer (Freezer number 7, the third lid from the left) 
 
Infection of C2C12 cells (1/12 - 2014) 
 All materials are found and brought to the cell laboratory 
 The procedure is now done sterile in the cell lab  
o All materials are sterilized before being put in the LAF bench 
 The harvested viral medium is found in the -80oC (Freezer number 7, the third  from the left) 
and brought to the LAF bench 
o But we decided not to use them before the second infection, and therefor they are put 
back into the -80oC freezer (Freezer number 7, the third lid from the left) 
 The eight 10cm dishes containing C2C12 cells are found in the 37oC, 5% CO2 incubator and 
monitored in the microscope (The Leica DM IRB) 
o Very few cells is observed 
 The growth medium is removed from all eight 10cm dishes  
 2.5mL serum free medium is added to each of the eight 10cm dishes containing C2C12 cells 
 The phoenix cells is brought to the LAF bench from the 37oC, 5% CO2 incubator 
o We observe that all the cells seems to have died from the infection 
 The complete volume from dish 3 containing the control infected cells, is sucked up using a 
needle and filtrated down into a new 15mL tube. This is the control tube 
 The complete volume from dish 4 containing the control infected cells, is also sucked up us-
ing a needle and filtrated down into the same tube (The control tube) 
o The total volume of the control tube was approximately 10mL 
 6μL polybrene is added to the control tube 
 The control tube is marked “Kontrol” and put aside 
 The LAF bench is sterilized using 70% ethanol 
 The eight 10cm dishes containing C2C12 cells are put back in to the incubator at 37oC, 5% 
CO2 
 A new 15mL tube is found and marked “miR-29a” 
 The complete volume from the dish 1 containing the miR-29a infected cells, is sucked up 
using a needle and filtrated down into a 15mL tube called “miR-29a”  
 The complete volume from dish 2 containing the miR-29a infected cells, is also sucked up 
using a needle and filtrated into the same 15mL tube (The tube called “miR-29a”) 
o The total volume of the miR-29a tube was approximately 8mL 
 6μL polybrene is added to the 15mL tube called “miR-29a” 
 The two tubes are incubated for 5 min. at room temperature 
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 The eight 10cm dishes containing the C2C12 cells are again brought to the LAF bench from 
the 37oC, 5% CO2 incubator 
 Three of the eight 10cm dishes containing the C2C12 cells are marked “miR-29a” 
 2.5mL of the sample in the miR-29a tube is added to each of the three dishes marked “miR-
29a” 
o The pipettip is change every time, and the dishes are gently mixed to distribute the 
infected medium on the whole dish 
 Three of the 10cm dishes containing C2C12 cell is marked “con” 
 2.5mL of the sample in the control tube is added to each of the three 10cm dishes marked 
“con” 
o The pipettip is change every time, and the dishes are gently mixed to distribute the 
infected medium on the whole dish 
 The eight 10cm dishes containing C2C12 cells are put back in to the 37oC, 5% CO2 incuba-
tor 
o Three of the 10cm dishes containing the C2C12 cells are infected with the miR-29a 
vira (The dishes called “miR-29a”) 
o Three of the other 10 cm dishes containing C2C12 cells are infected with the control 
vira (The dishes called “con”) 
o Two of the 10cm dishes containing the C2C12 cells have not been infected and are 
used as control dishes 
 The eight infected 10cm dishes are placed back in the 37oC, 5% CO2 incubator 
 
Restrike of Glycerol stocks (Control plasmid) (2/12 - 2014) 
 The control plasmid is back from sequencing 
 Based on the results from the sequencing, and the results from the NanoDrop, sample 5 is 
chosen for further procedures 
 The procedure is done wearing gloves 
 Two new ampicillin plates (100 mg/mL) are found in the cold storage  
 All other materials are found 
 Plates and materials are brought to the -80oC freezer  
 Glycerol sample nr. 5 are found in the -80oC freezer (Left lower corner, in a orange box 
called “SAMMN Julian miRNA”) 
 The plates are marked and divided in two divisions 
o The first plate is marked “Kontrolplasmid renstrygning glyc. 5 2/12-2014 Julian I” 
o The second plate is marked “Kontrolplasmid renstrygning glyc. 5 2/12-2014 Julian II 
 A sample of the glycerol stock nr. 5 are taken by a small pipettip, and put on the agar plates 
 The restrike is done with a small plastic needle 
 The glycerol stock nr. 5 is put back in to the -80oC freezer (Left lower corner, in a orange 
box called “SAMMN Julian miRNA”) 
 The plates are put in an incubator at 37oC, 5% CO2 O.N. 
 
Infection II (2/12 - 2014) 
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 The infected C2C12 cells are found in the 37oC, 5% CO2 incubator – They have now been 
infected for approximately 24 hours – Their medium was changed after 12 hours to a medi-
um that contained serum 
 The eight 10cm dishes containing the infected C2C12 cells are monitored in a microscope 
(Leica DM IRB) 
o No fluorescent is observed 
 The 8 10cm dishes are placed back in the incubator at 37oC, 5% CO2 
 All materials are found and brought to the cell lab 
 The procedure is now done sterile in the cell lab  
 All materials are sterilized before being put in the LAF bench 
 Two of the tubes containing miR-29a vira (Harvested after 48 hours of infection and called 
“Frost miR-29a 1 27/11, dag 2” and “Frost miR-29a 2 27/11, dag 2”) is brought to the cell 
lab from the -80oC freezer  
 3μL polybrene is added to each of the two tubes containing miR-29a vira  (“Frost miR-29a 1 
27/11, dag 2” and “Frost miR-29a 2 27/11, dag 2”) 
 The two tubes is inverted three times 
 The two tubes are incubated for 16 min. at room temperature 
 In the mean time four of the C2C12 10cm dishes are brought to the LAF bench from the 
37oC, 5% CO2 incubator (Two of the dishes called “miR-29a” and two of the dishes called 
“con”) 
 Two of the miR-29a vira infected dishes are market “2” meaning that they are infected twish 
 The media is removed from two of the infected control dishes  (The two dishes called “con 
2”) and two of the infected miR-29a dishes (the two dishes called “miR-29a 2”) 
 2mL serum free growth media is added to these four dishes 
 2μL of the tube called “Frost miR-29a 1 27/11, dag 2” is added to the two dishes called 
“miR-29a 2”  
 The tube containing the original empty plasmid (pMSCV PIG) is found 
 2μL of the tube called containing the empty plasmid sample is added to the two dishes 
called “con 2” 
 All four dishes are put back in to the incubator at 37oC, 5% CO2 
 
Change of growth medium containing serum (3/12 - 2014) 
 The infected C2C12 cells are found and brought from the 37oC, 5% CO2 incubator and to 
the LAF bench 
o The eight 10cm dishes called, “con”, miR-29a”, two dishes called “negative con-
trol”, two dishes called “miR-29a 2” and two dishes called “con 2” 
 All materials are found and brought to the cell lab 
 The procedure is now done sterile in the cell lab  
 All materials are sterilized before being put in the LAF bench 
 The medium from all eight 10cm dishes are removed 
 Each of the eight 10cm dishes are added 5mL medium containing serum 
 The eight 10cm dishes are put back in to the incubator at 37oC 
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O.N. culture for maxi preparation part I – Control plasmid (3/12 - 2014) 
 The work is now performed sterile. Everything is cleaned with 70% ethanol before use, and 
done wearing glows 
 The LB medium called “Julian LB med” are found in the cold storage in 15.0 
 The dishes called “Kontrolplasmid renstrygning glyc. 5 2/12-2014 Julian I” and “Kontrol-
plasmid renstrygning glyc. 5 2/12-2014 Julian II” are found in the 37oC, 5% CO2 incubator 
and examined 
o The restrike has been successful and single colonies are observed 
 A 50mL tube is marked “O.N. control 031214” 
 5mL LB medium is added the tube which should be used for the O.N. culturing 
 5μL ampicillin which makes the final concentration of ampicillin in the LB medium 
100μg/mL 
 One colony are picked from one of the plates using a pipettip and added to the tube 
 The tube is placed in the incubator (Gently shaken at 37oC) O.N. 
  
Infected C2C12 monitored 24 hours after 2. Infection (3/12 - 2014) 
 Two of the infected C2C12 dishes (One of the infected C2C12 cell called “con” and one 
called “miR-29a 2”) are brought from the 37oC, 5% CO2 incubator to the microscope Leica 
DM IRB  
 They are placed under the microscope and observed 
 No fluorescence is observed 
 
Selection (4/12 - 2014) 
 First the calculations have to be done 
o We want to add 5mL to each sample. Therefore the total volume should be 50mL 
o The stock concentration of pyromycin is 1mg/mL - The final concentration should be 
2μL/mL  
C1 * V1 = C2 * V1 
1000μg/μL * V1 = 2μg/μL * 50mL 
𝑉1 =
2𝜇𝑔/𝑚𝐿 ∙ 50𝑚𝐿
100𝜇𝑔/𝑚𝐿
= 0.1 𝑚𝐿 = 100𝜇𝐿 
 The eight 10cm dishes (The eight dishes called, “con”, miR-29a”, two dishes called “nega-
tive control”, two dishes called “miR-29a 2” and two dishes called “con 2”) are found in the 
incubator at 37oC, 5% CO2 
 All materials are found and brought to the cell lab 
 The procedure is now done sterile in the cell lab  
 All materials are sterilized before being put in the LAF bench 
 50mL C2C12 growth medium with serum is added to a 50mL tube 
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 100μL pyromycin is added to the same 50mL tube 
 The 50mL tube is inverted a few times 
 The medium is removed from all of the eight 10cm dishes containing infected C2C12 cells 
 Each dish is added 5mL of the growth medium containing 2μL/mL pyromycin from the 
50mL tube 
 All of the eight 10cm dishes (The eight dishes called, “con”, miR-29a”, two dishes called 
“negative control”, two dishes called “miR-29a 2” and two dishes called “con 2”) are put 
back into the 37oC, 5% CO2 incubator 
 
O.N. culture for maxi preparation part II - Control plasmid (4/12 - 2014) 
 All materials are found and brought to the immune laboratory 
o The 50mL tube called “O.N. control 031214” is picked from the 37oC incubator  
o The LB medium called “Julian LB med” are found in the cold storage in 15.0 
 The work is now performed sterile. Everything is cleaned with 70% ethanol before use, and 
done wearing glows 
 250mL of the LB medium called “Julian LB med” is added to a volumetric flask  
 250μL ampicillin is added to the volumetric flask and inverted a few times 
 The complete content of the 50mL tube called “O.N. control 031214” is added to the volu-
metric flask 
 The volumetric flask is placed in the 37oC incubator gently shaking O.N. 
 
Maxi Preparation (5/12 - 2014) 
 The maxi preparation is done using the kit (NucleoBond Xtra Maxi Colum REF 740414.50) 
 The volumetric flask containing the O.N. culture is found in the 37oC incubator 
 The flask is examined and the pipettip removed  
 The procedure is done wearing gloves 
 The centrifuge used for the maxi preparation (18/11) was out of use, and therefore a smaller 
one was used. 
 The complete content of the volumetric flask is added to six 50mL tubes 
 The six 50mL tubes were weighed 
o The content of the six 50mL tubes was distributed, so the weight of the six 50mL 
tubes were the same  
 The six 50mL tubes is centrifuged for 5min. at 4500xG 
 Resuspension buffer is picked from the refrigerator 
 4mL resuspension buffer is added to three of the six 50mL tubes 
o These three tubes is resuspended 
 The three tubes containing the resuspended content are added to the three remaining 50mL 
tubes 
o These last three tube is also resuspended 
 The complete content of the 50mL tubes is collected in one 50mL tube 
 12mL lysis buffer is added to the 50mL tube 
 The 50mL tube is inverted five times 
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 Then the 50mL tube is incubated for 5 min. at room temperature 
 In the meantime the next step is prepared  
o Here the filter of a NucleoBond Xtra column is moistened with 25mL equilibrium 
buffer  
 The 50mL tube was now done incubating 
 12mL neutralization buffer is added to the solution in the 50mL tube 
o The solution changes colour to first white, and thereafter yellow as we invert the so-
lution ten times 
 The complete content of the 50mL tube is added to the NucleoBond Xtra column 
o We expect the DNA to be bound in the lower filter 
 We are letting the column drip 
 15mL Equilibrium buffer is then added to the column 
 We are letting the column drip again 
 When the column doesn’t drip anymore the upper filter is removed 
 25mL wash buffer is added to the column 
 Again we are letting the column drip 
 In the meantime a new 50mL collection tube is found and marked “plasmid” 
 When the NucleoBond Xtra column doesn’t drip anymore the collection tube under it is 
change, so the new 50mL collection tube (marked “plasmid”) is placed under it 
 15mL elution buffer is added to the NucleoBond Xtra column 
 We are letting it run through the column until it doesn’t drip anymore 
o The plasmid should now be in the 50mL collection tube called “plasmid ” 
 10.5mL isopropanol is added to the 50mL collection tube called “plasmid” 
 The solution is mixed firmly 
 The 50mL collection tube (“plasmid”) containing the plasmid sample is weighed 
 Another 50mL collection tube is found. This one is called “counterweight”, and is filled 
with water, so it weights exactly the same as the 50mL collection tube containing the sample 
 The two 50mL collection tubes (“plasmid” and “counterweight”) are centrifuged together 
for 15 min., at 4500xG and around 18oC  
 The supernatant from the 50mL tube called “plasmid” is carefully removed by pouring 
 5mL 70% ethanol is added to the 50mL tube called “plasmid” 
 Water is filled in the 50mL tube called “counterweight”, so it weights exactly the same as 
the 50mL collection tube called “plasmid” 
 The two 50mL tubes (“plasmid” and “counterweight”) are again centrifuged together for 10 
min., at 4500xG and at room temperature 
 The supernatant from the 50mL tube called “plasmid” is carefully removed by pipetting 
 The rest of the content of the 50mL tube called “plasmid” are we letting dry completely 
 When the content is dry, 300μL milli-Q water is added to the 50mL tube called “plasmid” 
and resuspended 
 The complete content is then added to a new 1.5mL Eppendorf tube called “controlplasmid, 
5/12-2014”  
 The concentration of this plasmid sample is measured using NanoDrop Spectrophotometer 
ND-1000 
o Milli-Q water is used as a blank 
o The concentrations of the plasmid sample was 23ng/μL and the 260/280 ratio was 
1.88 
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 The sample are put in the freezer (-20oC) 
 
Selection - Second time (5/12 - 2014) 
 The eight 10cm dishes are found in the 37oC, 5% CO2 incubator (The eight 10cm dishes 
called, “con”, miR-29a”, two dishes called “negative control”, two dishes called “miR-29a 
2” and two dishes called “con 2”) 
 All materials are found and brought to the cell lab 
 The procedure is now done sterile in the cell lab  
 All materials are sterilized before being put in the LAF bench 
 50mL C2C12 growth medium with serum is added to a 50mL tube 
 The puromysin is thawed – The stock concentration is 1mg/mL 
 100μL pyromycin is added to the same 50mL tube  
o The final concentration of the puromycin will therefore be 2μL/mL 
 The 50mL tube is inverted a three times 
 The medium is removed from all four of the eight 10cm dishes (the two 10cm dishes called 
“miR-29a 2” and the two 10cm dishes called “con 2”) 
 Each dish is added 5mL of the growth medium containing 2μL/mL pyromycin from the 
50mL tube 
 The medium from remaining four 10cm dishes (The dishes called “con”, miR-29a”, two 
dishes called “negative control) is removed 
 5mL growth medium with serum is added to these four 10cm dishes (The dishes called 
“con”, miR-29a” and the two dishes called “negative control). 
 All eight 10cm dishes are put back into the 37oC, 5% CO2 incubator 
 
Monitoring the selection dishes (8/12 - 2014) 
 The eight 10cm dishes (The eight 10cm dishes called, “con”, miR-29a”, two dishes called 
“negative control”, two dishes called “miR-29a 2” and two dishes called “con 2”) containing 
the infected C2C12 cells were picked from the 37oC, 5% CO2 incubator and brought to the 
microscope Leica DM IRB 
 The cells are examined in the microscope in both ultraviolet light and in normal phase con-
trast 
o Not all the cells on the selection dishes (The two dishes called negative control) were 
dead, and it is therefore concluded that the selection has to run for a longer period 
o Fluorescence is observed in seven out of the eight dishes (The eight 10cm dishes 
called, “con”, miR-29a”, one of dishes called “negative control”, two dishes called 
“miR-29a 2” and two dishes called “con 2”) – The fluorescence in the negative con-
trol is seen in all the different filter, and may therefore be something else than the 
cells 
 Pictures are taken of the eight 10cm dishes (The eight 10cm dishes called, “con”, miR-29a”, 
two dishes called “negative control”, two dishes called “miR-29a 2” and two dishes called 
“con 2”) in both ultraviolet and normal light 
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Transfection with all three types of plasmids (8/12 - 2014) 
 All materials are found and brought to the cell lab 
 The three tubes containing the plasmid samples are picked from the -20oC freezer 
 The three tubes contain plasmids samples obtained from the maxi preparation: 
o An uncut plasmid (pMSCV PIG) with no insert (Called “LTD”) 
o An plasmid with the control sequence (Called “Control”) 
o An plasmid with the miR-29a sequence (Called “miR-29a”) 
 Calculations are now made: 
 
The concentrations of the three types of plasmid samples are: 
 LTD = 957.9ng/μL 
 Control = 23ng/μL 
 miR-29a = 1449.2ng/μL 
 
The final concentration of the plasmid should be 3μg/μL. Therefor the volume added should be: 
𝑉 =
𝑚
𝑐
 
𝑉𝐿𝑇𝐷 =
3.0
0.9579
= 3.1μL 
𝑉𝐶𝑜𝑛𝑡𝑟𝑜𝑙 =
3.0
0.023
= 130.4μL 
𝑉𝑚𝑖𝑅−29𝑎 =
3.0
1.4492
= 2.1μL 
 The procedure is now done sterile in the cell lab  
 All materials are sterilized before being put in the LAF bench 
 Three 1.5mL Eppendorf tubes are marked: 
o Tube 1 is marked “LTD” 
o Tube 2 is marked “C” 
o Tube 3 is marked “miR” 
 3.1μL of the tube containing the plasmid sample “LTD” is added to the 1.5mL Eppendorf 
tube called “LTD” 
 130.4μL of the tube containing the plasmid sample “Control” is added to the 1.5mL Eppen-
dorf tube called “C” 
 2.1μL of the tube containing the plasmid sample “miR-29a” is added to the 1.5mL Eppen-
dorf tube called “miR” 
 247μL saline (with a stock solution of 150mM) is added to the 1.5mL Eppendorf tube called 
“LTD” 
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 116μL saline (with a stock solution of 150mM) is added to the 1.5mL Eppendorf tube called 
“C” 
 248μL saline (with a stock solution of 150mM) is added to the 1.5mL Eppendorf tube called 
“miR” 
o The total volume of all three tubes is now be approximately 250μL 
 250μL Polyethylene imine (PEI-25) is added to each of the three 1.5mL Eppendorf tubes 
(The three tubes called “LTD”, “C” and “miR”) 
 All three 1.5mL Eppendorf tubes (The three tubes called “LTD”, “C” and “miR”) is vor-
texed and incubated at room temperature for 60 min. 
 In the meantime the medium from four 6cm dishes containing phoenix cell is removed 
 Then 4mL growth medium is added to each of the four dishes containing the phoenix cells 
 The four 6cm dishes containing the phoenix cells are marked 
o Dish 1 is marked “miR-29a” 
o Dish 2 is marked “Control” 
o Dish 3 is marked “LTD” 
o Dish 4 is marked “Tom” 
 After the 60 min. incubation the complete content of the three 1.5mL Eppendorf tubes is 
added to each of the three of 6cm dishes containing the phoenix cells 
o The complete content of the 1.5mL Eppendorf tube called “miR” is added to the dish 
called “miR-29a” 
o The complete content of the 1.5mL Eppendorf tube called “C” is added to the dish 
called “Control” 
o The complete content of the 1.5mL Eppendorf tube called “LTD” is added to the 
dish called “LTD” 
 All 4 dishes are placed in the incubator at 37oC, 5% CO2 
 
Selection third time (8/12 - 2014) 
 The eight 10cm dishes are found in the 37oC, 5% CO2 incubator (The eight 10cm dishes 
called, “con”, miR-29a”, two dishes called “negative control”, two dishes called “miR-29a 
2” and two dishes called “con 2”) 
 All materials are found and brought to the cell lab 
 The procedure is now done sterile in the cell lab  
 All materials are sterilized before being put in the LAF bench 
 50mL C2C12 growth medium containing is added to a 50mL tube 
 The puromycin is thawed – The stock concentration is 1mg/mL 
 100μL puromycin is added to the same 50mL tube  
o The final concentration of the puromycin will therefore be 2μL/mL 
 The 50mL tube is inverted a three times 
 The medium is removed from all of the four of the eight 10cm dishes (the two  dishes called 
“miR-29a 2” and the two dishes called “con 2”) 
 Each dish is added 5mL of the growth medium containing 2μL/mL puromycin from the 
50mL tube 
 The medium from remaining four 10cm dishes (The dishes called “con”, miR-29a”, two 
dishes called “negative control) is removed 
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 5mL growth medium containing serum is added to these four 10cm dishes (The dishes 
called “con”, miR-29a”, two dishes called “negative control). 
 All eight 10cm dishes are put back into the 37oC, 5% CO2 incubator 
  
Monitoring the transfected phoenix cells (10/12 - 2014) 
 The four 6cm dishes (The 4 dishes called, “Control”, “miR-29a”, “LTD” and “Tom”) con-
taining the transfected phoenix cells were picked from the 37oC, 5% CO2 incubator and 
brought to the microscope (Leica DM IRB) 
 The cells are examined in the microscope in both ultraviolet light and in normal phase con-
trast 
o Fluorescence is observed in three out of four 6 cm dishes (The dishes called “miR-
29a”, “Control” and “LTD”) 
o No fluorescence is observed in the dish called “Tom” 
 Pictures are taken of the four 6cm dishes (The four dishes called, “Control”, “miR-29a”, 
“LTD” and “Tom”) in both ultraviolet and normal light 
 The dishes are placed back in the incubator at 37oC, 5% CO2 
 
Infection of the C2C12 cells (10/12 - 2014) 
 All materials are found and brought to the cell lab 
 Four 10cm dishes containing C2C12 cells (Containing approximately 10000 C2C12 cells) is 
found in the incubator which is 37oC, 5% CO2 and brought to the LAF bench 
 The procedure is now done sterile in the cell lab  
 All materials are sterilized before being put in the LAF bench 
 The medium is removed from the four 10cm dishes containing C2C12 cells 
 The four 10cm dishes containing C2C12 cells (Containing approximately 10000 C2C12 
cells) is marked: 
o Dish 1 is marked: “miR-29a 101214” 
o Dish 2 is marked: “Control 101214” 
o Dish 3 is marked: “LTD 101214” 
o Dish 4 is marked: “Selektionsplade 101214” 
 The 10cm dish called “Selektionsplade 101214” is added 5mL serum free medium 
 The three 10cm dishes called “miR-29a 101214”, “Control 101214” and “LTD 101214” is 
added 2.5mL serum free medium 
 The four 10cm dishes (The dishes called “miR-29a 101214”, “Control 101214” “LTD 
101214” and “selektionsplade 101214”) is placed back in the incubator at 37oC and 5% CO2 
 Three 15mL tubes is found and marked 
o Tube 1 is marked “miR-29a” 
o Tube 2 is marked “Control” 
o Tube 3 is marked “LTD” 
 The three 6cm dishes containing transfected phoenix cells (The dishes called “miR-29a”, 
“Control” and “LTD”) is found in the 37oC, 5% CO2 incubator and brought to the LAF 
bench 
 The complete volume from the 6cm dish called “miR-29a”, is sucked up using a needle and 
filtrated down into the tube called “miR-29a” 
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 The complete volume from the 6cm dish called “Control”, is sucked up using a needle and 
filtrated down into the tube called “Control” 
 The complete volume from the 6cm dish called “LTD”, is sucked up using a needle and fil-
trated down into the tube called “LTD” 
 The three 6cm dishes containing the transfected phoenix cells (The dishes called “miR-29a”, 
“Control” and “LTD”) is each added 5mL growth medium containing serum  
 The three 6cm dishes containing the transfected phoenix cells (The dishes called “miR-29a”, 
“Control” and “LTD”) are placed back in the incubator at 37oC, 5% CO2 
 The three 10cm dishes containing C2C12 cells (The dishes called “miR-29a 101214”, “Con-
trol 101214” and “LTD 101214”) is found in the incubator at 37oC, 5% CO2 and brought to 
the LAF bench 
 Three new 15mL tubes are marked: 
o Tube 1 is marked “miR-29a’ ” 
o Tube 2 is marked “Control’ ” 
o Tube 3 is marked “LTD’ ” 
 1.5mL polybrene (With a stock concentration at [5mg(mL]) is added to each of the three 
15mL tubes (The tubes called “miR-29a’ ”, “Control’ ” and “LTD’ ”) using a pipet 
 2.5mL of the viral medium from the 15mL tube called “miR-29a” is added to the 15mL tube 
called “miR-29a’ ” and the content is resuspended 
 2.5mL of the viral medium from the 15mL tube called “Control” is added to the 15mL tube 
called “Control’ ” and the content is resuspended 
 2.5mL of the viral medium from the 15mL tube called “LTD” is added to the 15mL tube 
called “LTD’ ” and the content is resuspended 
 The complete content of the 15mL tube called “miR-29a’ “ is added to the 10cm dish called 
“miR-29a” 
  The complete content of the 15mL tube called “Control’ “ is added to the 10cm dish called 
“Control” 
 The complete content of the 15mL tube called “LTD’ “ is added to the 10cm dish called 
“LTD” 
 The four 10cm dishes (The four 10cm dishes called “miR-29a 101214”, “Control 101214”, 
“LTD 101214” and “Selektionsplade 101214”) are placed in the incubator at 37oC, 5% CO2 
 
Monitoring the C2C12 which have been selected (10/12 - 2014) 
 The eight 10cm dishes are found in the 37oC, 5% CO2 incubator (The eight 10cm dishes 
called, “con”, miR-29a”, two dishes called “negative control”, two dishes called “miR-29a 
2” and two dishes called “con 2”) and brought to the microscope (Leica DM IRB) 
 The C2C12 cells in the eight 10cm dishes are examined in the microscope in both ultraviolet 
light and in normal phase contrast 
 No cells are observed in the two dishes called “negative control”, meaning that the selection 
is ended 
 A few cells are found in the six remaining 10 cm dishes (The 10cm dishes called “con”, 
miR-29a”, two dishes called “miR-29a 2” and two dishes called “con 2”), and some light is 
observed when exposing the cells to ultraviolet light. However this light is also observed in 
other kinds of light, indicating that this light is not fluorescence caused by the GFP in the 
plasmid. 
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Monitoring the phoenix cells (11/12 - 2014) 
 The four 6cm dishes (The four 6cm dishes called, “Control”, “miR-29a”, “LTD” and 
“Tom”) containing the transfected phoenix cells were picked from the 37oC, 5% CO2 incu-
bator and brought to the microscope (Leica DM IRB) 
 The cells are examined in the microscope in both ultraviolet light and in normal phase con-
trast 
o Using normal light it is observed that the cells in the two 6cm dishes called “Con-
trol” and “miR-29a” is almost confluent. Furthermore it is observed that the cells in 
the 6cm dish called “LTD” contain fewer cells than the dishes called “Control” and 
“miR-29a”, and that they are not yet confluent 
o Fluorescence is observed in three out of four 6cm dishes (The 6cm dishes called 
“miR-29a”, “Control” and “LTD”) 
o No fluorescence is observed in the 6cm dish called “Tom”, however observed in 
normal light, the cells appears to be confluent 
 Pictures are taken of the four 6cm dishes (The four 6cm dishes called, “Control”, “miR-
29a”, “LTD” and “Tom”) in both ultraviolet and normal light 
 The four 6cm dishes are placed back in the incubator at 37oC, 5% CO2 
 
Monitoring the infected C2C12 cells (24 hours after the first infection) (11/12 - 2014) 
 The four 10cm dishes (The dishes called “miR-29a 101214”, “Control 101214”, “LTD 
101214” and “Selektionsplade 101214”) are found in the 37oC, 5% CO2 incubator and 
brought to the microscope (Leica DM IRB) 
 The C2C12 cells in the four 10cm dishes are examined in the microscope in both ultraviolet 
light and in normal phase contrast 
 Few cells is observed in the 10cm dishes called “miR-29a 101214”, “Control 101214” and 
“LTD 101214” 
o No fluorescence is observed in any of this 10cm dishes 
 Fewer cells are observed in the 10cm dish called “Selektionsplade 101214” 
o No fluorescence is observed on this 10cm dish 
 Pictures are taken of the four 10cm dishes (The four 10cm dishes called “miR-29a 101214”, 
“Control 101214”, “LTD 101214” and “Selektionsplade 101214”) in both ultraviolet and 
normal light 
 The four 10cm dishes are placed back in the incubator at 37oC, 5% CO2 
 
Second infection of the C2C12 cells (11/12 - 2014) 
 All materials are found and brought to the cell lab 
 Four 10cm dishes containing the infected C2C12 cells (The four 10cm dishes called “miR-
29a 101214”, “Control 101214”, “LTD 101214” and “Selektionsplade 101214”) is found in 
the incubator which is 37oC, 5% CO2 and brought to the LAF bench 
 The procedure is now done sterile in the cell lab  
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 All materials are sterilized before being put in the LAF bench 
 The medium is removed from the four 10cm dishes containing the infected C2C12 cells 
 The 10cm dish called “Selektionsplade 101214” is added 5mL serum free medium 
 The three 10cm dishes called “miR-29a 101214”, “Control 101214” and “LTD 101214” is 
added 2.5mL serum free medium 
 The four 10cm dishes (The dishes called “miR-29a 101214”, “Control 101214” “LTD 
101214” and “selektionsplade 101214”) is placed back in the incubator at 37oC, 5% CO2 
 Three 15mL tubes is found and marked: 
o Tube 1 is marked “miR-29a” 
o Tube 2 is marked “Control” 
o Tube 3 is marked “LTD” 
 The three 6cm dishes containing transfected phoenix cells (The three 6cm dishes called 
“miR-29a”, “Control” and “LTD”) is found in the incubator at 37oC, 5% CO2 and brought to 
the LAF bench  
 The complete volume from the 6cm dish called “miR-29a”, is sucked up using a needle and 
filtrated down into the tube called “miR-29a” 
 The complete volume from the 6cm dish called “Control”, is sucked up using a needle and 
filtrated down into the tube called “Control” 
 The complete volume from the 6cm dish called “LTD”, is sucked up using a needle and fil-
trated down into the tube called “LTD” 
 The three 6cm dishes containing the transfected phoenix cells (The three 6cm dishes called 
“miR-29a”, “Control” and “LTD”) is each added 5mL growth medium containing serum  
 The three 6cm dishes containing the transfected phoenix cells (The three 6cm dishes called 
“miR-29a”, “Control” and “LTD”) are placed back in the incubator at 37oC, 5% CO2 
 The three 10cm dishes containing C2C12 cells (The three 10cm dishes called “miR-29a 
101214”, “Control 101214” and “LTD 101214”) is found in the incubator at 37oC, 5% CO2 
and brought to the LAF bench  
 Three new 15mL tubes are marked: 
o Tube 1 is marked “miR-29a’ ” 
o Tube 2 is marked “Control’ ” 
o Tube 3 is marked “LTD’ ” 
 1.5mL polybrene (With a stock concentration at [5mg(mL]) is added to each of the three 
15mL tubes (The tubes called “miR-29a’ ”, “Control’ ” and “LTD’ ”) using a pipet 
 2.5mL of the viral medium from the 15mL tube called “miR-29a” is added to the 15mL tube 
called “miR-29a’ ” and the content is resuspended 
 2.5mL of the viral medium from the 15mL tube called “Control” is added to the 15mL tube 
called “Control’ ” and the content is resuspended 
 2.5mL of the viral medium from the 15mL tube called “LTD” is added to the 15mL tube 
called “LTD’ ” and the content is resuspended 
 The complete content of the 15mL tube called “miR-29a’ “ is added to the 10cm dish called 
“miR-29a” 
  The complete content of the 15mL tube called “Control’ “ is added to the 10cm dish called 
“Control” 
 The complete content of the 15mL tube called “LTD’ “ is added to the 10cm dish called 
“LTD” 
 The four 10cm dishes (The four 10cm dishes called “miR-29a 101214”, “Control 101214”, 
“LTD 101214” and “Selektionsplade 101214”) are placed in the incubator at 37oC, 5% CO2 
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Monitoring the infected C2C12 cells - 24 hours after the second infection (12/12 - 2014) 
 The four 10cm dishes (The 10cm dishes called “miR-29a 101214”, “Control 101214”, “LTD 
101214” and “Selektionsplade 101214”) are found in the 37oC, 5% CO2 incubator and 
brought to the microscope (Leica DM IRB) 
 The cells are examined in the microscope in both ultraviolet light and in normal phase con-
trast 
 Few cells (Like observed 24 hours after the first infection) is observed in the dishes called 
“miR-29a 101214”, “Control 101214” and “LTD 101214” 
o No fluorescence is observed in any of this dishes 
 Fewer cells are observed in the dish called “Selektionsplade 101214” 
o No fluorescence is observed on this dish 
 Pictures are taken of the four 10cm dishes (The four 10cm dishes called “miR-29a 101214”, 
“Control 101214”, “LTD 101214” and “Selektionsplade 101214”) in both ultraviolet and 
normal light 
 The four 10cm dishes are placed back in the incubator at 37oC, 5% CO2 
 
Selection of the infected C2C12 cell (12/12 - 2014) 
 All materials are found and brought to the cell lab 
 The procedure is now done sterile in the cell lab  
 The four 10cm dishes containing the infected C2C12 cells (The four 10cm dishes called 
“miR-29a 101214”, “Control 101214”, “LTD 101214” and “Selektionsplade 101214”) are 
found in the 37oC, 5% CO2 incubator and brought to the LAF bench 
 All materials are sterilized before being put in the LAF bench 
 50mL C2C12 growth medium, containing serum, is added to a 50mL tube 
 The puromycin is defrost – The stock concentration is 1mg/mL 
 100μL puromycin is added to the same 50mL tube  
o The final concentration of the puromycin will therefore be 2μL/mL 
 The 50mL tube is inverted a few times 
 The medium is removed from all of the four 10cm dishes (The four 10cm dishes called 
“miR-29a 101214”, “Control 101214”, “LTD 101214” and “Selektionsplade 101214”) 
 Each 10cm dish is added 5mL of the growth medium containing 2μL/mL puromycin from 
the 50mL tube 
 All the four 10cm dishes are put back into the incubator at 37oC, 5% CO2 
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Appendix C 
 
Figure 88 shows the DNA Ladders used in this experiment (from Thermo Scientific). 
 
 
 
 
 
